

US009273288B2

(12) United States Patent

Mason et al.

(54) **PSEUDOINFECTIOUS FLAVIVIRUS AND USES THEREOF**

- (75) Inventors: Peter W. Mason, Galveston, TX (US);
 Elena Frolova, Galveston, TX (US);
 Ilva Frolov, Galveston, TX (US)
- (73) Assignee: The Board of Regents of The University of Texas System, Austin, TX (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 647 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 13/561,002
- (22) Filed: Jul. 28, 2012

(65) **Prior Publication Data**

US 2013/0023031 A1 Jan. 24, 2013

Related U.S. Application Data

- (63) Continuation of application No. 11/711,532, filed on Feb. 27, 2007, now Pat. No. 8,252,574.
- (60) Provisional application No. 60/777,189, filed on Feb. 27, 2006.
- (51) **Int. Cl.**

C12N 7/00	(2006.01)
A61K 39/12	(2006.01)
A61K 39/00	(2006.01)

- (52) U.S. CI.
 CPC . C12N 7/00 (2013.01); A61K 39/12 (2013.01); A61K 2039/5254 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24162 (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,252,574 H	32	8/2012	Mason et al.
2004/0052818 A	41	3/2004	Heinz et al.
2004/0235133 A	41	11/2004	Frolov et al.
2006/0018928 A	41	1/2006	Pang
2007/0249032 A	41	10/2007	Pang et al.

FOREIGN PATENT DOCUMENTS

WO	WO/99/28487 A1	6/1999
WO	WO/00/14245 A1	3/2000
WO	WO/00/55378 A1	9/2000
WO	WO 02/72803 A2	2/2002
WO	WO/03/046189 A1	6/2003
WO	WO/2004/016794 A1	2/2004
WO	WO/2004/022761 A1	3/2004
WO	WO/2004/108936 A1	12/2004
WO	WO 2006/017206 A2	2/2006

(10) Patent No.: US 9,273,288 B2 (45) Date of Patent: *Mar. 1, 2016

OTHER PUBLICATIONS

Harvey, T. et al. "Tetracycline-Inducible Packaging Cell Line for Production of Flavivirus Replicon Particles". Journal of Virology, 78 (1), 2004.

Jones, C. et al. "Flavivirus Capsid is a Dimeric Alpha-Helical Protein". Journal of Virology, 77(12), 2003.

Kofler, R. "Mimicking Live Flavivirus Immunization with a Noninfectious RNA Vaccine". Proceedings of the National Academy of Sciences, 101 (7), 2004, 1951-1956.

Kofler, R. "Spontaneous Mutations Restore the Viability of Tick-Borne Encephalitis Virus Mutants with Large Deletions in Protein C". Journal of Virology, 77(1), 2003.

Mandl, C. "Flavivirus Immunization with Capsid-Deletion Mutants: Basics, Benefits, and Barriers". Viral Immunology, 17(4), 2004.

Aberle et al. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. Journal of Virology 79(24), 15107-13 (2005).

Dudek, T. and Knipe, D. Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230-239 (2006).

Harvey et al. Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development. Journal of Virology 77(14), 7796 (2003).

Harvey et al. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. Journal of Virology 78(1), 531-8 (2004).

Jones, C. et al. "Flavivirus Capsid is a Dimeric Alpha-Helical Protein". Journal of Virology, 77(12), 7143-7149 (2003).

Kofler, R. Capsid Protein C of Tick-Borne Encephalitis Virus Tolerates Large Internal Deletions and is a Favorable Target for Attenuation of Virulence. Journal of Virology 76(7), 3534-3543 (2002).

Kofler, R. Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with large deletions in protein C. Journal of Virology 77(1), 443-451 (2003).

Kofler, R. Mimicking Live Flavivirus Immunization with a Noninfectious RNA Vaccine. Proceedings of the National Academy of Sciences, 101 (7), 1951-1956 (2004).

Mandl, C. Flavivirus Immunization with Capsid-Deletion Mutants: Basics, Benefits, and Barriers. Viral Immunology, 17(4), 461-472 (2004).

Mason et al. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 351, 432-443 (2006). Scholle et al. Particles: trans-Packaged West Nile Virus-Like Particles: Infectious Properties in Vitro and in Infected Mosquito Vectors. Journal of Virology 78(21), 11605-14 (2004).

(Continued)

Primary Examiner - Stacy B Chen

(74) Attorney, Agent, or Firm — Norton Rose Fulbright US LLP

(57) ABSTRACT

The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.

24 Claims, 29 Drawing Sheets

(56) **References Cited**

OTHER PUBLICATIONS

Shustov et al. Production of Pseudoinfectious Yellow Fever Virus with a Two-Component Genome. Journal of Virology 81(21), 11737-11748 (2007).

Wagner et al. Rev-Independent Expression of Synthetic gag-pol Genes of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus: Implications for the Safety of Lentiviral Vectors. Human Gene Therapy 11, 2403-2413 (2000). Widman et al. Third-Generation Flavivirus Vaccines Based on Circle Cord Emergiation Polyton Virus Vaccines Based on

Widman et al. Third-Generation Flavivirus Vaccines Based on Single-Cycle, Encapsidation-Defective Viruses. Advances in Virus Research 72,77-126 (2008).



Fig.1





TTCAAČATČeTČACaGCÉAAĞAATCACGGCtCACCTGAAĞAĞGecTČTGGAAGATĞCTĞGACCCtcGeCAgGGGeTC GCGGTgCTcAGaAAgGTgAAGeGgGTeGTcGTcGCCtcccTGATGcGcG3ccTGTCCTCtcGcAAgaGgCGcTcCAcGAT arcaagcagaagaCcaagCraarcGccaacACCcGCaCCgagccGgGGcGrcCagGGgrrcArCrrcTrcrrccrG

ÅTGagcGGcCGgAAgGCTICAGGGcAAgACUCTDGGCBTgAAcATGGTgaGgCGcGGGGGGGGGGGGGGGGGGGGGGGCTCTCcAACAAg









gagtaaatcctgtgtgctaattgaggtgcattggtctgcaaatcgagttgctaggccaataaacacatttggattaattttaatcgt tcgttgagcgattagcagagaactgaccagaacatgtctggtcgtaaagctcagggaaaaaaccctgggcgtcaatatggt acgacgaggagttcgctccttgtcaaacaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctgg tcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgatgccacctacggcaag ctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtg cagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccagga gcgcaccatcttcttcaaggacgacggcaactacaagacccgcgcgaggtgaagttcgagggcgacaccctggtgaa ccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctgggggcacaagctggagtacaactacaaca gccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgagg acggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaac cactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtga ccgccgccgggatcactctcggcatggacgagctgtacaagcttggattgtcctcaaggaaacgccgttcccatgatgttct gactgtgcaattcctaattttgggaatgctgttgatgacgggtggagtgaccttggtgcggaaaaacagatggttgctcctaa cctacgcatgaaaaccatggtttgaagacccggcaagaaaaatggatgactggaagaatgggtgaaaggcaactccaa aagattgagagatggttcgtgaggaaccccttttttgcagtgacggctctgaccattgcctaccttgtgggaagcaacatgac gcaacgagtcgtgattgccctactggtcttggctgttggtccggcctactcagctcactgcattggaattactgacagggatttc attgagggggtgcatggaggaacttgggtttcagctaccctggagcaagacaagtgtgtcactgttatggcccctgacaag ccttcattggacatctcactagagacagtagccattgatagacctgctgaggtgaggaaagtgtgttacaatgcagttctcac tcatgtgaagattaatgacaagtgccccagcactggagaggcccacctagctgaagagaacgaaggggacaatgcgtg caagcgcacttattctgatagaggctggggcaatggctgtggcctatttgggaaagggagcattgtggcatgcgccaaattc acttgtgccaaatccatgagtttgtttgaggttgatcagaccaaaattcagtatgtcatcagagcacaattgcatgtaggggcc aagcaggaaaattggaataccgacattaagactctcaagtttgatgccctgtcaggctcccaggaagtcgagttcattgggt atggaaaagctacactggaatgccaggtgcaaactgcggtggactttggtaacagttacatcgctgagatggaaacagag agctggatagtggacagacagtgggcccaggacttgaccctgccatggcagagtggaagtgggggtgtggagagag atgcatcatcttgtcgaatttgaacctccgcatgccgccactatcagagtactggccctgggaaaccaggaaggctccttga aaacagctcttactggcgcaatgagggttacaaaggacacaaatgacaacaacctttacaaactacatggtggacatgttt cttgcagagtgaaattgtcagctttgacactcaaggggacatcctacaaaatatgcactgacaaaatgttttttgtcaagaac ccaactgacactggccatggcactgttgtgatgcaggtgaaagtgtcaaaaggagccccctgcaggattccagtgatagta gctgatgatcttacagcggcaatcaataaaggcattttggttacagttaaccccatcgcctcaaccaatgatgatgaagtgct gattgaggtgaacccaccttttgggagacagctacattatcgttgggagaggagattcacgtctcacttaccagtggcacaaa gagggaagetcaataggaaagttgttcactcagaccatgaaaggcgtggaacgectggecgtcatgggagacaccgect gggatttcagctccgctggagggttcttcacttcggttgggaaaggaattcatacggtgtttggctctgcctttcaggggctattt gtccatgagcatgatcttggtaggagtgatcatgatgtttttgtctctaggagttggggcggatcaaggatgcgccatcaacttt ggcaagagagagctcaagtgcggagatggtatcttcatatttagagactctgatgactggctgaacaagtactcatactatc cagaagatcctgtgaagcttgcatcaatagtgaaagcctcttttgaagaagggaagtgtggcctaaattcagttgactccctt gagcatgagatgtggagaagcagggcagatgagatcaatgccattittgaggaaaacgaggtggacatttctgttgtcgtg caggatccaaagaatgtttaccagagaggaactcatccattttccagaattcgggatggtctgcagtatggttggaagacttg gggtaagaaccttgtgttctcccccagggaggaagaatggaagcttcatcatagatggaaagtccaggaaagaatgcccgt tttcaaaccgggtctggaattctttccagatagaggagtttgggacgggagtgttcaccacacgcgtgtacatggacgcagt ctttgaatacaccatagactgcgatggatctatcttgggtgcagcggtgaacggaaaaaagagtgcccatggctctccaac attttggatgggaagtcatgaagtaaatgggacatggatgatccacaccttggaggcattagattacaaggagtgtgagtg ccactgacacatacgattggaacatcagttgaagagagtgaaatgttcatgccgagatcaatcggaggcccagttagctct gcccagggactagcgtgatcattgatggcaactgtgatggacggggaaaatcaaccagatccaccacggatagcggga aagttattcctgaatggtgttgccgctcctgcacaatgccgcctgtgagcttccatggtagtgatgggtgttggtatcccatgga aattaggccaaggaaaacgcatgaaagccatctggtgcgctcctgggttacagctggagaaatacatgctgtcccttttggt

tgctcttgggagcaatgctggtcgggcaagtaactctccttgatttgctgaaactcacagtggctgtgggattgcatttccatga gatgaacaatggaggagacgccatgtatatggcgttgattgctgccttttcaatcagaccagggctgctcatcggctttgggc tcaggaccctatggagccctcgggaacgccttgtgctgaccctaggagcagccatggtggagattgccttgggtggcgtga tgggcggcctgtggaagtatctaaatgcagtttctctctgcatcctgacaataaatgctgttgcttctaggaaagcatcaaata ccatcttgcccctcatggctctgttgacacctgtcactatggctgaggtgagacttgccgcaatgttcttttgtgccgtggttatcat aggggtccttcaccagaatttcaaggacacctccatgcagaagactatacctctggtggccctcacactcacatcttacctg ggcttgacacaaccttttttgggcctgtgtgcatttctggcaacccgcatatttgggcgaaggagtatcccagtgaatgaggca ctcgcagcagctggtctagtgggagtgctggcaggactggcttttcaggagatggagaacttccttggtccgattgcagttgg aggactcctgatgatgctggttagcgtggctgggagggtggatgggctagagctcaagaagcttggtgaagtttcatggga agaggaggcggagatcagcgggagttccgcccgctatgatgtggcactcagtgaacaaggggagttcaagctgctttctg tccttgctgggtggctgtttcatgtcaggggagctaggagaagtggggatgtcttgtggggatattcccactcctaagatcatcg aggaatgtgaacatctggaggatgggatttatggcatattccagtcaaccttcttggggggcctcccagcgaggagtgggagt ggcacagggaggggtgttccacacaatgtggcatgtcacaagaggagctttccttgtcaggaatggcaagaagttgattcc atcttgggcttcagtaaaggaagaccttgtcgcctatggtggctcatggaagttggaaggcagatgggatgggaggaag aggtccagttgatcgcggctgttccaggaaagaacgtggtcaacgtccagacaaaaccgagcttgttcaaagtgaggaat gggggagaaatcggggctgtcgctcttgactatccgagtggcacttcaggatctcctattgttaacaggaacggagagtg aagacaagacgtttcctcccacagatcttggccgagtgcgcacggagacgcttgcgcactcttgtgttggcccccaccagg agagaagtcattgatgccatgtgccatgccaccctaacttacaggatgttggaaccaactagggttgttaactgggaagtga tcattatggatgaagcccattttttggatccagctagcatagccgctagaggttgggcagcgcacagagctagggcaaatg aaagtgcaacaatcttgatgacagccacaccgcctgggactagtgatgaatttccacattcaaatggtgaaatagaagatg ttcaaacggacatacccagtgagccctggaacacagggcatgactggatcctagctgacaaaaggcccacggcatggtt ccttccatccatcagagctgcaaatgtcatggcgcctctttgcgtaaggctggaaagagtgtggtggtcctgaacaggaaaa cctttgagagagaataccccacgataaagcagaagaaacctgactttatattggccactgacatagctgaaatgggagcc aacctttgcgtggagcgagtgctggattgcaggacggcttttaagcctgtgcttgtggatgaagggaggaaggtggcaata aaagggccacttcgtatctccgcatcctctgctgctcaaaggaggggggcgcattgggagaaatcccaacagagatggag actcatactactattctgagcctacaagtgaaaataatgcccaccacgtctgctggttggaggcctcaatgctcttggacaac atggaggtgaggggtggaatggtcgccccactctatggcgttgaaggaactaaaacaccagtttcccctggtgaaatgag actgagggatgaccagaggaaagtcttcagagaactagtgaggaattgtgacctgcccgtttggctttcgtggcaagtggc caaggctggtttgaagacgaatgatcgtaagtggtgttttgaaggccctgaggaacatgagatcttgaatgacagcggtga aacagtgaagtgcagggctcctggaggagcaaagaagcctctgcgcccaaggtggtgtgatgaaagggtgtcatctgac gattlcctggctaaaaaaggtggagaggcaatggataccatcagtgtgttcctccactctgaggaaggctctagggcttacc atctttttcatgtctcccaaaggcatcagtagaatgtctatggcgatgggcacaatggccggctgtggatatctcatgttccttgg aaggtccatccaagacaaccaagtggcatacctcattattggcatcctgacgctggtttcagcggtggcagccaacgagct aggcatgctggagaaaaccaaagaggacctctttgggaagaagaacttaattccatctagtgcttcaccctggagttggcc ggatcttgacctgaagccaggagctgcctggacagtgtacgttggcattgttacaatgctctctcccaatgttgcaccactggat catgaagatgaatatctcggtcataatgctgctggtcagtggctggaattcaataacagtgatgcctctgctctgtggcatagg gtgcgccatgctccactggtctctcattttacctggaatcaaagcgcagcagtcaaagcttgcacagagaagggtgttccat agaaactggctctatatctccttcttgctctcagcctagcttctgttgccatgtgcagaacgcccttttcattggctgaaggcattgt cctagcatcagctgccttaggggccgctcatagagggaaacaccagccttctttggaatggacccatggctgtctccatgaca ggagtcatgaggggggaatcactatgcttttgtgggggtcatgtacaatctatggaagatgaaaactggacgccgggggag cgcgaatggaaaaactttgggtgaagtctggaagagggaactgaatctgttggacaagcgacagtttgagttgtataaaag

gaccgacattgtggaggtggatcgtgatacggcacgcaggcatttggccgaagggaaggtggacaccggggtggcggt ctccagggggaccgcaaagttaaggtggttccatgagcgtggctatgtcaagctggaaggtagggtgattgacctggggtg gccatgagaaacccatgaatgtgcaaagtctgggatggaacatcatcaccttcaaggacaaaactgatatccaccgccta agagttcttgatactgtagaaaaatggctggcttgtggggttgacaacttctgtgtgaaggtgttagctccatacatgccagat gttcttgagaaactggaattgctccaaaggaggtttggcggaacagtgatcaggaaccctctctcccaggaattccactcatg aaatgtactacgtgtctggagcccgcagcaatgtcacatttactgtgaaccaaacatcccgcctcctgatgaggagaatga acccctggacaaagaggccatagaagaaagggttgagaggataaaatctgagtacatgacctcttggttttatgacaatg acaacccctacaggacctggcactactgtggctcctatgtcacaaaaacctcaggaagtgcggcgagcatggtaaatggt cagcaaagagtgtttaaagaaaaagttgacaccagagcaaaggatccaccagcgggaactaggaagatcatgaaagt tgtcaacaggtggctgttccgccacctggccagagaaaagaaccccagactgtgcacaaaggaagaatttattgcaaaa gtccgaagtcatgcagccattggagcttacctggaagaacaagaacagtggaagactgccaatgaggctgtccaagacc caaagttctgggaactggtggatgaagaaaggaagctgcaccaacaaggcaggtgtcggacttgtgtgtacaacatgat ggggaaaagagagaagaagctgtcagagtttgggaaagcaaagggaagccgtgccatatggtatatgtggctgggagc gcggtatcttgagtttgaggccctgggattcctgaatgaggaccattgggcttccagggaaaactcaggaggaggagtgga gctggatgggacacgcgcatcacagaggcagaccttgatgatgaacaggagatcttgaactacatgagcccacatcaca aaaaactggcacaagcagtgatggaaatgacatacaagaacaaagtggtgaaagtgttgagaccagccccaggagg gaaagcctacatggatgtcataagtcgacgagaaccagagaggatccgggcaggtagtgacttatgctctgaacaccatc accaacttgaaagtccaattgatcagaatggcagaagcagagatggtgatacatcaccaacatgttcaagattgtgatgaa tcagttctgaccaggctggaggcatggctcactgagcacggatgtgacagactgaagaggatggcggtgagtggagacg actgtgtggtccggcccatcgatgacaggttcggcctggccctgtcccatctcaacgccatgtccaaggttagaaaggacat atctgaatggcagccatcaaaagggtggaatgattgggagaatgtgcccttctgttcccaccacttccatgaactacagctg aaggatggcaggaggattgtggtgccttgccgagaacaggacgagctcattgggaggggaggggtgtctccaggaaac ggctggatgatcaaggaaacagcttgcctcagcaaagcctatgccaacatgtggtcactgatgtattttcacaaaagggac atgaggctactgtcattggctgtttcctcagctgttcccacctcatgggttccacaaggacgcacaacatggtcgattcatggg aaaggggagtggatgaccacggaagacatgcttgaggtgtggaacagagtatggataaccaacaaccaccacatgca ggacaagacaatggtgaaaaaatggagagatgtcccttatctaaccaagagacaagacaagctgtgcggatcactgatt atacactgactacctaacagtcatggacaggtattctgtggatgctgacctgcaactgggtgagcttatctgaaacaccatct aacaggaataaccgggatacaaaccacgggtggagaaccggactccccacaacctgaaaccgggatataaaccacg gctggagaaccggactccgcacttaaaatgaaacagaaaccgggataaaaactacggatggagaaccggactccaca cattgagacagaagaagttgtcagcccagaaccccacacgagttttgccactgctaagctgtgaggcagtgcaggctggg caccctcccacgtggtggtagaaagacggggtctagaggttagaggagaccctccagggaacaaatagtgggaccata ttgacgccagggaaagaccggagtggttctctgcttttcctccagaggtctgtgagcacagtttgctcaagaataagcagac ctttggatgacaaacacaaaaccactgggtcggcatggcatctccacctcctcgcggtccgacctgggcatccgaaggag gacgcacgtccactcggatggctaagggagagccacgagctcctcgacagatcataatcagccataccacatttgtaga gcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttitcactgcattctagttgtggtttg tccaaactcatcaagatctcgagcaagacgtttcccgttgaatatggctcataacaccccttgtattactgtttatgtaagcaga cagttttattgttcatgatgatatatttttatcttgtgcaatgtaacatcagagattttgagacacaacgtggctttgttgaataaatc gaacttttgctgagttgaaggatcagatcacgcatcttcccgacaacgcagaccgttccgtggcaaagcaaaagttcaaaa ctggtatgagtcagcaacaccttcttcacgaggcagacctcagcgctagcggagtgtatactggcttactatgttggcactga tgagggtgtcagtgaagtgcttcatgtggcaggagaaaaaaggctgcaccggtgcgtcagcagaatatgtgatacaggat atattccgcttcctcgctcactgactcgctacgctcggtcgttcgactgcggcgggagaatggcttacggagcggg gatttcctggaagatgccaggaagatacttaacagggaagtgagagggccgcggcaaagccgtttttccataggctccgc

ccccctgacaagcatcacgaaatctgacgctcaaatcagtggtggcgaaacccgacaggactataaagataccaggcg tttcccctggcggctccctcgtgcgctctcctgttcctgcctttcggtttaccggtgtcattccgctgttatggccgcgtttgtctcatt ccacgcctgacactcagttccgggtaggcagttcgctccaagctggactgtatgcacgaaccccccgttcagtccgaccgc tgcgccttatccggtaactatcgtcttgagtccaacccggaaagacatgcaaaagcaccactggcagccactggtaat tgatttagaggagttagtcttgaagtcatgcgccggttaaggctaaactgaaaggacaagttttggtgactgcgctcctccaa gccagttacctcggttcaaagagttggtagctcagagaaccttcgaaaaaccgccctgcaaggcggttttttcgttttcagag caagagattacgcgcagaccaaaacgatctcaagaagatcatcttattaaggggtctgacgctcagtggaacgaaaact taaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttc atccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgatac cagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagta ctcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaacacgggataataccgcgcc acatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagat ccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacag gaaggcaaaatgccgcaaaaagggaataagggcgacacggaaatgttgaatactcatactctttcctttttcaatattattg aagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaatagggttccgcgcac atticcccgaaaagtgccacctgacgtgtcgacgcggccgctagcgatgaccctgctgattggttcgctgaccatttccgggt ggtctgcttcagtaagccagatgctacacaattaggcttgtacatattgtcgttagaacgcggctacaattaatacataacctt atgtatcatacacatacgatttaggtgacactata (SEQ ID NO: 6)

Fig.8D

cagcccattcctcagagctttgcagcggagcttcccgcagtttgaggtagaagccaagcaggtcactgataatgaccatgc taatgccagagcgttttcgcatctggcttcaaaactgatcgaaacggaggtggacccatccgacacgatccttgacattgga agtgcgcccgcccgcagaatgtattctaagcacaagtatcattgtatctgtccgatgagatgtgcggaagatccggacagat tgtataagtatgcaactaagctgaagaaaaactgtaaggaaataactgataaggaattggacaagaaaatgaaggagct ggccgccgtcatgagcgaccctgacctggaaactgagactatgtgcctccacgacgacgagtcgtgtcgctacgaaggg caagtcgctgtttaccaggatgtatacgcggttgacggaccgacaagtctctatcaccaagccaataagggagttagagtc gcctactggataggctttgacaccaccccttttatgtttaagaacttggctggagcatatccatcatactctaccaactgggccg acgaaaccgtgttaacggctcgtaacataggcctatgcagctctgacgttatggagcggtcacgtagagggatgtccattctt agaaagaagtatttgaaaccatccaacaatgttctattctctgttggctcgaccatctaccacgagaagagggacttactga gggtacgtcgttaaaagaatagctatcagtccaggcctgtatgggaagccttcaggctatgctgctacgatgcaccgcgag ggattcttgtgctgcaaagtgacagacacattgaacggggagagggtctcttttcccgtgtgcacgtatgtgccagctacatt gtgtgaccaaatgactggcatactggcaacagatgtcagtgcggacgacgcgcaaaaactgctggttgggctcaaccag cgtatagtcgtcaacggtcgccicccagagaaacaccaataccatgaaaaattaccttttgcccgtagtggcccaggcattt gctaggtgggcaaaggaatataaggaagatcaagaagatgaaaggccactaggactacgagatagacagttagtcatg gggtgttgttgggcttttagaaggcacaagataacatctatttataagcgcccggatacccaaaccatcatcaaagtgaaca gcgatttccactcattcgtgctgcccaggataggcagtaacacattggagatcgggctgagaacaagaatcaggaaaatg ttagaggagcacaaggagccgtcacctctcattaccgccgaggacgtacaagaagctaagtgcgcagccgatgaggct aaggaggtgcgtgaagccgaggagttgcgcgcagctctaccacctttggcagctgatgttgaggagcccactctggaagc cgatgtcgacttgatgttacaagaggctggggccggctcagtggagacacctcgtggcttgataaaggttaccagctacga tggcgaggacaagatcggctcttacgctgtgctttctccgcaggctgtactcaagagtgaaaaattatcttgcatccaccctct cgctgaacaagtcatagtgataacacactctggccgaaaagggcgttatgccgtggaaccataccatggtaaagtagtgg

tcgtaaacaggtacctgcaccatattgccacacatggaggagcgctgaacactgatgaagaatattacaaaactgtcaag agggctcacaggcgagctggtggatcctcccttccatgaattcgcctacgagagtctgagaacacgaccagccgctcctta ccaagtaccaaccataggggtgtatggcgtgccaggatcaggcaagtctggcatcattaaaagcgcagtcaccaaaaaa gatctagtggtgagcgccaagaaagaaaactgtgcagaaattataagggacgtcaagaaaatgaaagggctggacgtc aatgccagaactgtggactcagtgctcttgaatggatgcaaacaccccgtagagaccctgtatattgacgaagcttttgcttgt catgcaggtactctcagagcgctcatagccattataagacctaaaaaggcagtgctctgcggggatcccaaacagtgcgg tttttttaacatgatgtgcctgaaagtgcattttaaccacgagatttgcacacaagtcttccacaaaagcatctctcgccgttgca ctaaatctgtgacttcggtcgtctcaaccttgttttacgacaaaaaatgagaacgaagacgaaatccgaaagagactaagattgt atagattacaaaggcaacgaaataatgacggcagctgcctctcaagggctgacccgtaaaggtgtgtatgccgttcggta caaggtgaatgaaaatcctctgtacgcacccacctcagaacatgtgaacgtcctactgacccgcacggaggaccgcatc aggagtggcaagcagagcatgatgccatcatgaggcacatcttggagagaccggaccctaccgacqtcttccagaataa ggcaaacgtgtgttgggccaaggctttagtgccggtgctgaagaccgctggcatagacatgaccactgaacaatggaac actgtggattattttgaaacggacaaagctcactcagcagagatagtattgaaccaactatgcgtgaggttctttggactcgat ctggactccggtctattttctgcacccactgttccgttatccattaggaataatcactgggataactccccgtcgcctaacatgta cgggctgaataaagaagtggtccgtcagctctctcgcaggtacccacaactgcctcgggcagttgccactggaagagtct atgacatgaacactggtacactgcgcaattatgatccgcgcataaacctagtacctgtaaacagaagactgcctcatgcttt agtcctccaccataatgaacacccacagagtgacttttcttcattcgtcagcaaattgaagggcagaactgtcctggtggtcg gggaaaagttgtccgtcccaggcaaaatggttgactggttgtcagaccggcctgaggctaccttcagagctcggctggattt aggcatcccaggtgatgtgcccaaatatgacataatatttgttaatgtgaggaccccatataaataccatcactatcagcagt gtgaagaccatgccattaagcttagcatgttgaccaagaaagcttgtctgcatctgaatcccggcggaacctgtgtcagcat aggttatggttacgctgacagggccagcgaaagcatcattggtgctatagcgcggcagttcaagttttcccgggtatgcaaa ccgaaatcctcacttgaagagacggaagttctgtttgtattcattgggtacgatcgcaaggcccgtacgcacaatccttacaa gctttcatcaaccttgaccaacatttatacaggttccagactccacgaagccggatgtgcaccctcatatcatgtggtgcgag gggatattgccacggccaccgaaggagtgattataaatgctgctaacagcaaaggacaacctggcggaggggt gtgcggagcgctgtataagaaattcccggaaagcttcgatttacagccgatcgaagtaggaaaagcgcgactggtcaaa ggtgcagctaaacatatcattcatgccgtaggaccaaacttcaacaaagtttcggaggttgaaggtgacaaacagttggca gaggcttatgagtccatcgctaagattgtcaacgataacaattacaagtcagtagcgattccactgttgtccaccggcatctttt ccgggaacaaagatcgactaacccaatcattgaaccatttgctgacagctttagacaccactgatgcagatgtagccatat ctacagcacaagcgatggcaaaactttctcatatttggaagggaccaagtttcaccaggcggccaaggatatagcagaa attaatgccatgtggcccgttgcaacggaggccaatgagcaggtatgcatgtatatcctcggagaaagcatgagcagtatt ccagaaagagtacagcgcctaaaagcctcacgtccagaacaaattactgtgtgctcatcctttccattgccgaagtataga atcactggtgtgcagaagatccaatgctcccagcctatattgttctcaccgaaagtgcctgcgtatattcatccaaggaagtat ctcgtggaaacaccaccggtagacgagactccggagccatcggcagagaaccaatccacagaggggacacctgaac aaccaccacttataaccgaggatgagaccaggactagaacgcctgagccgatcatcatcgaagaggaagaagaggat agcataagtttgctgtcagatggcccgacccaccagtgtgctgcaagtcgaggcagacattcacgggccgccctctatatct accagcggggcaacgtcagccgagactaactcttacttcgcaaagagtatggagtttctggcgcgaccggtgcctgcgcct cgaacagtattcaggaaccctccacatcccgctccgcgcacaagaacaccgtcacttgcacccagcagggcctgctcga gaaccagcctagtttccaccccgccaggcgtgaatagggtgatcactagagaggagctcgaggcgcttaccccgtcacg cactectageaggteggtetegagaaceageetggteteeaaceegeeaggegtaaatagggtgattaeaagaggag tttgaggcgttcgtagcacaacaacaatgacggtttgatgcgggtgcatacatcttttcctccgacaccggtcaagggcattta cctcgaccaagaaaaaagaagaattactacgcaagaaattacagttaaatcccacacctgctaacagaagcagataccagtccaggaaggtggagaacatgaaagccataacagctagacgtattctgcaaggcctagggcattatttgaaggcagaa

ggaaaagtggagtgctaccgaaccctgcatcctgttcctttgtattcatctagtgtgaaccgtgccttttcaagccccaaggtc gcagtggaagcctglaacgccatgttgaaagagaactttccgactgtggcttcttactgtattattccagagtacgatgcctatt tggacatggttgacggagcttcatgctgcttagacactgccagtttttgccctgcaaagctgcgcagctttccaaagaaacac tcctatttggaacccacaatacgatcggcagtgccttcagcgatccagaacacgctccagaacgtcctggcagctgccac aaaaagaaattgcaatgtcacgcaaatgagagaattgcccgtattggattcggcggcctttaatgtggaatgcttcaagaa atatgcgtgtaataatgaatattgggaaacgtttaaagaaaaccccatcaggcttactgaagaaaacgtggtaaattacatt accaaattaaaaggaccaaaagctgctgctctttttgcgaagacacataatttgaatatgttgcaggacataccaatggaca ggtttgtaatggacttaaagagagacgtgaaagtgactccaggaacaaaacatactgaagaacggcccaaggtacagg tgatecaggetgecgatecgetageaacagegtatetgtgeggaatecacegagagetggttaggagattaaatgeggtee tgcttccgaacattcatacactgtttgatatgtcggctgaagactttgacgctattatagccgagcacttccagcctggggattgt gttctggaaactgacatcgcgtcgtttgataaaagtgaggacgacgccatggctctgaccgcgttaatgattctggaagactt aggtgtggacgcagagctgttgacgctgattgaggcggctttcggcgaaatttcatcaatacatttgcccactaaaactaaat ttaaattcggagccatgatgaaatctggaatgttcctcacactgtttgtgaacacagtcattaacattgtaatcgcaagcagag aaattaatggcagacaggtgcgccacctggttgaatatggaagtcaagattatagatgctgtggtgggcgagaaagcgcc ttatttcfgtggagggttlatttgfgtgactccgtgaccggcacagcgtgccgtgtggcagaccccctaaaaaggctgtttaag cttggcaaacctctggcagcagacgatgaacatgatgatgacaggagaagggcattgcatgaagagtcaacacgctgg aaccgagtgggtattctttcagagctgtgcaaggcagtagaatcaaggtatgaaaccgtaggaacttccatcatagttatgg ccatgactactctagctagcagtgttaaatcattcagctacctgagaggggcccctataactctctacggctaacctgaatgg actacgacatagtctagtccgccaagtctagaccatgtctggtcgtaaagctcagggaaaaaccctgggcgtcaatatggt aggtgttcaaggatttatctttttctttttgttcaacattttgactggaaaaaagatcacagcccacctaaagaggttgtggaaaa tgctggacccaagacaaggcttggctgttctaaggaaagtcaagagagtggtggccagtttgatgagaggattgtcctcaa ggaaacgccgttcccatgatgttctgactgtgcaattcctaattttgggaatgctgttgatgacgggtggataagggcccctat aactototacggotaacotgaatggactacgacatagtotagtccgocaagtotagagottaccatgaccgagtacaagco cacggtgcgcctcgccaccgcgacgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgc cacgogccacaccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgg gctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaag cgggggcggtgttcgccgagntcggcccgcgcatggccgagttgagcggttcccggctgccgcgcagcaacagatgg aaggootcotggcgccgcaccggcccaaggagcccgcgtggttoctggccaccgtcggcgtotcgcccgaccaccagg gcaagggtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcgcgcggggtgcccgccttcctggaga cctccgcgccccgcaacctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgagtgcccgaaggaccq gcacgaccccatgatcgctagaccatggggtaccgagtatgttacgtgcaaaggtgattgtcaccccccgaaagaccata ttgtgacacaccctcagtatcacgcccaaacatttacagccgcggtgtcaaaaaccgcgtggacgtggttaacatccctgct attgaatacagcagcaattggcaagctgcttacatagaactcgcggcgattggcatgccgccttaaaatttttattttattttiattttiatttitittt agacgaaagggccaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgta tccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcg cccttattccctttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagtt gggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttcca atgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcat acactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagaaatta ggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggtttatt gctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatc gtagttatctacacgacgggggggtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgatt

Fig. 8H

cagcccattcctcagagctttgcagcggagcttcccgcagttgaggtagaagccaagcaggtcactgataatgaccatgc taatgccagagcgttttcgcatctggcttcaaaactgatcgaaacggaggtggacccatccgacacgatccttgacattgga agtgcgcccgccgcagaatgtattctaagcacaagtatcattgtatctgtccgatgagatgtgcggaagatccggacagat tgtataagtatgcaactaagctgaagaaaaactgtaaggaaataactgataaggaattggacaagaaaatgaaggagct ggccgccgtcatgagcgacc.>tgacctggaaactgagactatgtgcctccacgacgacgagtcgtgtcgctacgaaggg caagtcgctgtttaccaggatgtatacgcggttgacggaccgacaagtctctatcaccaagccaataagggagttagagtc gcctactggataggctttgacaccaccccttttatgtttaagaacttggctggagcatatccatcatactctaccaactgggccg acgaaaccgtgttaacggctcgtaacataggcctatgcagctctgacgttatggagcggtcacgtagagggatgtccattctt agaaagaagtatttgaaaccatccaacaatgttctattctctgttggctcgaccatctaccacgagaagagggacttactga gggtacgtcgttaaaagaatagctatcagtccaggcctgtatgggaagccttcaggctatgctgctacgatgcaccgcgag ggattettgtgetgeaaagtgaeagaeacattgaaeggggagagggtetetttteeegtgtgeaegtatgtgeeagetaeatt gtgtgaccaaatgactggcatactggcaacagatgtcagtgcggacgacgcgcaaaaactgctggttgggctcaaccag cqtataqtcqtcaacqqtcqcacccaqaqaaacaccaataccatqaaaaattaccttttqcccqtaqtqqcccaqqcattt gctaggtgggcaaaggaatataaggaagatcaagaagatgaaaggccactaggactacgagatagacagttagtcatg gggtgttgttgggcttttagaaggcacaagataacatctatttataagcgcccggatacccaaaccatcatcaaagtgaaca gcgatttccactcattcgtgctgcccaggataggcagtaacacattggagatcgggctgagaacaagaatcaggaaaatg ttagaggagcacaaggagccgtcacctctcattaccgccgaggacgtacaagaagctaagtgcgcagccgatgaggct aaggaggtgcgtgaagccgaggagttgcgcgcagctctaccacctttggcagctgatgttgaggagcccactctggaagc cgatgtcgacttgatgttacaagaggctggggccggctcagtggagacacctcgtggcttgataaaggttaccagctacga tggcgaggacaagatcggctcttacgctgtgctttctccgcaggctgtactcaagagtgaaaaattatcttgcatccaccctct cgctgaacaagtcatagtgataacacactctggccgaaaagggcgttatgccgtggaaccataccatggtaaagtagtgg tcgtaaacaggtacctgcaccatattgccacacatggaggagcgctgaacactgatgaagaatattacaaaactgtcaag agggctcacaggcgagctggtggatcctcccttccatgaattcgcctacgagagtctgagaacacgaccagccgctcctta ccaagtaccaaccataggggtgtatggcgtgccaggatcaggcaagtctggcatcattaaaagcgcagtcaccaaaaaa gatctagtggtgagcgccaagaaagaaaactgtgcagaaattataagggacgtcaagaaaatgaaagggctggacgtc aatgccagaactgtggactcagtgctcttgaatggatgcaaacaccccgtagagaccctgtatattgacgaagcttttgcttgt catgcaggtactctcagagcgctcatagccattataagacctaaaaaggcagtgctctgcggggatcccaaacagtgcgg tttttttaacatgatgtgcctgaaagtgcattttaaccacgagatttgcacacaagtcttccacaaaagcatctctcgccattgca ctaaatctgtgacttcggtcgtctcaaccttgttttacgacaaaaaatgagaacgacgacgaatccgaaagagactaagattgt caaggtgaatgaaaatcctctgtacgcacccacctcagaacatgtgaacgtcctactgacccgcacggaggaccgcatc aggagtggcaagcagagcatgatgccatcatgaggcacatcttggagagaccggaccctaccgacgtcttccagaataa

ggcaaacgtgtgttgggccaaggctttagtgccggtgctgaagaccgctggcatagacatgaccactgaacaatggaac actgtggattattitgaaacggacaaagctcactcagcagagatagtattgaaccaactatgcgtgaggttctttggactcgat ctggactccggtctattttctgcacccactgttccgttatccattaggaataatcactgggataactccccgtcgcctaacatgta cqqqctqaataaagaagtqgtccgtcagctctctcgcaggtacccacaactgcctcgggcagttgccactggaagagtct atgacatgaacactggtacactgcgcaattatgatccgcgcataaacctagtacctgtaaacagaagactgcctcatgcttt agtectecaccataatgaacaccecacagagtgacttttetteattegtcagcaaattgaagggcagaactgteetggtggteg gggaaaagttgtccgtcccaggcaaaatggttgactggttgtcagaccggcctgaggctaccttcagagctcggctggattt aggcatcccaggtgatgtgcccaaatatgacataatatttgttaatgtgaggaccccatataaataccatcactatcagcagt gtgaagaccatgccattaagcttagcatgttgaccaagaaagcttgtctgcatctgaatcccggcggaacctgtgtcagcat aggttatggttacgctgacagggccagcgaaagcatcattggtgctatagcgcggcagttcaagttttcccgggtatgcaaa ccgaaatcctcacttgaagagacggaagttctgtttgtattcattgggtacgatcgcaaggcccgtacgcacaatccttacaa gctttcatcaaccttgaccaacatttatacaggttccagactccacgaagccggatgtgcaccctcatatcatgtggtgcgag gggatattgccacggccaccgaaggagtgattataaatgctgctaacagcaaaggacaacctggcggaggggtgtgcg gagcgctgtataagaaattcccggaaagcttcgatttacagccgatcgaagtaggaaaagcgcgactggtcaaaggtgc agctaaacatatcattcatgccgtaggaccaaacttcaacaaagtttcggaggttgaaggtgacaaacagttggcagagg cttatgagtccatcgctaagattgtcaacgataacaattacaagtcagtagcgattccactgttgtccaccggcatcttttccgg gaacaaagatcgactaacccaatcattgaaccatttgctgacagctttagacaccactgatgcagatgtagccatatactgc agggacaagaaatgggaaatgactctcaaggaagcagtggctaggagagaagcagtggaggagatatgcatatccga gcacaagcgatggcaaaactttctcatatttggaagggaccaagtttcaccaggcggccaaggatatagcagaaattaat gccatgtggcccgttgcaacggaggccaatgagcaggtatgcatgtatatcctcggagaaagcatgagcagtattaggtc aagagtacagcgcctaaaagcctcacgtccagaacaaattactgtgtgctcatcctttccattgccgaagtatagaatcact ggtgtgcagaagatccaatgctcccagcctatattgttctcaccgaaagtgcctgcgtatattcatccaaggaagtatctcgtg gaaacaccaccggtagacgagactccggagccatcggcagagaaccaatccacagaggggacacctgaacaacca ccacttataaccgaggatgagaccaggactagaacgcctgagccgatcatcatcgaagaggaagaagaggatagcat aagtttgctgtcagatggcccgacccaccaggtgctgcaagtcgaggcagacattcacgggccgccctctgtatctagctc cggggcaacgtcagccgagactaactcttacttcgcaaagagtatggagtttctggcgcgaccggtgcctgcgcctcgaac agtattcaggaaccctccacatcccgctccgcgcacaagaacaccgtcacttgcacccagcagggcctgctcgagaacc agcotagtttccaccccgccaggcgtgaatagggtgatcactagagaggagctcgaggcgcttaccccgtcacgcactcc tagcaggtcggtctcgagaaccagcctggtctccaacccgccaggcgtaaatagggtgattacaagagaggagtttgag gcgttcgtagcacaacaacaatgacggtttgatgcgggtgcatacatcttttcctccgacaccggtcaagggcatttacaac aaaaatcagtaaggcaaacggtgctatccgaagtggtgttggagaggaccgaattggagatttcgtatgccccgcgcctc gaccaagaaaaagaagaattactacgcaagaaattacagttaaatcccacacctgctaacagaagcagataccagtcc aggaaggtggagaacatgaaagccataacagctagacgtattctgcaaggcctagggcattatttgaaggcagaagga aaagtggagtgctaccgaaccctgcatcctgttcctttgtattcatctagtgtgaaccgtgccttttcaagccccaaggtcgcag tggaagcctgtaacgccatgttgaaagagaactttccgactgtggcttcttactgtattattccagagtacgatgcctatttgga catggttgacggagcttcatgctgcttagacactgccagtttttgccctgcaaagctgcgcagctttccaaagaaacactccta tttggaacccacaatacgatcggcagtgccttcagcgatccagaacacgctccagaacgtcctggcagctgccacaaaa agaaattgcaatgtcacgcaaatgagagaattgcccgtattggattcggcggcctttaatgtggaatgcttcaagaaatatgc gtgtaataatgaatattgggaaacgtttaaagaaaaccccatcaggcttactgaagaaaacgtggtaaattacattaccaa attaaaaggaccaaaagctgctgctgttttttgcgaagacacataatttgaatatgttgcaggacataccaatggacaggtttgt aatggacttaaagagagacgtgaaagtgactccaggaacaaaacatactgaagaacggcccaaggtacagtgatcc aggctgccgatccgctagcaacagcgtatctgtgcggaatccaccgagagctggttaggagattaaatgcggtcctgcttc cgaacattcatacactgtttgatatgtcggctgaagactttgacgctattatagccgagcacttccagcctggggattgtgttctg gaaactgacatcgcgtcgtttgataaaagtgaggacgacgccatggctctgaccgcgttaatgattctggaagacttaggtg tggacgcagagctgttgacgctgattgaggcggctttcggcgaaatttcatcaatacatttgcccactaaaactaaatttaaat tcggagccatgatgaaatctggaatgttcctcacactgtttgtgaacacagtcattaacattgtaatcgcaagcagagtgttga gagaacggctaaccggatcaccatgtgcagcattcattggagatgacaatatcgtgaaaggagtcaaatcggacaaatta atggcagacaggtgcgccacctggttgaatatggaagtcaagattatagatgctgtggtgggcgagaaagcgccttatttct

gtggagggtttattttgtgtgactccgtgaccggcacagcgtgccgtgtggcagaccccctaaaaaggctgtttaagcttggc aaacctctggcagcagacgatgaacatgatgatgacaggagaagggcattgcatgaagagtcaacacgctggaaccg agtgggtattctttcagagctgtgcaaggcagtagaatcaaggtatgaaaccgtaggaacttccatcatagttatggccatga ctactctagctagcagtgttaaatcattcagctacctgagaggggcccctataactctctacggctaacctgaatggactacg acatagtctagtccgccaagtctagaccatgtctggtcgtaaagctcagggaaaaaccctgggcgtcaatatggtacgacg caaggatttatctttttctttttgttcaacattttgactggaaaaaagatcacagcccacctaaagaggttgtggaaaatgctgga cccaagacaaggcttggctgttctaaggaaagtcaagaggtggtggccagtttgatgagaggattgtcctcaaggaaac gccgttcccatgatgttctgactgtgcaattcctaattttgggaatgctgttgatgacgggagtgaccttggtgcaaaaaa cagatggttgctcctaaatgtgacatctgaggacctcgggtaagggcccctataactctctacggctaacctgaatggacta cgacatagtctagtccgccaagtctagagcttaccatgaccgagtacaagcccacggtgcgcctcgccaccgcgacga cgtccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgccacgcgccacaccgtcgatccggaccg ccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgtgggtcgcg gcgcatggccgagttgagcggttcccggctggccgcagcaacagatggaaggcctcctggcgccgcaccggccca aggageccgcgtgtttcctggccaccgtcggcgtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgtt ccccggagtggaggcggccgagcgcgcggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctac gageggeteggetteacegteacegeegaegtegagtgeeegaaggaeeggegaeetggtgeatgaeeegeaageee ggtgcctgacgcccgccccacgacccgcagcgcccgaaaggagcgcacgaccccatgatcgctagaccatgg ggtaccgagtatgttacgtgcaaaggtgattgtcaccccccgaaagaccatattgtgacacaccctcagtatcacgcccaa acatttacagccgcggtgtcaaaaaccgcgtggacgtggttaacatccctgctgggaggatcagccgtaattattataattg cttacatagaactcgcggcgattggcatgccgccttaaaattttattttattttattttattttcttttcttttccgaatcggattttgtttttaatatttc ggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgata aatgetteaataatattgaaaaaggaagagtatgagtatteaacattteegtgtegeeettatteeettiittgeggeattttgeett cctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaac tggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatg actcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgat aacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcat gtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtag ggcggataaagttgcaggaccacttctgcgctcggcccttccggctggtttattgctgataaatctggagccggtgagc gtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacgggaagtca ggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagt ttactcatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaa aatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatccttiltttctgc ccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaag aactetgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttacc gggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacgggggttcgtgcacacagcccagct tggagcgaacgacctacaccgaactgagatacctacagcgtgagcattgagaaagcgccacgcttcccgaagggaga aaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcc aaaaacgccagcaacgcgagctcgatttaggtgacactata (SEQ ID NO: 8)

cagcccattcctcagagctttgcagcggagcttcccgcagtttgaggtagaagccaagcaggtcactgataatgaccatgc taatgccagagcgttttcgcatctggcttcaaaactgatcgaaacggaggtggacccatccgacacgatccttgacattgga agtgcgcccgccgcagaatgtattctaagcacaagtatcattgtatctgtccgatgagatgtgcggaagatccggacagat tgtataagtatgcaactaagctgaagaaaaactgtaaggaaataactgataaggaattggacaagaaaatgaaggagct ggccgccgtcatgagcgaccctgacctggaaactgagactatgtgcctccacgacgacgagtcgtgtcgctacgaaggg caagtcgctgtttaccaggatglatacgcggttgacggaccgacaagtctctatcaccaagccaataagggagttagagtc gcctactggataggctttgacaccaccccttttatgtttaagaacttggctggagcatatccatcatcataccaactgggccg acgaaaccgtgttaacggctcgtaacataggcctatgcagctctgacgttatggagcggtcacgtagagggatgtccattctt agaaagaagtatttgaaaccc/tccaacaatgttctattctctgtlggctcgaccatctaccacgagaagagggacttactga gggtacgtcgttaaaagaatagctatcagtccaggcctgtatgggaagccttcaggctatgctgctacgatgcaccgcgag ggattcttgtgctgcaaagtgacagacacattgaacggggagagggtctcttttcccgtgtgcacgtatgtgccagctacatt gtgtgaccaaatgactggcatactggcaacagatgtcagtgcggacgacgcgcaaaaactgctggttgggctcaaccag cgtatagtcgtcaacggtcgcacccagagaaacaccaataccatgaaaaattaccttttgcccgtagtggcccaggcattt gctaggtgggcaaaggaatataaggaagatcaagaagatgaaaggccactaggactacgagatagacagttagtcatg gggtgttgttggggcttttagaaggcacaagataacatctatttataagcgcccggatacccaaaccatcatcaaagtgaaca gcgatttccactcattcgtgctgcccaggataggcagtaacacattggagatcggggctgagaacaagaatcaggaaaatg ttagaggagcacaaggagccgtcacctctcattaccgccgaggacgtacaagaagctaagtgcgcagccgatgaggct aaggaggtgcgtgaagccgaggagttgcgcgcagctctaccacctttggcagctgatgttgaggagcccactctggaagc cgatgtcgacttgatgttacaagaggctggggccggctcagtggagacacctcgtggcttgataaaggttaccagctacga tggcgaggacaagatcggctcttacgctgtgctttctccgcaggctgtactcaagagtgaaaaattatcttgcatccaccctct cgctgaacaagtcatagtgataacacactctggccgaaaagggcgttatgccgtggaaccataccatggtaaagtagtgg tcgtaaacaggtacctgcaccatattgccacacatggaggagcgctgaacactgatgaagaatattacaaaactgtcaag agggctcacaggcgagctggtggatcctcccttccatgaattcgcctacgagagtctgagaacacgaccagccgctcctta ccaagtaccaaccataggggtgtatggcgtgccaggatcaggcaagtctggcatcattaaaagcgcagtcaccaaaaaa gatctagtggtgagcgccaagaaagaaaactgtgcagaaattataagggacgtcaagaaaatgaaagggctggacgtc aatgccagaactgtggactcagtgctcttgaatggatgcaaacaccccgtagagaccctgtatattgacgaagcttttgcttgt catgcaggtactctcagagcgctcatagccattataagacctaaaaaggcagtgctctgcggggatcccaaacagtgcgg tttttttaacatgatgtgcctgaaagtgcattttaaccacgagatttgcacacaagtcttccacaaaagcatctctcgccgttgca ctaaatctgtgacttcggtcgtctcaaccttgttttacgacaaaaaatgagaacgacgaatccgaaagagactaagattgt caaggtgaatgaaaatcctctgtacgcacccacctcagaacatgtgaacgtcctactgacccgcacggaggaccgcatc aggagtggcaagcagagcatgatgccatcatgaggcacatcttgggagagaccggaccctaccgacgtcttccagaataa ggcaaacgtgtgttgggccaaggctttagtgccggtgctgaagaccgctggcatagacatgaccactgaacaatggaac actgtggattattttgaaacggacaaagctcactcagcagagatagtattgaaccaactatgcgtgaggttctttggactcgat ctggactccggtctattttctgcacccactgttccgttatccattaggaataatcactgggataactccccgtcgcctaacatgta cgggctgaataaagaagtggtccgtcagctctctcgcaggtacccacaactgcctcgggcagttgccactggaagagtct atgacatgaacactggtacactgcgcaattatgatccgcgcataaacctagtacctgtaaacagaagactgcctcatgcttt agtcctccaccataatgaacacccacagagtgacttttcttcattcgtcagcaaattgaagggcagaactgtcctggtggtcg gggaaaagttgtccgtcccaggcaaaatggttgactggttgtcagaccggcctgaggctaccttcagagctcggctggattt aggcatcccaggtgatgtgcccaaatatgacataatatttgttaatgtgaggaccccatataaataccatcactatcagcagt gtgaagaccatgccattaagcttagcatgttgaccaagaaagcttgtctgcatctgaatcccggcggaacctgtgtcagcat aggttatggttacgctgacagggccagcgaaagcatcattggtgctatagcgcggcagttcaagttttcccgggtatgcaaa ccgaaatcctcacttgaagagacggaagttctgtttgtattcattgggtacgatcgcaaggcccgtacgcacaatccttacaa gctttcatcaaccttgaccaacatttatacaggttccagactccacgaagccggatgtgcaccctcatatcatgtggtgcgag gggatattgccacggccaccgaaggagtgattataaatgctgctaacagcaaaggacaacctggcggaggggtgtgcg

gagcgctgtataagaaattcccggaaagcttcgatttacagccgatcgaagtaggaaaagcgcgactggtcaaaggtgc agctaaacatatcattcatgccgtaggaccaaacttcaacaaagtttcggaggttgaaggtgacaaacagttggcagagg cttatgagtccatcgctaagattgtcaacgataacaattacaagtcagtagcgattccactgttgtccaccggcatcttttccgg gaacaaagatcgactaacccaatcattgaaccatttgctgacagctttagacaccactgatgcagatgtagccatatactgc agggacaagaaatgggaaatgactctccaaggaagcagtggctaggagaagcagtggaggagatatgcatatccga gcacaagcgatggcaaaactttctcatatttggaagggaccaagtttcaccaggcggccaaggatatagcagaaattaat gccatgtggcccgttgcaacggaggccaatgagcaggtatgcatgtatatcctcggagaaagcatgagcagtattaggtc aagagtacagcgcctaaaagcctcacgtccagaacaaattactgtgtgctcatcctttccattgccgaagtatagaatcact ggtgtgcagaagatccaatgctcccagcctatattgttctcaccgaaagtgcctgcgtatattcatccaaggaagtatctcgtg gaaacaccaccggtagacgagactccggagccatcggcagagaaccaatccacagaggggacacctgaacaacca ccacttataaccgaggatgagaccaggactagaacgcctgagccgatcatcatcgaaggaggaagaaggatagcat aagittgctgtcagatggcccgacccaccaggtgctgcaagtcgaggcagacattcacgggccgccctctgtatctagctc cggggcaacgtcagccgagactaactcttacttcgcaaagagtatggagtttctggcgcgaccggtgcctgcgcctcgaac agtattcaggaaccctccacatcccgctccgcgcacaagaacaccgtcacttgcacccagcagggcctgctcgagaacc agcctagtttccaccccgccaggcgtgaatagggtgatcactagagaggagctcgaggcgcttaccccgtcacgcactcc tagcaggtcggtctcgagaaccagcctggtctccaacccgccaggcgtaaatagggtgattacaagaggaggtggtgag gcgttcgtagcacaacaacaatgacggttgatgcgggtgcatacatcttttcctccgacaccggtcaagggcatttacaac aaaaatcagtaaggcaaaccgtgctatccgaagtggtgttggagaggaccgaattggagatttcgtatgccccgcgcctc gaccaagaaaaagaagaattactacgcaagaaattacagttaaatcccacacctgctaacagaagcagataccagtcc aggaaggtggagaacatgaaagccataacagctagacgtattctgcaaggcctagggcattatttgaaggcagaagga aaagtggagtgctaccgaaccctgcatcctgttcctttgtattcatctagtgtgaaccgtgccttttcaagccccaaggtcgcag tggaagcctgtaacgccatgttgaaagagaactttccgactgtggcttcttactgtattattccagagtacgatgcctatttgga catggttgacggagcttcatgctgcttagacactgccagtttttgccctgcaaagctgcgcagctttccaaagaaacactccta tttggaacccacaatacgatcggcagtgccttcagcgatccagaacacgctccagaacgtcctggcagctgccacaaaa agaaattgcaatgtcacgcaaatgagagaattgcccgtattggattcggcggcctttaatgtggaatgcttcaagaaatatgc gtgtaataatgaatattgggaaacgtttaaagaaaaccccatcaggcttactgaagaaaacgtggtaaattacattaccaa attaaaaggaccaaaagctgctgctgtttttgggaagacacataatttgaatatgttggaggacataccaatggacaggtttgt aatggacttaaagagagacqtgaaagtgactccaggaacaaaacatactgaagaacggcccaaggtacaggtgatcc aggctgccgatccgctagcaacagcgtatctgtgcggaatccaccgagagctggttaggagattaaatgcggtcctgcttc cgaacattcatacactgtttgatatgtcggctgaagactttgacgctattatagccgagcacttccagcctggggattgtgttctg gaaactgacatcgcgtcgtttgataaaagtgaggacgacgccatggctctgaccgcgttaatgattctggaagacttaggtg tggacgcagagctgttgacgctgattgaggcggctttcggcgaaatttcatcaatacatttgcccactaaaactaaatttaaat tcggagccatgatgaaatctggaatgttcctcacactgtttgtgaacacagtcattaacattgtaatcgcaagcagagtgttga gagaacggctaaccggatcaccatgtgcagcattcattggagatgacaatatcgtgaaaggagtcaaatcggacaaatta atggcagacaggtgcgccacctggttgaatatggaagtcaagattatagatgctgtgggggggagaaagcgccttatttct gtggagggtttattttgtgtgactccgtgaccggcacagcgtgccgtgtggcagaccccctaaaaaggctgtttaagcttggc aaacctctggcagcagacgatgaacatgatgatgacaggagaagggcattgcatgaagagtcaacacgctggaaccg agtgggtattctttcagagctgtgcaaggcagtagaatcaaggtatgaaaccgtaggaacttccatcatagttatggccatga ctactctagctagcagtgttaaatcattcagctacctgagaggggcccctataactctctacggctaacctgaatggactacg acatagtctagtccgccaagtotagaccatgtctggtcgtaaagctcagggaaaaaccctgggcgtcaatatggtacgacg caaggatttatctttttctttttgttcaacattttgactggaaaaaagatcacagcccacctaaagaggttgtggaaaatgctgga cccaagacaaggcttggctgttctaaggaaagtcaagagagtggtggccagtttgatgagaggattgtcctcaaggaaac gccgttcccatgatgttctgactgtgcaattcctaattttgggaatgctgttgatgacgggtggagtgaccttggtgcggaaaaa tttggaagccaagtactggtgcccagactcaatggaatacaactgtcccaatctcagtcccaagagaggagccagatgaca aagggccattgacttgcctacgcatgaaaaccatggtttgaagacccggcaagaaaaatggatgactggaagaatgggt

gaaaggcaactccaaaagattgagagatggttcgtgaggaaccccttttttgcagtgacggctctgaccattgcctaccttgt gggaagcaacatgacgcaacgagtcgtgattgccctactggtcttggctgttggtccggcctactcagctcactgcattgga attactgacagggatttcattgagggggtgcatggaggaacttgggtttcagctaccctggagcaagacaagtgtgtcactgt tatggcccctgacaagccttcattggacatctcactagagacagtagccattgatagacctgctgaggtgaggaaagtgtgt tacaatgcagttctcactcatgtgaagattaatgacaagtgccccagcactggagaggcccacctagctgaagagaacga aggggacaatgcgtgcaagcgcacttattctgatagaggctggggcaatggctgtggcctatttgggaaagggagcattgt aattgcatgtaggggccaagcaggaaaattggaataccgacattaagactctcaagtttgatgccctgtcaggctcccagg aagtcgagttcattgggtatggaaaagctacactggaatgccaggtgcaaactgcggtggactttggtaacagttacatcgc tgagatggaaacagagagctggatagtggacagacagtgggcccaggacttgaccctgccatggcagagtggaagtgg cggggtgtgggggggggggggggtgtgcstcatcttgtcgaatttgaacctccgcatgccgccactatcagagtactggccctgggaaa ccaggaaggctccttgaaaacagctcttactggcgcaatgagggttacaaaggacacaaatgacaacaacctttacaaa ctacatggtggacatgttlcttgcagagtgaaattgtcagctttgacactcaagggggacatcctacaaaatatgcactgacaa aatgttttttgtcaagaacccaactgacactggccatggcactgttgtgatgcaggtgaaagtgtcaaaaggagccccctgc caatgatgatgaagtgctgattgaggtgaacccaccttttggagacagctacattatcgttgggagaggagattcacgtctca cttaccagtggcacaaagagggaagctcaataggaaagttgttcactcagaccatgaaaggcgtggaacgcctggccgt catgggagacaccgcctgggatttcagctccgctggagggttcttcacttcggttgggaaaggaattcatacggtgtttggctc tgcctttcaggggctatttggcggcttgaactggataacaaaggtcatcatgggggcggtacttatatgggttggcatcaaca caagaaacatgacaatgtccatgagcatgatcttggtaggagtgatcatgatgtttttgtctctaggagttggggcgtaagcg gcccctataactctctacggctaacctgaatggactacgacatagtctagtccgccaagtctagagcttaccatgaccgagt acaageccaeggtgegeetegecaecegegaegaegteeceagggeegtaegeaeetegeegeegtegeegaet accccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactettectcacgc gcgtcgggctcgacatcggcaaggtgtgggtcgcggacgacggcgcgcggtggcggtctggaccacgccggagagc gtcgaagcggggggggggtgttcgccgagatcggcccgcgcatggccgagttgagcggttcccggctggccgcagcag cagatggaaggcotcotggcgccgcaccggcccaaggagcccgcgtggttcotggccaccgtcggcgtctcgcccgac caccagggcaaggtctgggcagcgccgtcgtgctccccggagtggaggcggcgagcgcggggtgcccgctt cctggagacctccgcgccccgcaacctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgagtgcccga aaggagcgcacgaccccatgatcgctagaccatggggtaccgagtatgttacgtgcaaaggtgattgtcacccccgaa agaccatattgtgacacaccctcagtatcacgcccaaacatttacagccgcggtgtcaaaaaccgcgtggacgtggttaac aaacataattgaatacagcagcaattggcaagctgcttacatagaactcgcggcgattggcatgccgccttaaaatttttattt aattettgaagacgaaagggccaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattc aaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatt tccgtgtcgcccttattccctttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagtgctga agatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaaga acgttiticcaafgatgagcacttitaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggt cgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaa ctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggct ggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagc cctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggt gatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgta ggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgt ccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttacca

Fig. 80

cagcccattcctcagagctttgcagcggagcttcccgcagttgaggtagaagccaagcaggtcactgataatgaccatgc taatgccagagcgttttcgcatctggcttcaaaactgatcgaaacggaggtggacccatccgacacgatccttgacattgga agtgcgcccgccgcagaatgtattctaagcacaagtatcattgtatctgtccgatgagatgtgcggaagatccggacagat tgtataagtatgcaactaagctgaagaaaaactgtaaggaaataactgataaggaattggacaagaaaatgaaggagct ggccgccgtcatgagcgaccctgacctggaaactgagactatgtgcctccacgacgacgagtcgtgtcgctacgaaggg caagtcgctgtttaccaggatgtatacgcggttgacggaccgacaagtctctatcaccaagccaataagggagttagagtc gcctactggataggctttgacaccaccccttttatgtttaagaacttggctggagcatatccatcatactctaccaactgggccg acgaaaccgtgttaacggctcgtaacataggcctatgcagctctgacgttatggagcggtcacgtagagggatgtccattctt agaaagaagtatttgaaaccatccaacaatgttctattctctgttggctcgaccatctaccacgagaagagggacttactga gggtacgtcgttaaaagaatagctatcagtccaggcctgtatgggaagccttcaggctatgctacgatgcaccgcgag ggattcttgtgctgcaaagtgacagacacattgaacggggagagggtctcttttcccgtgtgcacgtatgtgccagctacatt gtgtgaccaaatgactggcatactggcaacagatgtcagtgcggacgacgcgcaaaaactgctggttgggctcaaccag cgtatagtcgtcaacggtcgcacccagagaaacaccaataccatgaaaaattaccttttgcccgtagtggcccaggcattt gctaggtgggcaaaggaatataaggaagatcaagaagatgaaaggccactaggactacgagatagacagttagtcatg gggtgttgttggggcttttagaaggcacaagataacatctatttataagcgcccggatacccaaaccatcatcaaagtgaaca gcgatttccactcattcgtgctgccccaggataggcagtaacacattggagatcgggctgagaacaagaatcaggaaaatg ttagaggagcacaaggagccgtcacctctcattaccgccgaggacgtacaagaagctaagtgcgcagccgatgaggct aaggaggtgcgtgaagccgaggagttgcgcgcagctctaccacctttggcagctgatgttgaggagcccactctggaagc cgatgtcgacttgatgttacaagaggctggggccggctcagtggagacacctcgtggcttgataaaggttaccagctacga tggcgaggacaagatcggctcttacgctgtgctttctccgcaggctgtactcaagagtgaaaaattatcttgcatccaccctct cgctgaacaagtcatagtgataacacactctggccgaaaagggcgttatgccgtggaaccataccatggtaaagtagtgg tcgtaaacaggtacctgcaccatattgccacacatggaggagcgctgaacactgatgaagaatattacaaaactgtcaag agggctcacaggcgagctggtggatcctcccttccatgaattcgcctacgagagtctgagaacacgaccagccgctcctta ccaagtaccaaccataggggtgtatggcgtgccaggatcaggcaagtctggcatcattaaaagcgcagtcaccaaaaaa gatctagtggtgagcgccaagaaagaaaactgtgcagaaattataagggacgtcaagaaaatgaaagggctggacgtc aalgccagaactglggactcagtgctcttgaatggatgcaaacaccccgtagagaccctgtatattgacgaagcttttgcttgt catgcaggtactctcagagcgctcatagccattataagacctaaaaaggcagtgctctgcggggatcccaaacagtgcgg tttttttaacatgatgtgcctgaaagtgcattttaaccacgagatttgcacacaagtcttccacaaaagcatctctcgccgttgca ctaaatctgtgacttcggtcgtcicaaccttgttttacgacaaaaaatgagaacgacgaatccgaaagagactaagattgt atagattacaaaggcaacgaaataatgacggcagctgcctctcaagggctgacccgtaaaggtgtgtatgccgttcggta caaggigaalgaaaatcctctglacgcacccacctcagaacatgtgaacgtcctactgacccgcacggaggaccgcatc aggagtggcaagcagagcatgatgccatcatgaggcacatcttggagagaccggaccctaccgacgtcttccagaataa ggcaaacgtgtgttgggccaaggctttagtgccggtgctgaagaccgctggcatagacatgaccactgaacaatggaac actgtggattattttgaaacggacaaagctcactcagcagagatagtattgaaccaactatgcgtgaggttctttggactcgat

U.S. Patent

ctggactccggtctattttctgcacccactgttccgttatccattaggaataatcactgggataactccccgtcgcctaacatgta cgggctgaataaagaagtggtccgtcagctctctcgcaggtacccacaactgcctcgggcagttgccactggaagagtct atgacatgaacactggtacactgcgcaattatgatccgcgcataaacctagtacactgtaaacagaagactgcctcatgcttt agtcctccaccataatgaacacccacagagtgacttttcttcattcgtcagcaaattgaagggcagaactgtcctggtggtcg gggaaaagttgtccgtcccaggcaaaatggttgactggttgtcagaccggcctgaggctaccttcagagctcggctggattt aggcatcccaggtgatgtgcccaaatatgacataatatttgttaatgtgaggaccccatataaataccatcactatcagcagt gtgaagaccatgccattaagcttagcatgttgaccaagaaagcttgtctgcatctgaatcccggcggaacctgtgtcagcat aggttatggttacgctgacagggccagcgaaagcatcattggtgctatagcgcggcagttcaagttttcccgggtatgcaaa ccgaaatcctcacttgaagagacggaagttctgtttgtattcattgggtacgatcgcaaggcccgtacgcacaatccttacaa gctttcatcaaccttgaccaacatttatacaggttccagactccacgaagccggatgtgcaccctcatatcatgtggtgcgag gggatattgccacggccaccgaaggagtgattataaatgctgctaacagcaaaggacaacctggcggaggggtgtgcg gagcgctgtataagaaattccnggaaagcttcgatttacagccgatcgaagtaggaaaagcgcgactggtcaaaggtgc agetaaacatatcattcatgccgtaggaccaaacttcaacaaagtttcggaggttgaaggtgacaaacagttggcagagg cttatgagtccatcgctaagattgtcaacgataacaattacaagtcagtagcgattccactgttgtccaccggcatcttttccgg gaacaaagatcgactaacccaatcattgaaccatttgctgacagctttagacaccactgatgcagatgtagccatatactgc agggacaagaaatgggaaatgactctcaaggaagcagtggctaggagagaagcagtggaggagatatgcatatccga gcacaagcgatggcaaaactttctcatatttggaagggaccaagtttcaccaggcggccaaggatatagcagaaattaat gccatgtggcccgttgcaacggaggccaatgagcaggtatgcatgtatatcctcggagaaagcatgagcagtattaggtc aagagtacagcgcctaaaagcctcacgtccagaacaaattactgtgtgctcatcctttccattgccgaagtatagaatcact ggtgtgcagaagatccaatgctcccagcctatattgttctcaccgaaagtgcctgcgtatattcatccaaggaagtatctcgtg gaaacaccaccggtagacgagactccggagccatcggcagagaaccaatccacagaggggacacctgaacaacca ccacttataaccgaggatgagaccaggactagaacgcctgagccgatcatcatcgaagaggaagaagaggatagcat aagtttgctgtcagatggcccgacccaccaggtgctgcaagtcgaggcagacattcacgggccgccctctgtatctagctc cggggcaacgtcagccgagactaactcttacttcgcaaagagtatggagtttctggcgcgaccggtgcctgcgcctcgaac agtattcaggaaccetecacatecegetecegegeacaagaacacegteacttgeacceageagggeetgetegagaace agcctagtttccaccccgccaggcgtgaatagggtgatcactagagaggagctcgaggcgcttacccccgtcacgcactcc tagcaggtcggtctcgagaaccagcctggtctccaacccgccaggcgtaaatagggtgattacaagagaggtggagttgag gcgttcgtagcacaacaacaatgacggtttgatgcgggtgcatacatcttttcctccgacaccggtcaagggcatttacaac aaaaatcagtaaggcaaacggtgctatccgaagtggtgttggagaggaccgaattggagatttcgtatgccccgcgctc gaccaagaaaaagaagaattactacgcaagaaattacagttaaatcccacacctgctaacagaagcagataccagtcc aggaaggtggagaacatgaaagccataacagctagacgtattctgcaaggcctagggcattatttgaaggcagaagga aaagtggagtgctaccgaaccctgcatcctgttcctttgtattcatctagtgtgaaccgtgccttttcaagccccaagtcgcag tggaagcctgtaacgccatgttgaaagagaactttccgactgtggcttcttactgtattattccagagtacgatgcctatttgga catggttgacggagcttcatgctgdcttagacactgccagtttttgccctgcaaagctgcgcagctttccaaagaaacactccta tttggaacccacaatacgatcggcagtgccttcagcgatccagaacacgctccagaacgtcctggcagctgccacaaaa agaaattgcaatgtcacgcaaatgagagaattgcccgtattggattcggcggcctttaatgtggaatgcttcaagaaatatgc gtgtaataatgaatattgggaaacgtttaaagaaaaccccatcaggcttactgaagaaaacgtggtaaattacattaccaa attaaaaggaccaaaagctgctgctctttttgcgaagacacataatttgaatatgttgcaggacataccaatggacaggtttgt aatggacttaaagagagacgtgaaagtgactccaggaacaaaacatactgaagaacggcccaaggtacaggtgatcc aggetgecgatecgetageaacagegtatetgtgeggaatecaeegagagetggttaggagattaaatgeggteetgette cgaacattcatacactgtttgatatgtcggctgaagactttgacgctattatagccgagcacttccagcctggggattgtgttctg gaaactgacatcgcgtcgtttgataaaagtgaggacgacgacgactotgaccgcgttaatgattctggaagacttaggtg tggacgcagagctgttgacgctgattgaggcggctttcggcgaaatttcatcaatacatttgcccactaaaactaaatttaaat tcggagccatgatgaaatctggaatgttcctcacactgtttgtgaacacagtcattaacattgtaatcgcaagcagagtgttga gagaacggctaaccggatcaccatgtgcagcattcattggagatgacaatatcgtgaaaggagtcaaatcggacaaatta atggcagacaggtgcgccacctggttgaatatggaagtcaagattatagatgctgtggtgggcgagaaagcgccttatttct gtggagggtttattttgtgtgactccgtgaccggcacagcgtgccgtgtggcagaccccctaaaaaggctgtttaagcttggc aaacctctggcagcagacgatgaacatgatgatgacaggagaagggcattgcatgaagagtcaacacgctggaaccg

U.S. Patent

agtgggtattctttcagagctgtgcaaggcagtagaatcaaggtatgaaaccgtaggaacttccatcatagttatggccatga ctactctagctagcagtgttaantcattcagctacctgagaggggcccctataactctctacggctaacctgaatggactacg acatagtctagtccgccaagtctagaccatgagcggccggaaggctcagggcaagaccctgggcgtgaacatggtgag gcgcggcgtgcgcagcctctcccaacaagatcaagcagaagaccaagatcggcaacagacccggaccgagccg gggcgtccaggggttcatcttcttcttcttgttcaacatcctcacaggtaagaagatcacggctcacctgaagaggctctgga agatgctggaccctcgccagoggctcgcggtgctcagaaaggtgaagcgggtcgtcgcctccctgatgcgcggcctgtcc tctcgcaagaggcgctcccacgatgtgctcaccgtccaattcctcattctggaatgctgctgatgactggcggcgtgaccctg gtgcgcaagaaccgctggctgctgctgaatgtgaccagtgaggacctcgggtaagggcccctataactctctacggctaa cctgaatggactacgacatagtctagtccgccaagtctagagcttaccatgaccgagtacaagcccacggtgcgcctcgc caccegegaegaegtecceagggeegtaegeaecetegeegeegtegeegaetaeceegeeaecaecgt cgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaag cgagatcggcccgcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgcc gcaccggcccaaggagcccgcgtggttcctggccaccgtcggcgtctcgcccgaccaccagggcaagggtctgggcag cctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgcatga cccgcaagcccggtgcctgacgcccgcccacgaccgcagcgcccgacgaaggagcgcacgaccccatgatcg ctagaccatggggtaccgagtatgttacgtgcaaaggtgattgtcacccccgaaagaccatattgtgacacaccctcagt atcacgcccaaacatttacagccgcgdgtcaaaaaccgcgtggacgtggttaacatccctgctgggaggatcagccgta ttggcaagctgcttacatagaactcgcggcgattggcatgccgccttaaaatttttattttattttattttcttttcttttccgaatcgoatttt gtggcacttittcggggaaatgtgcgcggaacccctatttgtttattttictaaatacattcaaatatgtatccgctcatgagacaat aaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcg gcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggt tacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaa gttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatga cttggttgagtactcaccagtcaccagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgccataac catgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacat actggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggtttattgctgataaatctgga gccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacga cggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgt cagaccaagtttactcatatatactttagattgatttaaaacttcattittaatttaaaaggatctaggtgaagatcctttttgataat ctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaga ccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggcca ccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagt cgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcaca cagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagcattgagaaagcgccacqcttccc gaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgaggggggcttccaggg ggaaacgcctggtatctttatagtcctgtcggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggg gagcctatggaaaaacgccagcaacgcgagctcgatttaggtgacactata (SEQ ID NO: 10)

cagcccattcctcagagctttgcagcggagcttcccgcagtttgaggtagaagccaagcaggtcactgataatgaccatgc taatgccagagcgttttcgcatctggcttcaaaactgatcgaaacggaggtggacccatccgacacgatccttgacattgga agtgcgcccgccgcagaatgtattctaagcacaagtatcattgtatctgtccgatgagatgtgcggaagatccggacagat tgtataagtatgcaactaagctgaagaaaaactgtaaggaaataactgataaggaattggacaagaaaatgaaggagct ggccgccgtcatgagcgaccctgacctggaaactgagactatgtgcctccacgacgacgagtcgtgtcgctacgaaggg caagtcgctgtttaccaggatgtatacgcggttgacggaccgacaagtctctatcaccaagccaataagggagttagagtc gcctactggataggctttgacaccaccccttttatgtttaagaacttggctggagcatatccatcatcatactctaccaactgggccg acgaaaccgtgttaacggctcgtaacataggcctatgcagctctgacgttatggagcggtcacgtagagggatgtccattctt agaaagaagtattigaaaccatccaacaatgttctattctctgttggctcgaccatctaccacgagaagagggacttactga gggtacgtcgttaaaagaatagctatcagtccaggcctgtatgggaagccttcaggctatgctgctacgatgcaccgcgag ggattettgtgctgcaaagtgacagacacattgaacggggagagggtetetttteccgtgtgcacgtatgtgccagetacatt gtgtgaccaaatgactggcatactggcaacagatgtcagtgcggacgacgcgcaaaaactgctggttgggctcaaccag cgtatagtcgtcaacggtcgcacccagagaaacaccaataccatgaaaaattaccttttgcccgtagtggcccaggcattt gctaggtgggcaaaggaatataaggaagatcaagaagatgaaaggccactaggactacgagatagacagttagtcatg gggtgttgttgggcttttagaaggcacaagataacatctatttataagcgcccggatacccaaaccatcatcaaagtgaaca gcgatttccactcattcgtgctgccccaggataggcagtaacacattggagatcgggctgagaacaagaatcaggaaaatg ttagaggagcacaaggagccgtcacctctcattaccgccgaggacgtacaagaagctaagtgcgcagccgatgaggct aaggaggtgcgtgaagccgaggagttgcgcgcagctctaccacctttggcagctgatgttgaggagcccactctggaagc cgatgtcgacttgatgttacaagaggctggggccggctcagtggagacacctcgtggcttgataaaggttaccagctacga tggcgaggacaagatcggctcttacgctgtgctttctccgcaggctgtactcaagagtgaaaaattatcttgcatccaccctct cgctgaacaagtcatagtgataacacactctggccgaaaagggcgttatgccgtgaaccataccatggtaaagtagtgg tcgtaaacaggtacctgcaccatattgccacacatggaggagcgctgaacactgatgaagaatattacaaaactgtcaag agggctcacaggcgagctggtggatcctcccttccatgaattcgcctacgagagtctgagaacacgaccagccgctcctta ccaagtaccaaccataggggtgtatggcgtgccaggatcaggcaagtctggcatcattaaaagcgcagtcaccaaaaaa gatctagtggtgagcgccaagaaagaaaactgtgcagaaattataagggacgtcaagaaaatgaaagggctggacgtc aatgccagaactgtggactcagtgctcttgaatggatgcaaacaccccgtagagaccctgtatattgacgaagcttttgcttgt catgcaggtactotcagagcgctcatagccattataagacctaaaaaggcagtgctctgcggggatcccaaacagtgcgg ttitittaacatgatgtgcctgaaagtgcattttaaccacgagatttgcacacaagtcttccacaaaagcatctctcgccgttgca ctaaatctgtgacttcggtcgtctcaaccttgttttacgacaaaaaatgagaacgacgacgaatccgaaagagactaagattgt atagattacaaaggcaacgatatgacggcagctgcctctcaagggctgacccgtaaaggtgtgtatgccgttcggtacaa ggtgaatgaaaatcctctgtacgcacccacctcagaacatgtgaacgtcctactgacccgcacggaggaccgcatcgtgt agtggcaagcagagcatgatgccatcatgaggcacatcttggagagaccggaccctaccgacgtcttccagaataaggc aaacgtgtgttgggccaaggctttagtgccggtgctgaagaccgctggcatagacatgaccactgaacaatggaacactg tggattattttgaaacggacaaagctcactcagcagagatagtattgaaccaactatgcgtgaggttctttggactcgatctgg actcoggtctattttctgcacccactgttccgttatccattaggaataatcactgggataactccccgtcgcctaacatgtacgg gctgaataaagaagtggtccgtcagctctctcgcaggtacccacaactgcctcgggcagttgccactggaagagtctatga catgaacactggtacactgcgcaattatgatccgcgcataaacctagtacctgtaaacagaagactgcctcatgctttagtc ctccaccataatgaacaccccacagagtgactttcttcattcgtcagcaaattgaagggcagaactgtcctggtggtcgggg aaaagttgtccgtcccaggcaaaatggttgactggttgtcagaccggcctgaggctaccttcagagctcggctggatttagg catcccaggtgatgtgcccaaatatgacataatatttgttaatgtgaggaccccatataaataccatcactatcagcagtgtg aagaccatgccattaagcttagcatgttgaccaagaaagcttgtctgcatctgaatcccggcggaacctgtgtcagcatagg ttatggttacgctgacagggccagcgaaagcatcattggtgctatagcgcggcagttcaagttttcccgggtatgcaaaccg aaateetcacttgaagaggacggaagttetgtttgtatteattgggtacgategeaaggeeegtacgacaateettacaagett tcatcaaccttgaccaacatttatacaggttccagactccacgaagccggatgtgcaccctcatatcatgtggtgcgagggg atattgccacggccaccgaaggagtgattataaatgctgctaacagcaaaggacaacctggcggaggggtgtgcggag

cgctgtataagaaattcccggaaagcttcgatttacagccgatcgaagtaggaaaagcgcgactggtcaaaggtgcagct aaacatatcattcatgccgtaggaccaaacttcaacaaagtttcggaggttgaaggtgacaaacagttggcagaggcttat gagtccatcgctaagattgtccacgataacaattacaagtcagtagcgattccactgttgtccaccggcatcttttccgggaa caaagatcgactaacccaatcattgaaccatttgctgacagctttagacaccactgatgcagatgtagccatatactgcagg gacaagaaatgggaaatgactctcaaggaagcagtggctaggagaagcagtggaggagatatgcatatccgacga caagcgatggcaaaactttctcatatttggaagggaccaagtttcaccaggcggccaaggatatagcagaaattaatgcc atgtggcccgttgcaacggaggccaatgagcaggtatgcatgtatatcctcggagaaagcatgagcagtattaggtcgaa agtacagcgcctaaaagcctcacgtccagaacaaattactgtgtgctcatcctttccattgccgaagtatagaatcactggtg tgcagaagatccaatgctcccagcctatattgttctcaccgaaagtgcctgcgtatattcatccaaggaagtatctcgtggaa acaccaccggtagacgagactccggagccatcggcagagaaccaatccacagaggggacacctgaacaaccacca cttataaccgaggatgagaccaggactagaacgcctgagccgatcatcatcgaagaggaagaagaggatggcataagt ttgctgtcagatggcccgacccaccaggtgctgcaagtcgaggcagacattcacgggccgccctctgtatctagctcatcct gcaacgtcagccgagactaactcttacttcgcaaagagtatggagtttctggcgcgaccggtgcctgcgcctcgaacagta ttcaggaaccctccacatcccgctccgcgcacaagaacaccgtcacttgcacccagcagggcctgctcgagaaccagcc tagtttccaccccgccaggcgtgaatagggtgatcactagagaggagctcgaggcgcttaccccgtcacgcactcctagc aggtcggtctcgagaaccagctggtctccaacccgccaggcgtaaatagggtgattacaagagaggagtttgaggcgttc gtagcacaacaacaatgacggtttgatgcgggtgcatacatcttttcctccgacaccggtcaagggcatttacaacaaaaat cagtaaggcaaacggtgctatccgaagtggtgttggagaggaccgaattggagatttcgtatgccccgcgcctcgaccaa gaaaaagaagaattactacgcaagaaattacagttaaatccccacacctgctaacagaagcagataccagtccaggaag gtggagaacatgaaagccataacagctagacgtattctgcaaggcctagggcattatttgaaggcagaaggaaaagtgg agtgctaccgaaccctgcatcctgttcctttgtattcatctagtgtgaaccgtgccttttcaagccccaaggtcgcagtggaagc ctgtaacgccatgttgaaagagaactttccgactgtggcttcttactgtattattccagagtacgatgcctatttggacatggttg acggagcttcatgctgcttagacactgccagtttttgccctgcaaagctgcgcagctttccaaagaaacactcctatttggaac ccacaatacgatcggcagtgccttcagcgatccagaacacgctccagaacgtcctggcagctgccacaaaaagaaattg caatgtcacgcaaatgagagaattgcccgtattggattcggcggcctttaatgtggaatgcttcaagaaatatgcgtgtaata atgaatattgggaaacgtttaaagaaaaccccatcaggcttactgaagaaaacgtggtaaattacattaccaaattaaaag gaccaaaagctgctgctgcttttttgcgaagacacataatttgaatatgttgcaggacataccaatggacaggtttgtaatggact taaagagagacgtgaaagtgactccaggaacaaaacatactgaagaacggcccaaggtacaggtgatccaggctgcc gatccgctagcaacagcgtatctgtgcggaatccaccgagagctggttaggagattaaatgcggtcctgcttccgaacattc atacactgtttgatatgtcggctgaagactttgacgctattatagccgagcacttccagcctggggattgtgttctggaaactga catcgcgtcgtttgataaaagtgaggacgacgccatggctctgaccgcgttaatgattctggaagacttaggtgtggacgca gagctgttgacgctgattgaggcggctttcggcgaaatttcatcaatacatttgcccactaaaactaaattcaaattcggagcc atgatgaaatctggaatgttcctcacactgtttgtgaacacagtcattaacattgtaatcgcaagcagagtgttgagagaacg gctaaccggatcaccatgtgcagcattcattggagatgacaatatcgtgaaaggagtcaaatcggacaaattaatggcag acaggtgcgccacctggttgaatatggaagtcaagattatagatgctgtggtgggcgagaaagcgccttatttctgtggagg gtttattttgtgtgactccgtgaccggcacagcgtgccgtgtggcagaccccctaaaaaggctgtttaagcttggcaaacctct ggcagcagacgatgaacatgatgatgacaggagaagggcattgcatgaagagtcaacacgctggaaccgagtgggta ttctttcagagctgtgcaaggcagtagaatcaaggtatgaaaccgtaggaacttccatcatagttatggccatgactactcta gctagcagtgttaaatcattcagctacctgagaggggcccctataactctctacggctaacctgaatggactacgacatagt ctagtccgccaagtctagaccatgagcggccggaaggctcagggcaagaccctgggcgtgaacatggtgaggcgcgg cgtgcgcagcctctcccaacaagatcaagcagaagaccaagcagatcggcaacagacccggaccgagcggggcgtc caggggttcatcttcttcttcttgttcaacatcctcacaggtaagaagatcacggctcacctgaagaggctctggaagatgct ggaccctcgccaggggctcgcggtgctcagaaaggtgaagcgggtcgtcgcctccctgatgcgcggcctqtcctctcqca agaggcgctcccacgatgtgctcaccgtccaattcctcattctgggaatgctgttgatgacgggtggagtgaccttggtgcgg aaaaacagatggttgctcctaaatgtgacatctgaggacctcgggaaaacattctctgtgggcacaggcaactgcacaac aaacattttggaagccaagtactggtgcccagactcaatggaatacaactgtcccaatctcagtccaagagaggagccag gtcaagaagggccattgacttgcctacgcatgaaaaccatggtttgaagacccggcaagaaaaatggatgactggaaga

atgggtgaaaggcaactccaaaagattgagagatggttcgtgaggaaccccttttttgcagtgacggctctgaccattgcct accttgtgggaagcaacatgacgcaacgagtcgtgattgccctactggtcttggctgttggtccggcctactcagctcactgc attggaattactgacagggatttcattgagggggtgcatggaggaacttgggtttcagctaccctggagcaagacaagtgtg tcactgitatggcccctgacaagccttcattggacatctcactagagacagtagccattgatagacctgctgaggtgaggaa agtgtgttacaatgcagttctcactcatgtgaagattaatgacaagtgccccagcactggagaggcccacctagctgaaga gaacgaaggggacaatgcgtgcaagcgcacttattctgatagaggctggggcaatggctgtggcctatttgggaaaggg gagcacaattgcatgtaggggccaagcaggaaaattggaataccgacattaagactctcaagtttgatgccctgtcaggct cccaggaagtcgagttcattgggtatggaaaagctacactggaatgccaggtgcaaactgcggtggactttggtaacagtt gaagtggcggggtgtggagagagagatgcatcatcttgtcgaatttgaacctccgcatgccgccactatcagagtactggccct gggaaaccaggaaggctccttgaaaacagctcttactggcgcaatgagggttacaaaggacacaaatgacaacaacct ttacaaactacatggtggacatgtttcttgcagagtgaaattgtcagctttgacactcaaggggacatcctacaaaatatgca ctgacaaaatgttttttgtcaagaacccaactgacactggccatggcactgttgtgatgcaggtgaaagtgtcaaaaggagc acgtctcacttaccagtggcacaaagagggaagctcaataggaaagttgttcactcagaccatgaaaggcgtggaacgc ctggccgtcatgggagacaccgcctgggatttcagctccgctggagggttcttcacttcggttgggaaaggaattcatacggt atcaacaagaaacatgacaatgtccatgagcatgatcttggtaggagtgatcatgatgtttttgtctctaggagttggggc gtaageggcccctataactetetacggctaacetgaatggactacgacatagtetagtccgccaagtetagagettaccatg accgagtacaagcccacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgcgttc gccgactaccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactettc ctcacgcgcgtcgggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccg gagagegtegaagegggggggggtgttegeegagateggeeegegeatggeegagttgageggtteeegggtgteeegag cagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcggcgtctcg cccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcgcgcggggtgc ccgccttcctggagacctccgcgcccccgcaacctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgag gaccgaaaggagcgcacgaccccatgatcgctagaccatggggtaccgagtatgttacgtgcaaaggtgattgtcaccc cccgaaagaccatattgtgacacaccctcagtatcacgcccaaacatttacagccgcggtgtcaaaaaccgcgtggacgt ggttaacatccctgctgggaggatcagccgtaattattataattggcttggtgctggctactattgtggccatgtacgtgctgac caaccagaaacataattgaatacagcagcaattggcaagctgcttacatagaactcgcggcgattgcatgccgccttaaa gggaattaattettgaagacgaaagggccaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaa tacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtatt caacatticcgtgtcgcccttattcccttitttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaag atgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccc cgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtgttgacgccgggcaagagc aactoggtogcogcatacactattotcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcat gaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatg aagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcg ccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccag atggtaagccctcccgtatcgtagttatctacacgacgggggggtcaggcaactatggatgaacgaaatagacagatcgct aatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtca gctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagatac caaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaa

Fig. 8V







WN RepliVAX p0 Fig. 10 WN RepliVAX p10





Fig.12A





PSEUDOINFECTIOUS FLAVIVIRUS AND **USES THEREOF**

This application is a Continuation of U.S. patent application Ser. No. 11/711,532 filed Feb. 27, 2007 (currently pend-5 ing), which is a non-provisional application of U.S. Provisional Application No. 60/777,189 filed Feb. 27, 2006. Priority is claimed to all the above referenced applications and the content of each of the above-referenced applications is incorporated herein by reference in its entirety.

FEDERAL FUNDING LEGEND

This invention was produced in part using funds obtained through National Institute of Health grants (R01AI053135 15 and 1U54AI057156-010004). Consequently, the federal government has certain rights in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the fields of molecular biology, virology and immunology. In general, the present invention discloses construction of replication-deficient viruses belonging to the Flaviviridae family and their use as 25 vaccine in prevention of diseases caused by viruses belonging to this family. More specifically, the present invention provides replication-deficient flaviviruses or pseudoinfectious flaviviruses (PIV aka RepliVAX) and discloses its use as preventive vaccines against flavivirus-associated diseases. 30

2. Description of the Related Art

The Flavivirus genus of the Flaviviridae family contains a variety of important human and animal pathogens and have been classified into four distinct antigenic complexes based on differences in reactivity in immunological tests. Generally, 35 the flaviviruses circulate between avian or mammalian amplifying hosts and mosquito or tick vectors.

The flavivirus genome is a single-stranded capped RNA of positive polarity lacking a 3' terminal poly(A) sequence. It encodes a single polypeptide that is co- and post-translation- 40 ally processed into viral structural proteins, C, prM/M, and E, forming viral particles, and the nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, required for replication of viral genome and its packaging into infectious virions (Chambers, 1990). Virions contain a single copy of 45 viral genomic RNA packaged into a C protein-containing nucleocapsid, surrounded by lipid envelope holding heterodimers of M and E proteins. In contrast to many other enveloped viruses, interaction between nucleocapsid and envelope spikes is not very specific and M/E-containing enve- 50 lope can efficiently form around nucleocapsid derived from heterologous flavivirus, demonstrating limited level of homology in capsid sequence (Lorenz, 2002). Alternatively, expression of prM and E in the absence of C can lead to formation of subviral particles (SVPs), containing no RNA or 55 C protein (Mason, 1991).

PrM/M-E cassettes producing subviral particles have been the basis of several vaccine candidates that are known in the art. These vaccine candidates include subunit (Konishi, 1992; 2001; 2002; Qiao, 2004), DNA (Phillpotts, 1996; Kochel, 60 1997; Schmaljohn, 1997; Colombage, 1998; Aberle, 1999; Konishi, 2000; Konishi, 2000; Kochel, 2000; Davis, 2001), and live-vectored (Mason, 1991; Konishi, 1992; Pincus, 1992; Fonseca, 1994; Pugachev, 1995; Colombage, 1998; Kanesa, 2000; Minke, 2004) vaccines. However, these vac- 65 cines have serious disadvantages. For instance, the subunit vaccines are safe to use but difficult to produce large quanti-

ties; the DNA vaccines are poorly immunogenic, and the viral vectored vaccines suffer from lack of potency in the presence of vector immunity.

Therefore, in spite of a great concern about flavivirusassociated diseases and continuing spread of the flaviviruses into the new areas, antiviral therapeutics have not yet been developed for these infections, and a very limited number of approved vaccines have been produced to-date. Inactivated viral vaccines (INVs) have been licensed to prevent tickborne encephalitis (TBEV) and Japanese encephalitis (JEV). However, like other inactivated viral vaccines, these vaccines have low limited potency and require multiple vaccinations. Despite these drawbacks the Japanese encephalitis and tickborne encephalitis INVs have an advantage of good safety records. The only licensed live-attenuated vaccine (LAV) for a flavivirus is the widely utilized live-attenuated vaccine based on the yellow fever virus (YFV) 17D strain that was developed by serial passaging of the wild type Asibi strain of yellow fever virus in chicken embryo tissues. Although this 20 live-attenuated vaccine is considered very safe and effective, cases of yellow fever in vaccinees have been reported, including a recent case in a US military recruit (Gerasimon, 2005). Furthermore, this vaccine is not recommended for use in infants, pregnant women or the immunocompromised individuals due to adverse effects, including vaccine-associated encephalitis.

However, the development of the reverse genetics systems for flaviviruses has led to the production and designing of new types of live-attenuated vaccine, based on rational attenuation of these viruses. This new class of vaccines includes yellow fever virus 17D-based chimeras, in which the yellow fever virus prM-E-encoding genome fragment cassette has been replaced with the prM-E-cassette derived from heterologous flaviviruses (Chambers, 1999). Similar chimeric virus-based approach was applied for dengue- and TBE-based backbones (Pletnev, 2002; Huang, 2003). In most cases, chimeric flaviviruses demonstrate a highly attenuated phenotype and are capable of eliciting efficient protective immune response and protect against following infection with viruses, whose structural proteins are expressed by the chimeras (Monath, 2002). Effective vaccination with these chimeric vaccine candidates appears not to be prevented by pre-existing "vector" immunity (Monath, 2002), which has interfered with potency of recombinant viral vaccines based on other viral vectors. Further, although chimeric flaviviruses might provide a reasonably universal approach to producing new vaccines, there are concerns that the chimeras themselves might be pathogenic (Chambers, 1999) at least in the immunocompromised individuals, or that pathogenic chimeras might arise, since mutations have been detected during the process of propagation of these viruses (Pugachev, 2004).

Another promising direction in vaccine development is based on creating of irreparable deletions in flavivirus genome that make productive virus replication in the vaccinated host either a less efficient or an impossible event. In the latter case, viral genomes encoding the entire replicative machinery, but lacking, for instance, the C-coding region, can be delivered for in vivo immunization either as in vitrosynthesized RNA, capable of self-replication (Kofler, 2004; Aberle, 2005), or, probably, in DNA form (under control of the RNA polymerase II promoters or as in vitro-synthesized RNA, capable of self-replication (Kofler, 2004; Aberle, 2005). Direct immunization with in vitro synthesized defective RNA genomes, which specifies the production of SVPs in the absence of a complete viral replication cycle, has been demonstrated to be safe and effective in producing protective immunity (Kofler, 2004; Aberle, 2005). However, there may

be significant obstacles in producing an RNA-based vaccine candidate, due to synthesis, stability, and delivery issues.

Thus, prior art is deficient is deficient in a safe, potent and effective type of vaccine that can be used against diseases caused by infection with viruses belonging to the Flaviviridae ⁵ family. The present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, there is provided a replication-deficient pseudoinfectious virus of Flaviviridae family. Such a replication-deficient pseudoinfectious virus comprises: a deletion in the nucleotide sequence encoding capsid (C) protein such that the deletion does not ¹⁵ disrupt the RNA sequence required for genome cyclization, the signal sequence for prM protein that is required for the proper maturation of prM/M or a combination thereof, where the replication-deficient pseudoinfectious virus replicates only in cells expressing C protein or C, prM, envelope protein, mutated C protein, mutated prM, mutated envelope protein or combinations thereof of the virus of the Flaviviridae family.

In another related embodiment of the present invention, there is provided a cell culture system expressing C protein or ²⁵ C, prM, envelope protein, mutated C protein, mutated prM, mutated envelope protein or combinations thereof of the virus of the Flaviviridae family effective to enable propagation of the above-described replication-deficient pseudoinfectious virus of the Flaviviridae family under suitable conditions. ³⁰

In yet another embodiment of the present invention, there is provided a method of producing the replication-deficient pseudoinfectious virus of the Flaviviridae family described above. Such a method comprises generating a replicationdeficient pseudoinfectious virus of the Flaviviridae family 35 that comprises deletion in the capsid gene such that the deletion does not disrupt the RNA sequence required for genome cyclization, the signal sequence for prM protein that is required for the proper maturation of prM/M or a combination thereof; generating a cell line that expresses C protein or 40 C, prM, envelope protein, mutated C protein, mutated prM, mutated envelope protein or combinations thereof of the virus of the Flaviviridae family, where the cell line provides high levels of the proteins of the Flaviviridae needed for propagation of the replication-deficient pseudoinfectious virus of the 45 Flaviviridae family; and infecting the cell line with the pseudoinfectious virus of the Flaviviridae family, thereby producing the replication-deficient pseudoinfectious virus of the Flaviviridae family.

In another related embodiment of the present invention, ⁵⁰ there is provided a pharmaceutical composition, comprising the replication-deficient pseudoinfectious virus of the Flaviviridae family produced by the method described herein.

In a further related embodiment of the present invention, there is provided a method of protecting a subject from infec- ⁵⁵ tions resulting from exposure to Flaviviridae. Such a method comprises administering to the subject an immunologically effective amount of the pharmaceutical composition produced by the method described herein, that elicits an immune response against the Flaviviridae in the subject, thereby pro- ⁶⁰ tecting the subject from the infections.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of flavivirus PIV rep-65 lication in the cells producing C or all of the viral structural proteins for trans-complementation of the defect. Replication

of PIVs in normal cells in vivo or in vitro leads to release SVPs having no nucleocapsid.

FIGS. **2A-2**C show that YFV C and YFV C, prM and E-expressing cell lines can complement replication of YF PIV. FIG. **2**A is a schematic representation of YFV and GFPexpressing YF PIV genome. FIG. **2**B is a schematic representation of VEEV replicons expressing Pac gene and YFV C with the signal peptide of prM (anchored C; VEErep/C1/Pac), or anchored C with 20 a. a. of prM (VEErep/C2/Pac), or all of the YFV structural proteins (VEErep/C-prM-E/Pac). FIG. **2**C shows the release of YF PIV by the cell lines transfected with in vitro-synthesized PIV genome. Media was replaced at the indicated time points, and titers of PIVs were determined. Arrows indicate time points when cells were subpassaged at a 1:5 ratio. EIGS **3**A **3**B show growth curves of YE PIV on the pack

FIGS. **3**A-**3**B show growth curves of YF PIV on the packaging cell lines. BHK-21 cells containing VEErep/C2/Pac and VEErep/C-prM-E/Pac replicons were infected with YF PIV at indicated MOIs in infectious units per cell. At the indicated times, media was replaced and titers of released PIV were determined. Arrows indicate time points when cells were subpassaged at 1:5 ratio. FIG. **3**A shows growth curve at MOI 10 inf.u/cell and FIG. **3**B shows growth curve at MOI 0.1 inf.u/cell.

FIGS. 4A-4C show that cells expressing codon-optimized C gene produced YF PIV. FIG. 4A shows the nucleotide sequence of synthetic gene. The introduced mutations are indicated by lowercase letters (SEQ ID NO: 1). FIG. 4B shows growth curves of YF PIV on the packaging cell lines. BHK-21 cells containing VEErep/C2/Pac, VEErep/C-prM-E/Pac rep-licons were infected with YF PIV at indicated MOIs in infectious units per cell. At the indicated times, media was replaced and titers of released PIV were determined. FIG. 4C shows plaques developed in VEErep/C2opt/Pac-containing cell line by YFV and YF PIV after 4 days of incubation at 37° C.

FIGS. **5**A-**5**C show that WN PIV develops spreading infection in packaging cells. FIG. **5**A is a schematic representation of WN PIV genome and VEEV replicon expressing WNV structural genes. FIG. **5**B shows that WN PIV produced foci of WNV antigen-positive cells (revealed with an antibody to NS1-upon infection of BHK(VEErep/C*-E*-Pac) cells after 70 hours of incubation. FIG. **5**C shows the same WN PIV preparations produced only single infected cells (revealed at 70 hours post infection with the same tragacanth staining method used in FIG. **5**B) upon infection of Vero cell monolayers.

FIGS. 6A-6C show detection of E protein upon release from cells infected with YF and WN PIVs. In FIG. 6A, BHK-21 cells were infected with YF PIV at an MOI of 5 inf.u/cell. The released SVPs were harvested and purified by ultracentrifugation. Samples were resolved by SDS PAGE, transferred to filters, E protein was detected by D1-4G2 MAB. Media harvested from uninfected cells, lane 1; media harvested from the cells infected with YF PIV at 48 h post infection, lane 2; media harvested from the cells infected with YF PIVs at 72 h post infection, lane 3; YFV $(2 \times 10^7 \text{ PFU})$, lane 4. In FIG. 6B, vero cells were infected with WN PIV for 24 hrs, and then portions of the clarified culture fluid (collected before any cell lysis was detected), were resolved by SDS PAGE, transferred to filters, and reacted with an E-specific MAB (7H2; Bioreliance). Reaction of the same samples with polyclonal sera failed to reveal any cell-associated non-structural proteins in this preparation (results not shown) confirming that the E protein was actively secreted. Sample of WNV, lane 1; media harvested from uninfected cells, lane 2; media harvested from the cells infected with WN PIV at 48 h post infection, lane 3. In FIG. **6**C, a western blot showing E protein content of fractions prepared form a sucrose density gradient obtained from SVPs harvested from normal (non-packaging) BHK cells electroporated with YFV PIV RNA. The peak of E protein reactivity (at 32% sucrose) corresponded to the density of SVPs and in agreement with this fact, migrated more slowly than YFV run in a side-by-side analyses (42%).

FIGS. 7A-7F show schematic representation of plasmids used for Yellow fever (YF) and West Nile (WN) pseudoinfectious virus (PIV) production. FIG. 7A shows pYFPIV, FIG. 10 7B shows pWNPIV, FIG. 7C shows pVEErep/C1/Pac, FIG. 7D shows pVEErep/C2/Pac, FIG. 7E shows pVEErep/C3/ PAc, FIG. 7F shows pVEErep/C*-E*-Pac.

FIGS. **8**A-**8**V show the sequences of the plasmids used herein. FIGS. **8**A-**8**D shows sequence of pYFPIV (SEQ ID 15 NO: 6), FIGS. **8**E-**8**H shows sequence of pVEErep/C1/Pac (SEQ ID NO: 7), FIGS. **8**I-**8**K shows sequence of pVEErep/ C2/Pac (SEQ ID NO: 8), FIGS. **8**L-**80** shows sequence of pVEErep/C-prM-E/Pac (SEQ ID NO: 9), FIGS. **8**P-**8**R shows sequence of pVEErep/C2opt/pac (SEQ ID NO: 10), FIGS. 20 **8**S-**8**V shows sequence of pVEErep/Copt-prM-E/Pac (SEQ ID NO:11).

FIG. **9** shows a schematic representation of overlapping regions of RepliVAX and the VEE replicon used to provide C in trans. ¹Thirty-six mutations were inserted into the VEErep/ ²⁵ pac-Ubi-C* to minimize homologous recombination with the fragment of C encoded by the RepliVAX genome. ²Position of 5' and 3' CS sequences in the RepliVAX genome.

FIG. **10** shows side by side comparison of infectious foci produced in the C-expressing cell line {BHK(VEErep/Pac- ³⁰ Ubi-C*)} by WN RepliVAX at passage 0 (from electroporation) and passage 10 reveals that better-growing variants are readily selected.

FIG. **11** shows titration of RepliVAX PIV produced in WHO-certified Vero cells containing a C-expression cassette ³⁵ (VEErep/Pac-Ubi-C*). Although the resulting PIV is of a slightly lower titer than that produced in BHK cells, the Vero cells multiple harvests of high titer PIV, which is not possible with BHK cells.

FIGS. 12A-12B show cyclization mutants. FIG. 12A 40 shows replication of WNV/IRES-RLuc replicon with singlebase, matching CS mutations demonstrates that some singlebase mutations replicate at WT levels. Left part of panel shows the test genome above the 5' and 3' CS sequences. Right side shows replication levels detected using Rluc 45 reporter, as a percentage of the WT replication levels. Underlined bases denotes mutated bases. FIG. 12B shows replication of WNV/IRES-RLuc replicon with matching the doublebase changes (m17) derived by combining m10 and m13 (Panel A), compared to replication levels detected with 50 mutants that combine the WT and mutated CS in either possible format, along with a mutant designed to produce an inactive polymerase (negative control). Left part of panel shows the test genome above the 5' and 3' CS sequences. Right side shows replication levels detected using Rluc 55 reporter, as a percentage of the WT replication levels. Underlined bases denotes mutated bases. * denotes no replication detected.

DETAILED DESCRIPTION OF THE INVENTION

60

Safe and effective vaccines have only been produced for a handful of diseases caused by flaviviruses. The classical inactivated viral vaccine (INV) and live-attenuated vaccine (LAV) methods that have been used to produce vaccines to YF, JE, 65 and TBEV have not yet yielded licensed products to prevent diseases caused by other flaviviruses, notably dengue and 6

West Nile encephalitis (WNE). There remain safety concerns about existing LAVs (residual virulence or reversion to virulence) and INV products (reactogenicity due to antigen load and adventitious antigens). Additionally, INVs usually require multiple vaccinations. Further, both types of vaccines are subject to production concerns, including the need to avoid reversion to virulence during propagation of live-attenuated vaccine, and due to the amounts of material needed to produce strong immune responses to the inactivated viral vaccine products and the need for high containment facilities to propagate the virulent viruses used to produce INV products. Although there are promising candidates for new types of flavivirus vaccines, the road to their development will need to overcome these problems.

The present invention in general, is drawn to construction and utilization of replication-deficient pseudoinfective viruses belonging to the Flaviviridae family. In this regard, the present invention describes the development a new type of replication-deficient flaviviruses also referred to as RepliVAX that combines the safety of inactivated vaccines with the efficacy and scalability of live attenuated vaccines. These flaviviruses also identified as pseudo-infectious viruses (PIVs) in the present invention contain genetically engineered flavivirus genomes with a deletion of most of the capsid (C)-encoding region, thereby preventing this genome from producing infectious progeny in normal cell lines or vaccinated animals. However, these pseudo-infectious viruses can be propagated in cell lines expressing either C, or a C-prM-E cassette, where they replicate to high levels. Thus, these pseudoinfectious flaviviruses cannot develop spreading infection in normal cells in vitro or in vivo due to lack of trans-complementation by C protein, and therefore are incapable of causing disease in animals.

In contrast to the vaccines and the methods to generate these vaccines that are known in the art, the present invention provides a system for industrial-scale production of pseudoinfectious flaviviruses that would make such vaccines cheaper to produce than inactivated vaccines at the same time making it safer to use than live-attenuated vaccines. It does so by providing a new type of recombinant vaccine that is capable of only single round of replication in the immunized animals or humans leading to release of subviral particles (SVPs) lacking the genetic material but serving as efficient immunogens.

The present invention has demonstrated that pseudoinfectious flaviviruses can be generated for either yellow fever virus (YFV) or West Nile virus (WNV). Based on this, the present invention contemplates that the method described herein could be broadly applicable to the development of vaccines against other flaviviruses. Further, infection of normal cell lines with such pseudoinfectious flaviviruses produced SVPs that lacked nucleocapsid and a genetic material. The pseudoinfectious flaviviruses described herein demonstrated inability to cause any disease and thus were safe. Additionally, these pseudoinfectious flaviviruses were immunogenic in mice due to competency for single round of replication and release of SVPs, presenting viral antigens. WN PIVs also protected mice from a lethal encephalitis following challenge with WNV.

The PIVs described herein could be produced in a manner that allows for high-yield production in cell culture, and inability to cause disease in animals. These products could be delivered to animals where their defective replication process prevents spread and disease, but permitted the production of SVPs, a flavivirus subunit immunogen that has been shown to be effective in eliciting an efficacious immune response against disease caused by several flaviviruses. The present invention also demonstrated that the pseudoinfectious flaviviruses approach could be applied to two distantly related mosquito-borne flaviviruses. The applicability of a similar technology to the development of RNA-based vaccines for a tick-borne flavivirus (Kofler, 2004) indicates 5 that the PIV-based technology will be applicable to more distantly related flaviviruses. Additionally, the work with TBEV RNA-based vaccines indicates that in addition to antibody responses to the SVPs (similar to that described herein), the introduction of replicationally active flavivirus genomes 10 into the cells of the vaccinated hosts will produce T-cell responses as well (Kofler, 2004; Aberle, 2005). Although the T cell responses were not measured herein, it is contemplated that the PIVs are capable of inducing T cell response that mimics those produced by viral infection. 15

Although the PIV vaccines described herein rely on the same flavivirus replication and SVP production strategy that was utilized by the RNA-based vaccines prepared for TBEV (Kofler, 2004; Aberle, 2005), these PIV vaccines do not require gene-gun delivery to animals, can be readily grown in 20 cell cultures, and can subjected to the same types of stabilization and storage (freeze drying) conditions currently being applied to the commercially produced YFV 17D vaccine, thus providing a scalable, storable, and marketable vaccine product. Preliminary studies on stability of WN RepliVAX have 25 shown that freeze-dried preparations show no detectable loss in titer when stored for 30 days at 4 C.

To develop the high-level growth conditions required for efficient trans-complementation (and hence yield) of pseudoinfectious flaviviruses, the present invention utilized cells 30 expressing high levels of C (or C-prM-E) from VEEV replicons. VEEV replicons are less cytopathic than the replicons derived from other alphaviruses and readily establish persistent replications in some cell lines of vertebrate and insect origin. This system appears to be suitable for production of 35 pseudoinfectious flaviviruses, since i) VEEV replicons are highly efficient in synthesis of heterologous proteins and, in the present invention synthesized C to the level required for flavivirus genome incapsidation. ii) VEEV replicons do not detectably interfere with flavivirus replication (Petrakova, 40 2005). Moreover, VEE replicons and the YF PIV genomes can replicate together in BHK-21 cells without causing CPE. iii) VEEV replicons can be packaged at high-titers into VEE virions that can be used for rapid establishment of the packaging cell lines producing flavivirus structural protein(s). 45

Furthermore, examination of the effect of context of C expression on yield of PIV indicated that the packaging cells expressing anchored form of C with an additional 20 a.a. of prM produced more particles than cells expressing anchored C alone, suggesting the importance of the proper sequence of 50 processing events in virions formation. The basis fcr the enhanced packaging efficiency by the construct containing the first 20 amino acids of prM is unclear but this phenomenon might be explained by a requirement of specific order of cleavage at the two nearby cleavage sites (NS2B/NS3- and 55 signal peptidase-specific) (Yamshchikov and Compans, 1994) and/or differences in distribution/stability of C protein products in these two different contexts. In addition, it was observed that co-expression of C with prM and E (VEErep/ C-prM-E/Pac) caused only minor increase in PIV yield com- 60 pared to VEErep/C2/Pac, which expressed anchor C with the fragment of prM.

When the codon-optimization of the VEEV replicon-encoded C genes was examined to determine if this alteration of the C gene sequence enhanced yield of PIV, it did not reveal 65 a strong difference in YFV PIV release from the cells not expressing a codon-optimized C gene. This observation sug8

gested that even with the non-optimized gene VEEV replicons appear to produce C at a saturating level. These results were consistent with other studies demonstrating that the cell lines that expressed VEEV replicons encoding the WNV C-E cassette produced level of E greater than those detected in WNV-infected cells. Despite the inability of the trans-expressed optimized C gene to increase vield of YF PIV, the cells harboring the VEEV replicon expressing Copt developed CPE and produced plaques when infected with YF PIV. This made a PIV infection in the Copt cells even more similar to infection developed by replication-competent virus. An additional advantage of the use of VEEV replicons encoding a YFV Copt gene in pseudoinfectious flavivirus production was the level of safety, since the changes in the codons reduced the chance of homologous recombination with the pseudoinfectious flavivirus genome. Furthermore, the Copt gene was also altered in its cyclization sequence (as described herein for the WNV C coding region in the BHK(VEErep/ C*-E*-Pac) cells), to reduce the chance of the recombination producing a replicationally active C-encoding flavivirus. To date, neither the WN nor YF PIV systems described herein have produced replicationally active flaviviruses that could be detected in either cell culture, or in highly susceptible animals. Additionally, in vivo experiments demonstrated that both YF and WN PIVs were safe and could not cause any disease even after i.c. inoculation of 3- to 4-day-old mice with the highest dose of the PIVs. Nevertheless, WN PIVs were capable of inducing high levels of neutralizing antibodies and protected mice against infection with replication competent WNV.

Furthermore, Hepatitis C ranks with AIDS as a major infectious cause of morbidity and mortality for which no vaccine is currently available. In Japan and Korea, HCV now exceeds hepatitis B in contributing to the development of hepatocellular carcinoma, one of the most common types of cancer and a common mode of death due to liver disease. This pattern is likely to become increasingly common in other Asian countries and elsewhere in the developing world, due to the increasing prevalence of HCV coupled with effective immunization against hepatitis B. In some communities in Egypt and elsewhere, the prevalence of hepatitis C infection is spectacularly high, likely due at least in part to traditional health care practices and/or the introduction of dangerous Western technologies in the past (e.g., needle-borne transmission of the virus during public health campaigns directed against schistosomiasis).

In many developing countries, where rates of liver cancer and cirrhosis are high, there is little effective control of hepatitis C during blood transfusion. Hepatitis C is also a major public health problem within the United States, where there are approximately 4 million carriers of HCV, many of whom are at risk of death due to end-stage liver disease or liver cancer. Currently it is estimated that there are between 8,000 and 10,000 deaths annually due to hepatitis C in the United States. This number is likely to triple over the next 10-20 years, potentially exceeding the number of deaths due to AIDS, in the absence of new therapeutic or preventive measures.

Yet, no vaccine is available for prevention of this infection, and efforts (both national and international) to develop a vaccine are severely limited due to perceived technical difficulties, little interest in vaccine development generally on the part of big pharma, and the inertia of major funding agencies. And, as with many infectious diseases, it is the disadvantaged who are at greatest risk of serious liver disease or death due to hepatitis C.

To date attempts to create an effective vaccine against HCV infection have been unsuccessful. However, within last few years, the HCV field started to rapidly develop, and now this virus replicates in tissue culture to reasonably high titers, approaching 10^6 inf.u/ml. There is a number of obvious simi- 5 larities between the HCV genome and the genomes of other flaviviruses, like YF, JEV, TBE and others. Therefore, the strategy of designing replication-deficient flaviviruses can be applied not only to the members of the Flavivirus genus, but to *Hepacivirus* genus (that include HCV) as well. The HCV 10 capsid protein can produced by recombinant alphavirus replicons (based on SINV, VEEV EEEV and others) in a number of cell lines, including Huh-7 and Huh-7.5 cells that are currently known to be susceptible to HCV infection. Replication-deficient HCV genomes, lacking the capsid gene can 15 be transfected into the capsid-producing cell lines and will be packaged into infectious, capsid-containing particles. The successive rounds of infection required for the large-scale production, can be performed on these cells as well. However, in vivo, in the naïve hepatocytes (and possibly other cell 20 types), the HCV genomes lacking the complete capsid gene or no capsid gene at all, will produce only the nonstructural viral proteins, and glycoproteins E1 and E2. These proteins will be presented to immune system i) after proteasome degradation; ii) on the cell surface and iii) in the form of virus-like 25 particles with E1- and E2-containing envelope. Capsid deficiency will make virus incapable of spreading, and thus limited to the cells infected by the vaccinating dose.

In summary, the present invention demonstrated that capsid-deficient, pseudoinfectious flaviviruses i) could pro-30 duce a spreading infection in the cell lines expressing capsid or all of the flavivirus structural genes; ii) PIVs were incapable of producing spreading infection in normal cells, (iii) PIVs produced E protein containing SVPs when they infected normal cells; (iv) PIVs displayed a high level of safety in the 35 animals; (v) PIVs protected the mice from subsequent flavivirus infection. Taken together, the present invention demonstrated that flavivirus PIVs might be a safe, potent, and efficacious platform for development of vaccines against flavivirus infections and infections caused by viruses similar 40 to Flavivirus.

The present invention is directed to a replication-deficient pseudoinfectious Flaviviridae, comprising: a deletion in the nucleotide sequence encoding capsid (C) protein such that the deletion does not disrupt the RNA sequence required for 45 genome cyclization, the signal sequence for prM protein that is required for the proper maturation of prM/M or a combination thereof, where the Flaviviridae replicate only in cells expressing Cprotein or C, prM, envelope protein, mutated C protein, mutated prM, mutated envelope protein or combina- 50 tions thereof of a virus of the Flaviviridae family. Generally, the Flaviviridae comprises a virus belonging to the genus flavivirus, Hepacivirus or Pestivirus or other chimeras of said viruses created by exchanging the prM-E cassettes of other viruses with the prM-E cassettes of the pseudoinfectious Fla-55 viviridae. The examples of the viruses belonging to the genus Flavivirus are not limited to but may include yellow fever virus, West Nile virus, dengue virus, tick-borne encephalitis virus, Saint Louis encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis virus. Furthermore, the 60 example of the virus belonging to the genus Hepacivirus includes but is not limited to Hepatitis C virus and those belonging to the genus Pestivirus include but are not limited to Bovine virus diarrhea, a swine fever virus or a hog cholera virus.

In case of flavivirus, the nucleotide sequence encoding the C protein of the Flavivirus that is deleted may encode amino

acids 26 to 100 or a combination of amino acids within amino acids 26 to 100 of the C protein. Such combinations may include but are not limited to amino acids 26-93, 31-100 or 31-93. One of ordinary skill in the art can use the same guidelines to delete nucleotide sequence of C protein from other viruses belonging to the Flaviviridae family or other viruses having the same genetic makeup as these viruses. In general and applicable to all the viruses, the deleted gene is replaced by a gene encoding a marker protein or an antigen. The example of a marker protein may include but is not limited to a green fluorescent protein.

The present invention is also directed to a cell culture system expressing C protein or C, prM, envelope protein, mutated C protein, mutated prM, mutated envelope protein or combinations thereof of a virus of the Flaviviridae family, effective to enable propagation of the above-described replication-deficient Flaviviridae under suitable conditions. For this purpose, the cells expressing wild type or mutated proteins of the Flaviviridae may be generated using genetically engineered replicons derived from viral vectors.

In general, the gene encoding the protein(s) of the virus of the virus Flaviviridae family in the replicon is replaced by a codon-optimized version of the gene encoding the protein(s) of the virus such that the replacement reduces the ability of the cell line-encoded genes to recombine with the genome of the pseudoinfectious virus of the Flaviviridae family and/or increases the production of the pseudoinfectious virus of the Flaviviridae family.

For instance, such replicons may express a C protein that comprises mutations in at least 36 nucleotide positions of the gene encoding C protein of the virus of the Flaviviridae family. The replicon may express a C protein in the replicon that comprises unnatural cyclization sequences such that presence of the cyclization sequences reduces the chances of productive recombination of the replication-deficient pseudoinfective virus with natural viruses. Further, the replicon may express proteins comprising altered nucleotide sequences encoding truncated C-prM junction such that presence of such altered sequences enhances yield of the replicationdeficient pseudoinfective virus in cell culture, prM/E containing SVP yield in vivo or a combination thereof.

Furthermore, the replicons expressing the proteins of Flaviviridae are introduced into the cells by transfection with in vitro synthesized replicon RNAs, by transfection with plasmid DNAs designed to synthesize functional alphaviral replicons from cellular RNA-polymerase II-specific promoters or by infection with alphaviral replicons packaged inside the alphaviral structural proteins. The viral vectors used herein may be alphaviruses. Representative examples of such alphaviruses are not limited but may include Venezuelan Equine Encephalitis Virus (VEEV), Sindbis virus, Eastern Equine Encephalitis virus (EEEV), Western Equine Encephalitis virus (WEEV) or Ross River virus.

The present invention is further directed to a method of producing a replication-deficient pseudoinfectious virus of the Flaviviridae family, comprising; generating a replicationdeficient pseudoinfectious virus of the Flaviviridae family that comprises a deletion in the capsid gene such that the deletion does not disrupt the RNA sequence required for genome cyclization, the signal sequence for prM protein that is required for the proper maturation of prM/M or a combination thereof; generating a cell line that expresses C protein or C, prM, envelope protein, mutated C protein, mutated prM, mutated envelope protein or combinations thereof of a virus of the Flaviviridae family, where the cell line provides high levels of the proteins needed for propagation of the replication-deficient pseudoinfectious virus of the Flaviviridae fam-
ily; and infecting the cell line with the pseudoinfectious virus of the Flaviviridae family, thereby producing the replicationdeficient pseudoinfectious virus of the Flaviviridae family. All other aspects regarding the types of viruses, the position of deletions in the capsid gene, the method of generation of the cell line expressing the mutated and wild type proteins of the Flaviviridae, the type of replicons and the mutations within the replicons and the modifications in the gene encoding the mutated and wild type proteins of the Flaviviridae in the replicons are the same as discussed supra.

The present invention is also directed to a pharmaceutical composition, comprising the replication-deficient pseudoinfectious virus of the Flaviviridae family produced by the method described supra. The present invention is further 15 directed to a method of protecting a subject from infections resulting from exposure to Flaviviridae, comprising administering to the subject an immunologically effective amount of the pharmaceutical composition described herein, where the composition elicits an immune response against the Fla- 20 viviridae in the subject, thereby protecting the subject from the infections. Such a composition may be administered via intraperitoneal, intradermal, subcutaneous, intramuscular, oral, or intranasal route. Furthermore, the subject benefiting from use of this composition may be a human, or an animal. 25

As used herein, the term, "a" or "an" may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising", the words "a" or "an" may mean one or more than one. As used herein "another" or "other" may mean at least a second or more of the same or 30 different claim element or components thereof. As used herein, the term, "Flaviviridae" includes the genera Flavivirus, Hepacivirus and Pestivirus. The examples of virus belonging to the genus Flavivirus include but are not limited to yellow fever virus, West Nile virus, dengue virusm a tick 35 borne encephalitis virusm a Saint Louis encephalitis virus, a Japanese encephalitis virus or a Murray Valley encephalitis virus, Similarly, the example of virus belonging to the genus Hepacivirus includes but is not limited to Hepatitis C virus and those belonging to the genus Pestivirus include but are 40 not limited to Bovine virus diarrhea, a swine fever virus or a hog cholera virus.

Furthermore, although the present invention discloses the construction and utility of a replication-deficient pseudoinfectious Flaviviridae belonging to the genus Flavivirus, one 45 of ordinary skill in the art can use the same guidelines to construct chimeras comprising other viruses belonging to the Flaviviridae or to construct chimeras by exchanging the prM-E cassettes of viruses within the Flaviviridae or other similar viruses and the viruses within the Falviviridae.

The pharmaceutical compositions comprising the pseudoinfectious viruses belonging to the Flaviviridae family discussed herein may be administered concurrently or sequentially with each other or with other pharmaceutical composition(s). The effect of co-administration of such com- 55 positions is to protect an individual from the infections caused by such viruses and other vaccine-treatable disease. The composition described herein, the other pharmaceutical composition, or combination thereof can be administered independently, either systemically or locally, by any method standard 60 in the art, for example, subcutaneously, intravenously, parenterally, intraperitoneally, intradermally, intramuscularly, topically, enterally, rectally, nasally, buccally, vaginally or by inhalation spray, by drug pump or contained within transdermal patch or an implant. Dosage formulations of the 65 composition described herein may comprise conventional non-toxic, physiologically or pharmaceutically acceptable

carriers or vehicles suitable for the method of administration and are well known to an individual having ordinary skill in this art.

The composition described herein, the other pharmaceutical composition or combination thereof may be administered independently one or more times to achieve, maintain or improve upon a therapeutic effect. It is well within the skill of an artisan to determine dosage or whether a suitable dosage of either or both of the compositions comprises a single administered dose or multiple administered doses. An appropriate dosage depends on the subject's health, the protection of the individual from flaviviral infections, the route of administration and the formulation used.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

Example 1

Cell Cultures

The BHK-21 cells were provided by Paul Olivo (Washington University, St. Louis, Mo.). They were maintained at 37° C. in alpha minimum essential medium (aMEM) supplemented with 10% fetal bovine serum (FBS) and vitamins. WHO-certified Vero cells, originally prepared for use in human vaccine manufacture were provided by Dr. Steve Whitehead of the NIH. Vero cells were maintained in MEM containing 6% FBS.

Example 2

Plasmid Constructs

Standard recombinant DNA techniques were used for all plasmid constructions. A schematic representation of the plasmids used are shown in FIGS. 7A-7F. Maps and sequences are shown in FIGS. 8A-8F. The parental low-copy number plasmid pACNR/FLYF-17Dx containing infectious cDNA of YFV 17D strain genome was described elsewhere (Bredenbeek et al., 2003) and provided by Dr. Charles M. Rice (Rockefeller University, New York, N.Y.). pYFPIV contained defective YFV genome (YF PIV), in which fragment encoding amino acid. 26-93 of YF capsid gene was replaced by codon-optimized GFP gene derived from pEGFP-N1 (Clontech). The WN PIV genome (pWNPIV) was derived from a Texas 2002 infectious cDNA (Rossi et al., 2005), by fusion of codon 30 of C to codon 101 of C (see FIG. 5A). The plasmids pVEErep/C1/Pac, pVEErep/C2/Pac and pVEErep/ C-prM-E/Pac (FIG. 2A) encoded double subgenomic VEEV replicons, in which the first subgenomic promoter was driving transcription of the RNAs containing 5'UTR of VEEV 26S RNA followed by sequences, corresponding to nt 119-481, 119-541 and 119-2452 of YFV genome, respectively. The second subgenomic promoter was driving the expression of puromycin acetyltransferase (Pac) gene, whose product was making cells resistant to translational arrest caused by puromycin (Pur). Non-cytopathic VEEV replicons expressing the C-prM-E cassette of WNV {derived from a Sindbis virus replicon (Scholle et al., 2004)} fused to the Pac gene

55

(designated pVEErep/C*-E*-Pac) was created from a VEE non-cytopathic replicon (Petrakova et al., 2005); E-coding sequence was fused with Pac gene through a linker consisting of the first 9 codons of NS1 and the last 25 codons of NS2B, followed by 2 codons of NS3 fused directly to FMDV 2A (see FIG. **5**A). The codon-optimized sequence encoding YFV 17D capsid and first 20 amino acid of prM was designed using the codon frequency data described elsewhere (Haas et al., 1996). This gene was synthesized by PCR from the overlapping synthetic oligonucleotides. The amplified fragment was sequenced before cloning into expression cassettes VEErep/ C2opt/Pac and VEErep/Copt-prM-E/Pac. The latter replicons had essentially the same design as pVEErep/C2/Pac and pVEErep/C-prM-E/Pac, but contained codon-optimized sequence presented in FIG. **4**A.

Additionally, a chimeric WN-RepliVAX expressing the JEV prM-E has also been generated. This was constructed by substituting the prM and E genes of Nakayama strain of JEV in A RepliVAX encoding the WNV genome. The gene 20 exchange was achieved by direct fusion of the last codon of the truncated WNV C protein to the first codon of the prM coding sequence of JEV (Nakayama strain). The same fusion strategy was employed at the 3' end of the cassette, with the final codon of the JEV E protein fused directly to the first 25 codon of NS1 of WNV. These fusions were introduced into a BAC plasmid encoding the entire WN RepliVAX cDNA bounded by a T7 promoter and a ribozyme, and RNA recovered from this BAC DNA was introduced into BHK(VEErep/ Pac-Ubi-C*) cells. The resulting RepliVAX (designated JE 30 RepliVAX) formed spreading infectious foci on BHK (VEErep/Pac-Ubi-C*). As for WN RepliVAX, the foci formed on this cell line are smaller than those produced by a fully infectious WNV-JEV chimera. JE RepliVAX grows to titers approximately 10 times lower than WN RepliVAX, 35 achieving titers of over 106 U/ml in BHK(VEErep/Pac-Ubi-C*). As expected, JE RepliVAX reacts with JE-specific MAbs, and it is anticipated that like chimeric flaviviruses, JE RepliVAX will induce high levels of JEV-neutralizing antibodies, and protect against JE.

Example 3

RNA Transciptions

Plasmids were purified by centrifugation in CsCl gradients. Before the transcription reaction, the plasmids were linearized by XhoI (for pYFPIV) or MhuI (for VEE replicon and VEE helper encoding plasmids) or SwaI (for pWNPIV). RNAs were synthesized by SP6 or T7 RNA polymerase in the ⁵⁰ presence of cap analog. The yield and integrity of transcripts were analyzed by gel electrophoresis under non-denaturing conditions. Aliquots of transcription reactions were used for electroporation without additional purification.

Example 4

RNA Transfections and PIV Replication Analysis

Electroporation of BHK-21 cells was performed under 60 previously described conditions (Liljestrom et al., 1991). For establishing packaging cell cultures, Pur was added to the media to a concentration of 10 g/ml 24 h post electroporation of the VEEV replicons. Transfection of in vitro-synthesized YF PIV genome was performed 5 days later, when replicon-65 containing cells resumed efficient growth. Samples were harvested at the time points indicated in the figures by replacing

the media with the same media, containing Pur. In many experiments, PIV-secreting cells were split upon reaching the confluency.

VEEV replicons were packaged into VEEV infectious virions by co-electroporation of the in vitro synthesized replicon and 2 helper RNAs (Volkova et al., 2006) into BHK-21 cells. Replicon-containing viral particles were harvested 24 h post transfection and used for infecting of naïve BHK-21 cells, followed by Pur selection. In the case of WN PIV, the in vitro-synthesized PIV RNA was transfected into BHK cells containing VEErep/C*-E*-Pac replicon expressing WN C, prM and E and Pac [BHK(VEErep/C*-E*-PAC) cells]. THE scheme of the VEErep/C*-E*-PAC genome is presented in FIG. **5**A. Harvested PIVs were passaged on these cells using standard methods (Rossi et al., 2005).

Example 5

Measuring the Titers of YF PIV

For measuring the titers of released YF PIV, BHK-21 cells were seeded into six-well Costar dishes at a concentration of 5×10^5 cells/well. Four hours later, cells were infected with different dilutions of packaged replicons, and after 1 h incubation at 37° C. in an 5% CO₂ incubator, they were overlaid with 2 ml of MEM supplemented with 10% FBS. The numbers of infected cells were estimated by counting GFP-positive cells under an inverted UV microscope. The fraction of infected cells from the seed quantity was determined via counting of fluorescence-producing cells in a defined area of microscopic field. Counts for 5 different fields were averaged and recalculated for the titer corresponding to each serial dilution.

In the later experiments, titers were also measured by ³⁵ plaque assay on the monolayers of BHK-21 cells, carrying VEErep/Copt-prM-E/Pac replicon, using previously described conditions (Lemm et al., 1990), except cells were incubated under agarose for plaque development for 5 days, then fixed by 2.5% formaldehyde and stained with crystal ⁴⁰ violet.

Example 6

Passaging of YF PIVs

Packaging cell lines were established either by transfection of the in vitro-synthesized VEEV replicon RNAs or by infecting cells with the same replicons packaged into VEEV structural proteins at a multiplicity of infection (MOI) of 10 inf.u/ cell. After Pur selection, they were infected with YF PIV at different MOIs. Samples were harvested at the time points indicated in the figures by replacing the media.

Example 7

Analysis of YF SVP Production

BHK-21 cells were seeded at a concentration of 2×10^6 per 100-mm dish. After 4 h incubation at 37° C., cells were infected with YF PIV at an MOI of 10 inf.u/cell, and then incubated for 24 h in 10 ml of MEM supplemented with 10% FBS. Then the medium was replaced by 10 ml of serum-free medium VP-SF (Invitrogen) that was replaced every 24 h to analyze SVP release. The collected VP-SF samples were clarified by low-speed centrifugation (5,000 r.p.m, 10 min, 4° C.), and then concentrated by ultracentrifugation through 2 ml of 10% sucrose, prepared on PBS, in SW-41 rotor at

39,000 r.p.m, 4° C. for 6 h. Pellet material was dissolved in the loading buffer for SDS-polyacrylamide gel electrophoresis, lacking b-mercaptoethanol (to preserve binding to D1-4G2 MAB) and further analyzed by Western blotting. After protein transfer, the nitrocellulose membranes were processed by ⁵ D1-4G2 MAB, and horseradish peroxidase (HRP)-conjugated secondary donkey anti-mouse antibodies purchased from Santa Cruz Biotechology. HRP was detected using the Western Blotting Luminol Reagent according to the manufacurer's recommendations (Santa Cruz Biotechnology). To ¹⁰ obtain positive control sample, YFV (2×10⁸ PFU) was subjected to ultracentrifugation through 10% sucrose cushion as described above for SVPs.

For sucrose density gradient analysis of YFV SVPs, BHK-21 cells were electroporated with the in vitro synthesized YF ¹⁵ PIV genome RNA. At 24 hours post-transfection, the complete MEM was replaced by VP-SF medium, which was harvested 24 hours later. At this time, more than 95% of the cells were GFP-positive and did not exhibit any signs of CPE. The harvested sample was clarified by low-speed centrifuga-²⁰ tion (5000 rpm, 10 min, 4° C.) and then concentrated by overnight centrifugation in a SW-28 rotor at 25,000 rpm, 4° C. The resulting pellet was suspended in TN buffer (10 nm Tris HCl (pH 7.5), 100 mM NaCl, 0.1% BSA) and further analysis was performed as described (Schalich et al., 1996). ²⁵

Briefly, 0.5 ml samples were loaded in to the discontinuous sucrose gradient (1.5 ml of 50%, 1.5 ml of 35% and 1.5 ml of 10% sucrose prepared in PBS buffer). Centrifugation was performed in SW-55 rotor at 45,000 rpm at 4° C. for 1 h in Optima MAX Ultracentrifuge (Beckman). Pellets were dis- 30 solved in the loading buffer for SDS polyacrylamide gel electrophoresis, lacking b-mercaptoethanol (to preserve binding to D1-4G2 MAB) and further analyzed by Western blotting. After protein transfer, the nitrocellulose membranes were processed by D1-4G2 MAB and horse radish peroxidase 35 (HRP)-conjugated secondary donkey anti-mouse antibodies purchased from Santa Cruz Biotechnology. HRP was detected using Western Blotting Luminol Reagebbr according to the manufacturer's recommendation (SantaCruz Biotechnology). Side by side gradient analyses were performed 40with YFV (2×10^8 PFU), subjected to the same procedures as described above for YFV-PIV derived SVPs.

Example 8

Analyses of WN PIV

Titers of WN PIV were determined by infecting Vero cell monolayers with serial dilutions of virus, and then fixing 24 hours later and immunohistochemically staining with a polyclonal hyperimmune mouse ascite fluid specific for WNV, as previously described (Rossi et al., 2005). Infected cells were enumerated and used to determine the titer. To evaluate the ability of WN PIV for foci formation on Vero cells or the BHK(VEErep/C*-E*-PAC) cells, monolayers were infected ⁵⁵ with dilutions of WN PIV, overlaid with a semisolid tragacanth overlay, incubated at 37 C, and then fixed and stained with a MAB specific for WNV NS1 (provided by E. Konishi, Kobe, Japan), as described above.

Example 9

PIV Safety Studies

PIV safety was established by inoculation of different 65 doses of virus (YFV 17D or WNV TX02 recovered from parental infectious cDNAs) or PIV into 3- to 4-day-old mice

(outbred Swiss Webster, Harlan) by the intracranial (i.c.) route (20 ml volume), or 4-5 week old female mice (outbred Swiss Webster, Harlan) by the intraperitoneal (i.p.) route (100 ml volume). Mice were monitored for 14 days for signs of disease and death, animals that were moribund, and appeared to be unable to survive until the next day were humanely euthanized and scored as "dead" the following day.

Example 10

WN PIV Potency and Efficacy Studies

Selected animals inoculated with WN PIV as described above were euthanized and bled at 21 days post inoculation. Sera were harvested from the animals, pooled, and tested for their ability to reduce WNV focus formation on Vero cell monolayers using the methods described above. The remaining animals were inoculated with 1,000 inf.u (determined by focus-forming assay on Vero cells), corresponding to approximately 100 LD₅₀ of the NY99 strain of WNV (Xiao et al., 2001), and animals were then observed for an additional 14 days as described above.

Example 11

Both YFV C- and YFV C-prM-E-expressing Cassettes can Complement Replication of YFV PIV

The general strategy for complementation of a C deletion defect in the flavivirus genome is presented FIG. **1**. It is based on development of genomes lacking the C gene, and propagation of these pseudoinfectious viral genomes (PIV genomes) in cells expressing C (or all of the viral structural proteins), but not in normal cells. Replication in the latter cells, producing no viral structural proteins required for transcomplementation of the defect in PIV genome, leads to release of SVPs containing the critical protective immunogen E, but lacking the nucleocapsid containing C and the viral genetic material.

A recombinant YFV genome (YF PIV genome) was engineered to contain GFP in place of amino acid 26-93 of C, cloned in-frame with the rest of the polypeptide (FIG. 2A). The expression of GFP provided a convenient way of determining the titers of genome-containing PIVs in the experisoner. The deletion in the C-coding sequence from this PIV genome was expected to destroy the ability of C to form a functional nucleocapsid, but it was not expected to affect production of functional forms of prM and E. Thus, cells expressing this genome, which produced GFP fluorescence
 could not release infectious virus. However, infectious progeny was expected to be produced from "packaging" cells expressing high levels of C.

For rapid development of the cell lines for efficient PIV production, the Venezuelan equine encephalitis virus
(VEEV) genome-based expression system (replicons) (Petrakova et al., 2005) was used. VEEV replicons are less cytopathic than replicons derived from other alphaviruses and readily establish persistent replication in some cell lines of vertebrate and insect origin. The expression cassettes were
designed as double subgenomic constructs (FIG. 2B), in which one of the subgenomic promoters was driving the expression of Pac, providing an efficient means to eliminate cells in the transfected cultures that do not contain the Pacexpressing VEEV replicon. The second subgenomic promoter was driving the transcription of subgenomic RNA encoding YFV structural proteins. To identify the most efficient packaging cassettes, VEEV replicons encoding either i)

YFV C with the signal peptide of prM, also known as anchored C (Lindenbach and Rice, 2001), (VEErep/C1/Pac), or ii) C with the signal peptide and 20 amino acid of prM (VEErep/C2/Pac), or iii) all of the YFV structural proteins (VEErep/C-prM-E/Pac). The rationale of the design was to retain the signal peptide in the C-coding cassettes that was expected to be essential for targeting C into proper cellular compartment.

The in vitro-synthesized VEEV replicon RNAs were transfected into BHK-21 cells and the Pur^{R} stable cell lines were 10 selected over the next 4-5 days in the Pur-containing medium. During the first 2-3 days post transfection, replication of VEEV-derived RNAs caused growth-arrest, then, as described our previously (Petrakova et al., 2005), replication became less efficient and cells resumed their growth. The 15 resulting Pur^{R} cultures were transfected with the in vitrosynthesized YF PIV RNAs, and at different times post transfection, titers of the released infectious particles, containing GFP-expressing genomes were determined (FIG. 2C). Surprisingly, the presence of two different replicating RNAs 20 (YFV- and VEEV-specific) in BHK-21 cells did not result in cytopathic effect (CPE), and maintained both resistance to Pur and expression of high level of GFP, indicating replication of both the VEEV replicon and YF PIV RNA. As shown in FIG. 2C, cultures expressing both of these marker genes 25 were capable of growing and required subpassaging (at ~1:5 ratio every 4 days) to prevent the cultures from reaching confluency. The experiments shown in FIG. 2 demonstrated that all three VEEV replicons were capable of supplying YFV C at levels sufficient for formation of infectious PIVs; no 30 infectious particles were released from the naive BHK-21 cells transfected with the YF PIV RNA in the absence of VEEV replicons (data not shown). However, cells expressing these packaging cassettes differed in their ability to produce PIV. Constructs expressing YFV C followed by the prM sig-35 nal peptide (anchored C; VEErep/C1/Pac) demonstrated the lowest level of YF PIV RNA packaging, compared to cassettes expressing longer protein sequences. The basis for the lower packaging efficiency is by the C1 construct is unclear, but this phenomenon might be explained by a requirement for 40 a specific ordering of cleavage at the two nearby cleagage sties (NS2B/NS3 and signal peptidase) (Yamshchikov and Compans, 1994), and/or differences in distribution/stability of the C protein produced in these two different contexts. of the stability of this protein. Thus, after these experiments, 45 VEErep/C1/Pac was eliminated from all further experiments. Both VEErep/C2/Pac and VEErep/C-prM-E/Pac replicons packaged YF PIV to the similar titers approaching above 10^7 inf.u/ml. Moreover, the release of PIV particles continued until the experiments were terminated, with each cell releas- 50 ing ~20 infectious YF PIV per 24 h time period. The same cells were probably also releasing prM/E-containing SVPs lacking the nucleocapsid and genome, but this possibility was not further investigated.

Example 12

YF PIVs with Defective Genomes can be Produced at a Large Scale

The ultimate utility of PIV as vaccine candidates is dependent upon the ability to produce these particles at the scales needed, for instance, for commercial production. Reliance on an RNA-based trans-complementation system (VEEV replicons) for vaccine manufacture requires further standardization since there is a possibility of accumulation of mutations in the heterologous genes cloned into genomes of RNA

viruses. The use of low-passage cell lines, is one of the solutions for overcoming this limitation. Alternatively, accumulation of mutations in the VEErep genomes can be minimized by repeated transfection of the replicon into naïve cells, or by production of packaged VEEV replicons followed by infection of naïve cells. The use of packaged VEE replicons was considered to be one simple and efficient means for establishing the packaging cell lines.

To efficiently produce PIVs, a technology that permits production of alpha virus replicon expressing cell cultures in previously packaged VEEV replicons was used. Briefly, VEEV replicons were packaged into VEEV infectious virions using previously described two-helper system (Volkova et al., 2006), into preparations that contained titers approaching 10^9 inf.u/ml. BHK-21 cells infected with these particles and selected in the presence of Pur could be used to obtain YFV structural protein-encoding cell cultures in 3-5 days. Following establishment, the VEErep/C2/Pac- and VEErep/C-prM-E/Pac-containing cell lines were infected with previously generated samples of YF PIVs at high (10 inf.u/cell) and low (0.1 inf.u/cell) MOIs. In all cases, the defective YFVs replicated productively (see FIG. 3) and infected all of cells in the monolayers producing high titers of PIVs. Thus, rapid establishment of packaging cell lines by infecting cells with packaged VEEV replicons, followed by infection with PIVs appears to be a simple and efficient system a for large-scale production of PIVs with the deleted C sequence in the genome.

Example 13

Production of YF PIVs Using VEE Replicons Expressing Codon-Optimized Form of YFV C Gene

Another possible problem in using the packaging systems to support replication of defective viruses is recombination between the defective viral genomes and the RNAs encoding the trans-complementing gene(s). Such recombination might lead to generation of the infectious viruses. In the experiments described herein, infectious YFV using a plaque assay were never detected, but it was necessary to rule out the possibility that live virus can be formed in these cells.

In addition, the proteins encoded by many arthropod-borne viruses are expected to have evolved to utilize the translational machinery in two very different hosts. Thus, their codon usage is not expected to be optimal for expression in either host. Therefore, the C-coding sequence in the expression cassettes was modified to achieve two goals: i) to enhance the yield of C production and ii) to reduce possibility of homologous recombination between YF PIV genome and C-coding subgenomic RNA of VEE replicons. YFV C was synthesized using the codon frequency found in the most efficiently translated mammalian genes (FIG. 4A). These silent mutations also disrupted the cyclization sequence 55 required for flavivirus genome replication, thus, reducing the possibility of generating replication competent YFV in an event of recombination between YF PIV genome and YFV C-coding RNA of VEEV replicon.

The Copt gene was cloned into VEErep constructs, VEErep/Copt/Pac and VEErep/Copt-prM-E/Pac, using the same strategy as VEErep/C2/Pac and VEErep/C-prM-E/Pac, and trans-complementing Pur^{*R*} cell lines were established either by RNA transfection or by infecting the cells with packaged RNAs. Transfection of these cells with the in vitro-55 synthesized PIV genome RNA produced PIV with efficiencies that were similar to those selected with the cells expressing VEEV replicons expressing the non-optimized YFV C

60

gene (FIG. **4**B). However, the cells expressing the codonoptimized C proved to be a useful reagent in that they were capable of developing CPE and forming clearly visible plaques when infected with YF PIV and overlaid with agarose containing media with low concentration of FBS (FIG. **4**C). ⁵ Thus, although codon optimization of YFV C gene did not alter PIV production from these cells, the cells expressing the codon-optimized YFV C represent a very useful system for evaluation of YF PIVs, particularly those expressing no fluorescent markers. In additional tests, a very good correlation ¹⁰ was observed between the titers of the same samples determined in plaque-forming assays and GFP-foci assays.

Plaques formed by YF PIV were smaller than those of YFV indicating that structural proteins were most likely produced in cis functio more efficiently in viral particle formation. The ¹⁵ reason for attaining the ability to form plaques is not completely understood yet. However, it is speculated that YFV C has some level of cytotoxicity because of cell lines containing VEEV replicons expressing the codon-optimized version of this protein demonstrated lower growth rates (data not ²⁰ shown) than corresponding counterparts with replicon encoding natural C gene. Thus, YF PIV genome replication might lead to additional changes in the intracellular environment that were sufficient to cause CPE.

Example 14

PIVs can be Generated for Other Flaviviruses

To prove that PIVs can be easily generated for other flaviviruses, the strategy described above was applied to WNV. To this end, a WN PIV genome with a 35-amino acid-long C protein was created (FIG. **5**A). To package this WN PIV genome, a packaging cell line generated by transfection of BHK cells with a non-cytopathic VEEV replicon expressing WNV C/prM/E and Pac [BHK(VEErep/C*-E*-Pac) was used. To minimize the chance that recombination between WN PIV genomes replicating in this cell line and the VEErep RNA-encoded C protein could lead to generation of the infectious WNV, the WNV C-coding gene in the VEEV replicon was modified to contain clustered silent mutations in the WNV cyclization domain.

Media harvested from BHK (VEErep/C*-E*-Pac) cells transfected with the synthetic WN PIV genome were capable of producing antigen-positive foci in the packaging cells 45 (FIG. 5B) indicating that infectious WN PIV had been produced. However, only antigen-positive cells were detected upon infection of Vero cell monolayers with same samples (FIG. 5C). Titers of up to 1×10^8 inf.u/ml of WN PIV were produced on the packaging cells, and as expected, WN PIV 50 could be repeatedly passed on this cell line. Thus, using an established cell line, high titer stocks of WN PIV could be readily obtained using the same complementation system described above for YFV. Interestingly, in the case of the WNV packaging cell line and WN PIV, it was observed that 55 the virus yields plateaued late in infection, simultaneously with the appearance of CPE (results not shown), whereas the cells co-replicating YF PIV genome and VEEV replicons continued to produce PIV for many days (FIG. 2).

Example 15

Cells Infected with YF or WN PIVs Produce SVPs

To demonstrate that cells infected with PIVs produced 65 SVPs, BHK-21 cells were either transfected with the in vitrosynthesized YF PIV RNA or infected with YF PIVs produced in C-expressing cells. The particles released from the BHK-21 cells were purified by ultracentrifugation, and analyzed by western blotting using a mouse monoclonal antibody (MAB) specific for E, D1-4G2 (Gentry et al., 1982). Both RNAtransfected and PIV-infected cells produced E protein that could be pelleted from the media (FIG. 6A), indicating that it was present in a particulate form. Since these cells did not exhibit any CPE, and the samples were clarified at low-speed centrifugation prior to ultracentrifugation, it is unlikely that the E protein detected in the pelleted fraction represented cellular debris. Similarly, western blot analyses demonstrated that Vero cells infected with the WN PIV produced (before development of any signs of CPE) extracellular forms of E that were indistinguishable in size from those produced by WNV-infected Vero cells (FIG. 6B).

To further evaluate the physical nature of the E protein released by PIV-infected cells, media collected from cells containing replicating PIV genomes only were subjected to sucrose density gradient analysis in agreement with published data (Schalich et al., 1996). SVPs were found in the fraction having 2% sucrose (FIG. 6C). In the same experiment, YFV virions demonstrated high density and were detected in the fraction with 42% sucrose. E protein-containing particles that migrate at the expected size of WNV SVPs have also been detected in cultures infected with WNV PIVs. The presence of E in the media of PIV-infected cells was consistent with the production of SVPs by cells expressing only prM/E or TBEV RNA vaccines lacking a functional C gene.

Example 16

PIV Safety, Potency, and Efficacy in Animals

Safety of WN and YF PIVs was established by i.c. inoculation of litters of 3 to 4-day-old mice. These studies showed that mice inoculated with WT YFV or WNV were quickly killed, and these viruses displayed a 50-percent lethal dose (LD_{50}) of approximately 1 PFU in these animals (Table 1). However, WN and YF PIVs inoculated into suckling mice at a dose of 2×10^6 inf.u failed to kill any mice (Table 1). Safety was further documented by i.p. inoculation of adult mice with wild type (wt) viruses and WN PIVs. These studies showed that the WN PIVs were completely safe in adult mice (Table 2). Furthermore, wt WNV killed a significant portion of adult mice, with an LD₅₀ of less than 1 PFU, and doses of up to 3×10^6 inf.u of WN PIV failed to cause any death (Table 2). Most interestingly, however, is the finding that the WN PIVs were very potent immunogens (NEUT titers were detected with inoculation of as few as 30,000 inf.u), and 100% of the animals vaccinated with 3×10^4 , 3×10^5 , or 3×10^6 inf.u were protected from a $100LD_{50}$ challenge of the NY99 strain of WNV (Table 2).

TABLE 1

		Safety of PIV	/s in suckling mi	ce.
	Inoculum ^a	Dose $(\inf \cdot \mathbf{u})^b$	% Survival ^c	Average survival time ^d
)	WN PIV	2,000,000	100 (9/9)	NA^e
	WNV TX02	0.2	56 (5/9)	8.5 (+/-2.9)
	WNV TX02	2	0 (0/9)	5.4 (+/-0.5)
	WNV TX02	20	0 (0/8)	6 (+/-0)
	WNV TX02	200	0 (0/10)	4.9 (+/-0.3)
	YF PIV	2,000,000	100 (10/10)	NA^{e}
	YFV 17D	0.2	89 (8/9)	8 (+/-0)
	YFV 17D	2	56 (5/9)	7 (+/-0)

10

TABLE 1-continued

Safety of PIVs in suckling mice.								
Inoculum ^a	Dose $(\inf \cdot \mathbf{u})^b$	% Survival ^c	Average survival time ^d					
YFV 17D YFV 17D	20 200	$\begin{array}{c} 11 \ (1/9) \\ 0 \ (0/12) \end{array}$	6.9 (+/-2.4) 6 (+/-0)					

"Inoculated preparation, diluted in culture media with 10% FBS

^bDelivered by i.c. route in a volume of 20 ml/animal

^cSurvival at 14 days postinoculation (live/dead)

^dAverage survival time from animals that died from infection (standard deviation) "Not applicable

TA	BL	Æ	2

•	2
	4

2

(in each case with infection at an MOI of 0.01), and the resulting RepliVAX was characterized in detail. To determine if this passage 10-(p10) population contained any live virus, Vero cell monolayers were infected at multiplicities of 0.1, 1, and 10 with the p10 WN RepliVAX, and washed extensively to remove extracellular RepliVAX. These monolayers were re-washed 24 hours later, and then harvested 2 days later. Passage of supernatant fluids from these cultures onto fresh Vero cell cultures failed to reveal any immunopositive cells when stained with a highly sensitive polyclonal antibody for WNV, indicating that RepliVAX had not productively recombined with the C protein encoded by the packaging cell line.

Safety, potency and efficacy of PIV in adult mice									
Inoculum"	Dose $(\inf \cdot \mathbf{u})^b$	% Survival ^c	Average survival time ^d	NEUT titer ^e	% Protection ^f				
none	0	100 (8/8)	NA^g	$<\!\!1:\!40^{h}$	14 (1/7)				
(diluent)									
WN PIV	30,000	100 (10/10)	NA^g	1:40	100 (8/8)				
WN PIV	300,000	100 (10/10)	NA^g	1:160	100 (8/8)				
WN PIV	3,000,000	100 (10/10)	NA^{g}	1:160	100 (8/8)				
WNV TX02	1	40 (4/10)	8.5 (+/-1.4)						
WNV TX02	10	30 (3/10)	8 (+/-1.2)						
WNV TX02	100	10 (1/10)	7.8 (+/-1.4)						

"Inoculated preparation, diluted in culture media with 10% FBS

^bDelivered by i.p. route in a volume of 100 ml/animal.

^cSurvival at 14 days postinoculation (live/dead).

^dAverage survival time from animals that died from infection (standard deviation).

Average survival at the non-animats that the non-animats distribution (standard definition), "NEUT titer of pooled series collected from 2 animals at 21 days postinoculation (titer shown is the highest dilution giving 80% reduction of WNV foci formation). "Protection from challenge with 100LD₅₀ of the NY99 strain of WNV demonstrated by survival at 14 days post-challenge; single survivor from the dilutent-inoculated group showed signs of disease (hunched back; ruffled fur, and malaise) from days 8-14. None of the PIV inoculated animals displayed any signs of disease in the 14-day postchallenge theorem the provided strain and the strain of the PIV inoculated animals displayed any signs of disease in the 14-day postchallenge

observation period. Not applicable.

^hNEUT titers in sera from unimmunized mice tested side-by-side with sera from the WN PIV-inoculated mice.

Example 17

Further Modifications to Increase the Yield and Safety of PIVs/RepliVAX

The present invention demonstrates that repeated passaging of RepliVAX did not result in recombination, but variants with enhanced growth were selected: The WNV RepliVAX has been repeatedly passaged on a cell line that encodes the 45 WNV C protein. This C protein was produced by fusing a copy of the WNV C gene to a Pac gene driven by the subgenomic promoter of a non-cytopathic VEErep (Petrakova et al., 2005). In the resulting construct (VEErep/Pac-Ubi-C*), the ubiquitin (Ubi) gene was inserted in front of the C gene, 50 and C was followed by a stop codon. In this context, a Pac-Ubi fusion protein would be produced along with a mature C protein (lacking the hydrophobic anchor; see FIG. 9). The C gene in this VEErep (denoted as "C*") was further modified by insertion of 36 mutations that ablate the CS signal, con- 55 verting this 11-base region from GUCAAUAUGCU (SEQ ID NO: 2) to GUgAAcAUGuU (SEQ ID NO: 3) while maintaining C coding capacity. This large number of mutations dramatically reduces the likelihood of homologous recombination, and furthermore, if recombination did occur between the 60 genomes, the production of a replicationally active genome could not occur, since the resulting RNA would have unmatched CSs, preventing replication (FIG. 9).

To test for the unlikely possibility of productive recombination, a clonal cell line was derived from BHK cells express- 65 ing VEErep/Pac-Ubi-C* {BHK(VEErep/Pac-Ubi-C*)}, and this cell line was used to passage the WN RepliVAX 10 times

Interestingly, when the p10 WN RepliVAX was compared to p0 RepliVAX on the BHK(VEErep/Pac-Ubi-C*) cell line, the p10 RepliVAX produced polymorphic foci of infection, 40 many of which were much larger than those produced by the p0 RepliVAX (FIG. 10). Furthermore, p10 RepliVAX replicates 10 times higher than p0 RepliVAX at early time points, with an endpoint titer twice as high.

Analyses of the PCR products obtained from cDNA produced from Vero cells infected with this p10 RepliVAX demonstrated that there were no products that contained a fulllength C coding region. However, sequence analyses of the C-prM junction of the product spanning these regions revealed that two mutations had arisen during passaging. As expected from the heterogeneous nature of the foci produced by the p10 RepliVAX on the packaging cells (FIG. 10), both mutations were present as mixtures with the original RepliVAX sequence. One of the mutations, which appeared to be present over half of the nucleic acid population in these sequence reactions (sequenced in both directions), consisted of a AGC>uGC (S>C) mutation at the P4 position preceding the signal peptidase cleavage site (S(c)VGA|VTLS (SEQ ID NO: 4) in the RepliVAX genome. The second mutation, which was present in only about 30% of the amplified sequences (again in reactions completed in both directions) consisted of an AAG>AuG (K>M) at position P3 following the NS2B/NS3 cleavage site (QKKR|GGK(m)T) (SEQ ID NO: 5). Although these mutations are in the position of the deleted SL5, they do not alter predicted RNA structures. The rapid selection (only 10 growth cycles) of a better-growing RepliVAX is very exciting since it indicates that selection of better-growing variants is a powerful method to improve RepliVAX. The positions of these mutations was not unexpected since it is known that altering efficiency of NS2B/NS3 versus signal peptidase cleavage can influence flavivirus particle yield and infectivity (Keelapang et al., 2004; Lee et al., 2000; Lobigs and Lee, 2004; Yamschikov et al., 1997). Stud-5 ies are continuing on selection of even better growing variants, and these two mutations are being targeted for insertion into second-generation RepliVAX constructs, to confirm their ability to work separately (or together) to improve RepliVAX yield and antigen production. Nevertheless, the 10 data presented herein indicate that under these passage conditions: 1) no recombination occurred, 2) positive selection could be used to produce improved RepliVAXs.

Blind passage of JE RepliVAX similarly yielded bettergrowing variants with mutations in the same regions of the 15 genome. The ability to blind passage RepliVAX products to produce better growing variants is a key feature of this invention, and a clear advantage over traditional LAV, where production of better-growing variants is always complicated by the concern that these better-growing variants may have lost 20 their attenuation in man.

Furthermore, the mutated, improved C-expression cassette (VEErep/Pac-Ubi-C*), which has been shown to be stable, and demonstrated freedom from recombination when used in a BHK cell line (not approved for human vaccine generation), 25 has also been shown to be stable and useful for PIV propagation when introduced into Vero cells (an accepted cell line for the production of human vaccines). Specifically, RNAs corresponding to the VEE replicon have been introduced Vero cells from a certified seed using the same methods applied to 30 BHK cells. Following introduction of the RNA into these Vero cells, the cells were maintained in serum free media (an important issue for vaccine generation) containing puromycin, and these cells were shown to be useful for PIV propagation. Under these propagation conditions, these cells have 35 been shown to produce slightly lower titers of PIV than similarly derived BHK cells, but the VEErep/Pac-Ubi-C*-Vero cells hold up better under these culture conditions, permitting multiple harvests. FIG. 11 shows the production of PIV from these cells can be obtained for multiple harvests under serum- 40 free conditions.

In summary, propagation of PIVs in cell lines that express C (especially C cassettes that contain the signal sequence of prM, or this region plus portions of the prM and E genes) can theoretically recombine with the PIV genome, producing a 45 live virus that could cause disease, increasing the risk of the method of vaccine generation. To overcome this problem, the present invention demonstrated that cell lines for the propagation of WN PIV can be produced using a C protein that ends precisely at the NS2B/NS3 cleavage site, minimizing the 50 chance of recombination at this region of the PIV genome, providing an advantage over other propagation methods in which cell lines encode RNAs that encode the portion of the anchor of C (that is also know as the signal peptide of prM) that are shared by the PIV.

To further enhance the safety of this C-expression cassette, the present invention demonstrated that the portion of the cassette that is used to make the VEErep-encoded C that complements the PIV genome (namely the first 30 codons encoding the amino acid sequence that are required to produce a replicating PIV genome due to underlying RNA elements required for viral replication) could be specifically mutated to produce a cassette that differs from the PIV genome at 36 nucleotide positions (introduced without altering the protein product) resulting in a C gene that has a 65 dramatically reduced probability of recombination with the PIV genome (FIG. 9). Furthermore, this mutated C gene was

created to have three mutations in the cyclization signal (CS) that must be complementary to a CS in the 3'UTR of the PIV genome to allow viral replication, providing a further safety feature to prevent recombination (FIG. 9). Finally, this C gene was inserted into the VEEreplicon following the selectable marker gene (pac), by using a ubiquitin gene to the intact C product from the resulting polyprotein (alternative self-cleaving sequences such as the auto-proteinase 2A of FMDV, or other related sequences could easily be substituted for ubiquitin). Creation of this single-polyprotein cassette provides the advantage of producing a genetically more stable VEEreplicon, reducing the chance of recombination within the propagating cell lines, eliminating the C-expression cassette, and reducing PIV yield. The resulting construct (VEErep/Pac-Ubi-C*, FIG. 9) was introduced into BHK cells, and the cells were used to produce a clonal cell line expressing the VEE replicon using established methods (Fayzulin et al., Virology 2006).

One clonal cell line was examined after 18 passages from single-cell cloning, and found to have no evidence of any genetic deletion of the C cassettes (by RT-PCR), nor was it found to have any detectable mutations within the C-expression cassette. Most importantly, this cell line displayed similar ability to propagate the WNV PIV at a passage level as high as 41. Finally, following 10 passages of PIV on this cell line, no evidence of recombination producing PIV-recombinants capable of productive replication on cells that do not express the C cassette (namely WT Vero cells), and no evidence of introduction of C-encoding sequences into the PIV genome by RT PCR was observed.

Furthermore, to address concerns that PIV might recombine with flaviviruses in vaccines at the time of their vaccination, producing novel, virulent flaviviruses, the present invention demonstrated that WNV genomes with "unnatural" cyclization signals (CS) present in all known naturally circulating flaviviruses, can be generated that replicate to high levels. Evidence has been produced in several laboratories that the two CS found at the 5' and 3' ends of the genomes of all flaviviruses must be 100% complementary to provide productive viral replication (Khromykh et al. J. Virol., 2001; Lo et al., J. Virol., 2003; Alvarez et al., Virol., 2003). These studies also demonstrated that unnatural CSs could produce replicating genomes, as long as the CS were 100% complementary. However these investigators reported that all genomes with unnatural CS sequences had replication defects. By systematic analysis of CS in WNV genomes, specifically the testing the ability of carefully selected single base swaps to produce high-level replication, single-base changes, and subsequent double-base changes that permit high-levels of genome replication (FIG. 12A) were identified. FIG. 12B demonstrates that high-level replication of WNV genome with two-base substitutions is possible, and that genomes intentionally created with mis-matched CS sequences (namely WT and the 2-base mutant) are not replicationally active. This mutation, and others like it, can therefore be utilized to produce PIV with a superior safety profile, since any recombinant virus resulting from a single-point genetic recombination between the CS-modified PIV vaccine and a virus circulating in areas where people are undergoing vaccination would not be replicationally active, and hence could not cause disease.

Example 18

BHK Cells Expressing WNV C Gene Maintain their Phenotype for Multiple Passages

Studies with a WNV C-expressing clonal cell line derived from BHK cells transfected with VEErep/Pac-Ubi-C* has demonstrated its long-term stability and utility in generating RepliVAX for several reasons. Firstly, these cells were useful for repeated passaging of RepliVAX. Secondly, side-by side focus-formation assays on cells at two different passage levels (passages 8 & 24 after single-cell cloning) showed indis-5 tinguishable WN RepliVAX titers and foci sizes. Finally, direct analysis of the sequence of the C-encoding cassette in these cells at the passage-24 level revealed no changes relative to the original VEErep sequence. Taken together these data indicate that cells harboring C-expressing VEEreps should be stable enough for use in the currently accepted master cell seed lot format used to produce human vaccines. Furthermore, the fact that VEEreps have already been used in human trials, make it likely that the application of the VEErep-cell technology to Vero cells will not encounter any unexpected hurdles during regulatory approval.

Example 19

Lymphoid Tissue Targeting of WNV VLPs

As indicated supra, WNV VLPs are similar to RepliVAX, except in place of the flavivirus prM/E proteins, they can encode a reporter gene, or they can simply contain a flavivirus replicon without a reporter. VLPs can be readily produced in packaging cells expressing all three WNV structural proteins, and have been produced at high titer (Fayzulin et al., 2006). When 10⁷ U of VLP were inoculated into mice, these animals produced 1,000 to 5,000 U/ml of type I interferon (IFN) in their serum 24 hr post-inoculation. IFN responses were produced by both ip and subcutaneous footpad injection (fp). Furthermore, popliteal lymph nodes dissected 24 hrs after fp inoculation with b-galactosidase-expressing VLPs contained large numbers of b-galactosidase-positive cells, indicating that VLPs, which enter cells in a manner indistinguishable from RepliVAX, are targeting important lymph organs. This result is consistent with the high levels of IFN elicited by VLP-injection and suggests that similar targeting is responsible for the high potency and efficacy of RepliVAX.

The following references were cited herein: Aberle, J. H. et al., 1999, *J Immunol* 163, 6756-61. Aberle, J. H. et al., 2005, *J Virol* 79, 15107-13. Bredenbeek, P. J. et al., 2003 *J Gen Virol* 84, 1261-8. Chambers, T. J. et al., 1999 *J Virol* 73, 3095-101. Clyde and HArris, 2006, *J Virol* 80: 2170-2182. Colombage, G. et al. 19.98, *Virology* 250, 151-63. Davis, B. S. et al., 2001, *Journal of Virology* 75, 4040-4047.

Fayzulin et al., 2006, *Virology* 351: 196-209.

- Filomatori et al., 2006, Genes Dev 20: 2238-2249.
- Fonseca, B. A., et al., 1994, Vaccine 12, 279-85.
- Gentry, M. K et al., 1982, Am J Trop Med Hyg 31, 548-55.
- Gerasimon, G., and Lowry, K., 2005, *South Med J*98, 653-6. Haas, J., et al., 1996 *Curr Biol* 6, 315-24.

- Hall, R. A., et al., 2003, Proc Natl Acad Sci USA 100, 10460-10464.
- Huang, C. Y., et al., 2003, J Virol 77, 11436-47.
- Kanesa, T. N., et al., 2030 Vaccine 19, 483-491.
- Keelapang et al., 2004, J Virol 78: 2367-2381.
- Kochel, T et al., 1997, Vaccine 15, 547-52.
- Kochel, T. J. et al., 2000. Vaccine 18, 3166-3173.
- Kofler, R. M., et al., 2004, Proc Natl Acad Sci USA 101, 1951-6.
- Konishi, E., and Fujii, A., 2002, Vaccine 20, 1058-67.
- Konishi, E et al., 2001 *Journal of Virology* 75, 2204-2212. Konishi, E et al., 1992a *Virology* 190, 454-8.
- Konishi, E et al., 1992b, *Virology* 188, 714-20.
- Konishi, E et al., 2000a, Vaccine. Jan. 18, 1133-1139.
- Konishi, E. et al., 2000b, Virology 268, 49-55.
- Lee et al., 2000, *J Virol*; 74: 24-32. Lemm, J. A et al., 1990, *J Virol* 64, 3001-11. Liljestrom, P et al., 1991 *J Virol* 65, 4107-13.
- Lobigs and Lee, 2004, J Virol 78: 178-186.
- Lindenbach et al., 2001, 2001, Flaviviridae: the viruses and their replication Knipe et al., (Eds. 4th Ed. Fields Virology, Vol. 1, Lippincott Williams and Wilkins, Philadelphia., pp. 991-1041(2 vols)).
 - Lorenz, I. C. et al., 2002 J Virol 76, 5480-91.
- Mason, P. W. et al., 1991, *Virology* 180, 294-305.
 - Minke, J. M. et al., 2004, Arch Virol Suppl, 221-30.
 - Mishin, V. P. et al., 2001 Virus Research 81, 113-123.
 - Monath, T. P. 1991, Am J Trop Med Hyg 45, 1-43.
 - Monath, T. P. et al., 2002 Vaccine 20, 1004-18.
 - Petrakova, O et al., 2005 J Virol 79, 7597-608.
- ³⁰ Phillpotts, R. J. et al., 1996 Arch Virol 141, 743-9. Pincus, S., et al., 1992 Virology 187, 290-7.
 - Pletnev et al., 2002, Proc. National Academy of Sciences USA 99, 3036-3041.
- Pugachev, K. V. et al., 2004 J Virol 78, 1032-8.
- ³⁵ Pugachev, K. V. et al., 2004 *J Virol 78*, 1052-8.
 ³⁵ Pugachev, K. V., et al., 1995 *Virology* 212, 587-94.
 Qiao, M. e al., 2004 *J Infect Dis* 190, 2104-8.
 Rossi, S. L. et al., 2005, *Virology* 331, 457-70.
 Schalich et al., 1996, *Virology*, 70: 4549-4557.
 Schmaljohn, C. et al., 1997, *J Virol* 71, 9563-9.
- ⁴⁰ Scholle, F. et al., 2004, *J Virol* 78, 11605-14.
 Volkova, E. et al., 2006, *Virology* 344, 315-27.
 Xiao, S. Y. et al. 2001, *Emerging Infectious Diseases Jul. Aug.* 7, 714-721.
- Yamshchikov, V. F., and Compans, R. W., 1994), *J Virol* 68, 5765-71.
 - Yamshchikov et al., 1997, J Virol, 71: 4364-4371.

Zuker, 2003, Nucleic Acid Res 31: 3406-3415.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 42

<210> SEQ ID NO 1 <211> LENGTH: 423 <212> TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 1

atgageggee ggaaggetea gggeaagaee etgggegtga acatg	gtgag gcgcggcgtg	60
cgcagcctct ccaacaagat caagcagaag accaagcaga tcggc	aacag acccggaccg	120
ageeggggeg teeaggggtt catettette tteetgttea acate	ctcac aggtaagaag	180
atcacggete acetgaagag getetggaag atgetggaee etege	caggg gctcgcggtg	240
ctcagaaagg tgaagegggt egtegeetee etgatgegeg geetg	teete tegeaagagg	300
cgctcccacg atgtgctcac cgtccaattc ctcattctgg gaatg	ctgct gatgactggc	360
ggcgtgaccc tggtgcgcaa gaaccgctgg ctgctgctga atgtg	accag tgaggacctc	420
aaa		423
<210> SEQ ID NO 2 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 2		
gucaauaugo u		11
<210> SEQ ID NO 3 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 3		
gugaacaugu u		11
<210> SEQ ID NO 4 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic peptide <400> SEQUENCE: 4		
Ser Val Gly Ala Val Thr Leu Ser 1 5		
<210> SEQ ID NO 5 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic peptide		
<400> SEQUENCE: 5		
Gln Lys Lys Arg Gly Gly Lys Thr 1 5		
<210> SEQ ID NO 6 <211> LENGTH: 14295 <212> TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEOUENCE: 6		

30

29

aacacatttg	gattaatttt	aatcgttcgt	tgagcgatta	gcagagaact	gaccagaaca	120	
tgtctggtcg	taaagctcag	ggaaaaaccc	tgggcgtcaa	tatggtacga	cgaggagttc	180	
gctccttgtc	aaacaccatg	gtgagcaagg	gcgaggagct	gttcaccggg	gtggtgccca	240	
tcctggtcga	getggaegge	gacgtaaacg	gccacaagtt	cagcgtgtcc	ggcgagggcg	300	
agggcgatgc	cacctacggc	aagetgaeee	tgaagttcat	ctgcaccacc	ggcaagctgc	360	
ccgtgccctg	geecaccete	gtgaccaccc	tgacctacgg	cgtgcagtgc	ttcagccgct	420	
accccgacca	catgaagcag	cacgacttct	tcaagtccgc	catgcccgaa	ggctacgtcc	480	
aggagcgcac	catcttcttc	aaggacgacg	gcaactacaa	gacccgcgcc	gaggtgaagt	540	
tcgagggcga	caccctggtg	aaccgcatcg	agctgaaggg	catcgacttc	aaggaggacg	600	
gcaacatcct	ggggcacaag	ctggagtaca	actacaacag	ccacaacgtc	tatatcatgg	660	
ccgacaagca	gaagaacggc	atcaaggtga	acttcaagat	ccgccacaac	atcgaggacg	720	
gcagcgtgca	gctcgccgac	cactaccagc	agaacacccc	catcggcgac	ggccccgtgc	780	
tgctgcccga	caaccactac	ctgagcaccc	agteegeeet	gagcaaagac	cccaacgaga	840	
agcgcgatca	catggtcctg	ctggagttcg	tgaccgccgc	cgggatcact	ctcggcatgg	900	
acgagctgta	caagcttgga	ttgtcctcaa	ggaaacgccg	ttcccatgat	gttctgactg	960	
tgcaattcct	aattttggga	atgctgttga	tgacgggtgg	agtgaccttg	gtgcggaaaa	1020	
acagatggtt	gctcctaaat	gtgacatctg	aggacctcgg	gaaaacattc	tctgtgggca	1080	
caggcaactg	cacaacaaac	attttggaag	ccaagtactg	gtgcccagac	tcaatggaat	1140	
acaactgtcc	caatctcagt	ccaagagagg	agccagatga	cattgattgc	tggtgctatg	1200	
gggtggaaaa	cgttagagtc	gcatatggta	agtgtgactc	agcaggcagg	tctaggaggt	1260	
caagaagggc	cattgacttg	cctacgcatg	aaaaccatgg	tttgaagacc	cggcaagaaa	1320	
aatggatgac	tggaagaatg	ggtgaaaggc	aactccaaaa	gattgagaga	tggttcgtga	1380	
ggaacccctt	ttttgcagtg	acggctctga	ccattgccta	ccttgtggga	agcaacatga	1440	
cgcaacgagt	cgtgattgcc	ctactggtct	tggctgttgg	tccggcctac	tcagctcact	1500	
gcattggaat	tactgacagg	gatttcattg	aggggggtgca	tggaggaact	tgggtttcag	1560	
ctaccctgga	gcaagacaag	tgtgtcactg	ttatggcccc	tgacaagcct	tcattggaca	1620	
tctcactaga	gacagtagcc	attgatagac	ctgctgaggt	gaggaaagtg	tgttacaatg	1680	
cagtteteac	tcatgtgaag	attaatgaca	agtgccccag	cactggagag	gcccacctag	1740	
ctgaagagaa	cgaaggggac	aatgcgtgca	agcgcactta	ttctgataga	ggctggggca	1800	
atggctgtgg	cctatttggg	aaagggagca	ttgtggcatg	cgccaaattc	acttgtgcca	1860	
aatccatgag	tttgtttgag	gttgatcaga	ccaaaattca	gtatgtcatc	agagcacaat	1920	
tgcatgtagg	ggccaagcag	gaaaattgga	ataccgacat	taagactctc	aagtttgatg	1980	
ccctgtcagg	ctcccaggaa	gtcgagttca	ttgggtatgg	aaaagctaca	ctggaatgcc	2040	
aggtgcaaac	tgcggtggac	tttggtaaca	gttacatcgc	tgagatggaa	acagagagct	2100	
ggatagtgga	cagacagtgg	gcccaggact	tgaccctgcc	atggcagagt	ggaagtggcg	2160	
gggtgtggag	agagatgcat	catcttgtcg	aatttgaacc	tccgcatgcc	gccactatca	2220	
gagtactggc	cctgggaaac	caggaaggct	ccttgaaaac	agctcttact	ggcgcaatga	2280	
gggttacaaa	ggacacaaat	gacaacaacc	tttacaaact	acatggtgga	catgtttctt	2340	
gcagagtgaa	attgtcagct	ttgacactca	aggggacatc	ctacaaaata	tgcactgaca	2400	
aaatgttttt	tgtcaagaac	ccaactgaca	ctggccatgg	cactgttgtg	atgcaggtga	2460	

aagtgtcaaa	aggagccccc	tgcaggattc	cagtgatagt	agctgatgat	cttacagcgg	2520
caatcaataa	aggcattttg	gttacagtta	accccatcgc	ctcaaccaat	gatgatgaag	2580
tgctgattga	ggtgaaccca	ccttttggag	acagctacat	tatcgttggg	agaggagatt	2640
cacgtctcac	ttaccagtgg	cacaaagagg	gaagctcaat	aggaaagttg	ttcactcaga	2700
ccatgaaagg	cgtggaacgc	ctggccgtca	tgggagacac	cgcctgggat	ttcagctccg	2760
ctggagggtt	cttcacttcg	gttgggaaag	gaattcatac	ggtgtttggc	tctgcctttc	2820
agggggctatt	tggcggcttg	aactggataa	caaaggtcat	catgggggggg	gtacttatat	2880
gggttggcat	caacacaaga	aacatgacaa	tgtccatgag	catgatcttg	gtaggagtga	2940
tcatgatgtt	tttgtctcta	ggagttgggg	cggatcaagg	atgcgccatc	aactttggca	3000
agagagagct	caagtgcgga	gatggtatct	tcatatttag	agactctgat	gactggctga	3060
acaagtactc	atactatcca	gaagatcctg	tgaagettge	atcaatagtg	aaagcetett	3120
ttgaagaagg	gaagtgtggc	ctaaattcag	ttgactccct	tgagcatgag	atgtggagaa	3180
gcagggcaga	tgagatcaat	gccatttttg	aggaaaacga	ggtggacatt	tctgttgtcg	3240
tgcaggatcc	aaagaatgtt	taccagagag	gaactcatcc	attttccaga	attcgggatg	3300
gtctgcagta	tggttggaag	acttggggta	agaaccttgt	gttctcccca	gggaggaaga	3360
atggaagctt	catcatagat	ggaaagtcca	ggaaagaatg	cccgttttca	aaccgggtct	3420
ggaattettt	ccagatagag	gagtttggga	cgggagtgtt	caccacacgc	gtgtacatgg	3480
acgcagtctt	tgaatacacc	atagactgcg	atggatctat	cttgggtgca	gcggtgaacg	3540
gaaaaaagag	tgcccatggc	tctccaacat	tttggatggg	aagtcatgaa	gtaaatggga	3600
catggatgat	ccacaccttg	gaggcattag	attacaagga	gtgtgagtgg	ccactgacac	3660
atacgattgg	aacatcagtt	gaagagagtg	aaatgttcat	gccgagatca	atcggaggcc	3720
cagttagctc	tcacaatcat	atccctggat	acaaggttca	gacgaacgga	ccttggatgc	3780
aggtaccact	agaagtgaag	agagaagctt	gcccagggac	tagcgtgatc	attgatggca	3840
actgtgatgg	acggggaaaa	tcaaccagat	ccaccacgga	tagcgggaaa	gttattcctg	3900
aatggtgttg	ccgctcctgc	acaatgccgc	ctgtgagctt	ccatggtagt	gatgggtgtt	3960
ggtatcccat	ggaaattagg	ccaaggaaaa	cgcatgaaag	ccatctggtg	cgctcctggg	4020
ttacagctgg	agaaatacat	gctgtccctt	ttggtttggt	gagcatgatg	atagcaatgg	4080
aagtggtcct	aaggaaaaga	cagggaccaa	agcaaatgtt	ggttggagga	gtagtgctct	4140
tgggagcaat	gctggtcggg	caagtaactc	tccttgattt	gctgaaactc	acagtggctg	4200
tgggattgca	tttccatgag	atgaacaatg	gaggagacgc	catgtatatg	gcgttgattg	4260
ctgccttttc	aatcagacca	gggctgctca	tcggctttgg	gctcaggacc	ctatggagcc	4320
ctcgggaacg	ccttgtgctg	accctaggag	cagccatggt	ggagattgcc	ttgggtggcg	4380
tgatgggcgg	cctgtggaag	tatctaaatg	cagtttctct	ctgcatcctg	acaataaatg	4440
ctgttgcttc	taggaaagca	tcaaatacca	tcttgcccct	catggctctg	ttgacacctg	4500
tcactatggc	tgaggtgaga	cttgccgcaa	tgttctttg	tgccgtggtt	atcatagggg	4560
tccttcacca	gaatttcaag	gacacctcca	tgcagaagac	tatacctctg	gtggccctca	4620
cactcacatc	ttacctgggc	ttgacacaac	ctttttggg	cctgtgtgca	tttctggcaa	4680
cccgcatatt	tgggcgaagq	agtatcccaq	tgaatgagge	actegeagea	gctggtctag	4740
tqqqaqtqct.	qqcaqqactq	qcttttcaqq	aqatqqaqaa	cttccttaat.	ccqattqcaq	4800
555 5-5-5	55 5555		5 55 55		5 5 5 5 5 5	

-continued

ttgg agaa atga ggga ttct tctt	gaggact agcttgg atgtggc accaggt tgctggt tgtggga atggcat gaggggt agaagtt ggaagtt	cctgatgatg tgaagtttca actcagtgaa tgtgatgacc ccttgctggg tattcccact attccagtca gttccacaca gattccatct	ctggttagcg tgggaagagg caaggggagt tcgctggcct tggctgtttc cctaagatca accttcttgg atgtggcatg	tggctgggag aggcggagat tcaagctgct tggttggggc atgtcagggg tcgaggaatg gggcctccca	ggtggatggg cagcgggagt ttctgaagag tgccctccat agctaggaga tgaacatctg	ctagagetea teegeeeget aaagtgeeat ceatttgete agtggggatg	4860 4920 4980 5040 5100
agaa atga ggga ttct tctt	agettgg atgtgge aceaggt tgetggt tgtggga atggeat ggaggggt agaagtt ggaagtt	tgaagtttca actcagtgaa tgtgatgacc ccttgctggg tattcccact attccagtca gttccacaca gattccatct	tgggaagagg caaggggagt tcgctggcct tggctgtttc cctaagatca accttcttgg atgtggcatg	aggcggagat tcaagctgct tggttggggc atgtcagggg tcgaggaatg gggcctccca	cagcgggagt ttctgaagag tgccctccat agctaggaga tgaacatctg	tccgcccgct aaagtgccat ccatttgctc agtggggatg	4920 4980 5040 5100
atga ggga ttct tctt	atgtggc accaggt tgctggt tgtggga atggcat gaggggt agaagtt ggaagtt	actcagtgaa tgtgatgacc ccttgctggg tattcccact attccagtca gttccacaca gattccatct	caaggggagt tcgctggcct tggctgtttc cctaagatca accttcttgg atgtggcatg	tcaagctgct tggttggggc atgtcagggg tcgaggaatg gggcctccca	ttctgaagag tgccctccat agctaggaga tgaacatctg	aaagtgccat ccatttgctc agtggggatg	4980 5040 5100
ggga ttet tett	accaggt tgctggt tgtggga atggcat gaggggt agaagtt ggaagtt ggaagat	tgtgatgacc ccttgctggg tattcccact attccagtca gttccacaca gattccatct	tcgctggcct tggctgtttc cctaagatca accttcttgg atgtggcatg	tggttggggc atgtcagggg tcgaggaatg gggcctccca	tgccctccat agctaggaga tgaacatctg	ccatttgctc agtgggggatg	5040 5100
ttet tett	tgctggt tgtggga atggcat gaggggt agaagtt ggaagtt ggaagtt	ccttgctggg tattcccact attccagtca gttccacaca gattccatct	tggctgtttc cctaagatca accttcttgg atgtggcatg	atgtcagggg tcgaggaatg gggcctccca	agctaggaga tgaacatctg	agtgggggatg	5100
tcti ttta	tgtggga atggcat gagggggt agaagtt ggaagtt gaaagaa	tattcccact attccagtca gttccacaca gattccatct	cctaagatca accttcttgg atgtggcatg	tcgaggaatg gggcctccca	tgaacatctg	asaastaaas	
ttta	atggcat gaggggt agaagtt ggaagtt gaaagaa	attccagtca gttccacaca gattccatct	accttcttgg atgtggcatg	gggcctccca		gaggacggga	5160
	gaggggt agaagtt ggaagtt gaaagaa	gttccacaca gattccatct	atgtggcatg		gcgaggagtg	ggagtggcac	5220
agg	agaagtt ggaagtt gaaagaa	gattccatct		tcacaagagg	agctttcctt	gtcaggaatg	5280
gcaa	ggaagtt gaaagaa		tgggcttcag	taaaggaaga	ccttgtcgcc	tatggtggct	5340
cate	qaaaqaa	ggaaggcaga	tgggatggag	aggaagaggt	ccagttgatc	gcggctgttc	5400
cage	J J	cgtggtcaac	gtccagacaa	aaccgagctt	gttcaaagtg	aggaatgggg	5460
gaga	aaatcgg	ggctgtcgct	cttgactatc	cgagtggcac	ttcaggatct	cctattgtta	5520
acaç	ggaacgg	agaggtgatt	gggctgtacg	gcaatggcat	ccttgtcggt	gacaactcct	5580
tcgt	tgtccgc	catatcccag	actgaggtga	aggaagaagg	aaaggaggag	ctccaagaga	5640
tcco	cgacaat	gctaaagaaa	ggaatgacaa	ctgtccttga	ttttcatcct	ggagctggga	5700
agad	caagacg	tttcctccca	cagatcttgg	ccgagtgcgc	acggagacgc	ttgcgcactc	5760
ttgt	tgttggc	ccccaccagg	gttgttcttt	ctgaaatgaa	ggaggctttt	cacggcctgg	5820
acgt	tgaaatt	ccacacacag	gctttttccg	ctcacggcag	cgggagagaa	gtcattgatg	5880
ccat	tgtgcca	tgccacccta	acttacagga	tgttggaacc	aactagggtt	gttaactggg	5940
aagt	tgatcat	tatggatgaa	gcccattttt	tggatccagc	tagcatagcc	gctagaggtt	6000
9990	cagcgca	cagagctagg	gcaaatgaaa	gtgcaacaat	cttgatgaca	gccacaccgc	6060
ctg	ggactag	tgatgaattt	ccacattcaa	atggtgaaat	agaagatgtt	caaacggaca	6120
taco	ccagtga	gccctggaac	acagggcatg	actggatcct	agctgacaaa	aggcccacgg	6180
cato	ggttcct	tccatccatc	agagctgcaa	atgtcatggc	tgcctctttg	cgtaaggctg	6240
gaaa	agagtgt	ggtggtcctg	aacaggaaaa	cctttgagag	agaatacccc	acgataaagc	6300
agaa	agaaacc	tgactttata	ttggccactg	acatagctga	aatgggagcc	aacctttgcg	6360
tgga	agcgagt	gctggattgc	aggacggctt	ttaagcetgt	gcttgtggat	gaagggagga	6420
aggt	tggcaat	aaaagggcca	cttcgtatct	ccgcatcctc	tgctgctcaa	aggaggggggc	6480
gcat	ttgggag	aaatcccaac	agagatggag	actcatacta	ctattctgag	cctacaagtg	6540
aaaa	ataatgc	ccaccacgtc	tgctggttgg	aggcctcaat	gctcttggac	aacatggagg	6600
tga	ggggtgg	aatggtcgcc	ccactctatg	gcgttgaagg	aactaaaaca	ccagtttccc	6660
ctg	gtgaaat	gagactgagg	gatgaccaga	ggaaagtett	cagagaacta	gtgaggaatt	6720
gtga	acctgcc	cgtttggctt	tcgtggcaag	tggccaaggc	tggtttgaag	acgaatgatc	6780
gtaa	agtggtg	ttttgaaggc	cctgaggaac	atgagatctt	gaatgacagc	ggtgaaacag	6840
tgaa	agtgcag	ggctcctgga	ggagcaaaga	agcctctgcg	cccaaggtgg	tgtgatgaaa	6900
gggt	tgtcatc	tgaccagagt	gcgctgtctg	aatttattaa	gtttgctgaa	ggtaggaggg	6960
gago	ctgctga	agtgctagtt	gtgctgagtg	aactccctga	tttcctggct	aaaaaaggtg	7020
gaga	aggcaat	ggataccatc	agtgtgttcc	tccactctga	ggaaggetet	agggettace	7080
gcaa	atgcact	atcaatgatg	cctgaggcaa	tgacaatagt	catgctgttt	atactggctg	7140
gact	tactgac	atcgggaatg	gtcatctttt	tcatgtctcc	caaaggcatc	agtagaatgt	7200

ctatggcgat	gggcacaatg	gccggctgtg	gatatctcat	gttccttgga	ggcgtcaaac	7260
ccactcacat	ctcctatgtc	atgctcatat	tctttgtcct	gatggtggtt	gtgatccccg	7320
agccagggca	acaaaggtcc	atccaagaca	accaagtggc	atacctcatt	attggcatcc	7380
tgacgctggt	ttcagcggtg	gcagccaacg	agctaggcat	gctggagaaa	accaaagagg	7440
acctctttgg	gaagaagaac	ttaattccat	ctagtgcttc	accctggagt	tggccggatc	7500
ttgacctgaa	gccaggagct	gcctggacag	tgtacgttgg	cattgttaca	atgctctctc	7560
caatgttgca	ccactggatc	aaagtcgaat	atggcaacct	gtctctgtct	ggaatagccc	7620
agtcagcctc	agtcctttct	ttcatggaca	aggggatacc	attcatgaag	atgaatatct	7680
cggtcataat	gctgctggtc	agtggctgga	attcaataac	agtgatgcct	ctgctctgtg	7740
gcatagggtg	cgccatgctc	cactggtctc	tcattttacc	tggaatcaaa	gcgcagcagt	7800
caaagcttgc	acagagaagg	gtgttccatg	gcgttgccga	gaaccctgtg	gttgatggga	7860
atccaacagt	tgacattgag	gaagctcctg	aaatgcctgc	cctttatgag	aagaaactgg	7920
ctctatatct	ccttcttgct	ctcagcctag	cttctgttgc	catgtgcaga	acgccctttt	7980
cattggctga	aggcattgtc	ctagcatcag	ctgccttagg	gccgctcata	gagggaaaca	8040
ccagcettet	ttggaatgga	cccatggctg	tctccatgac	aggagtcatg	aggggggaatc	8100
actatgcttt	tgtgggagtc	atgtacaatc	tatggaagat	gaaaactgga	cgccggggga	8160
gcgcgaatgg	aaaaactttg	ggtgaagtct	ggaagaggga	actgaatctg	ttggacaagc	8220
gacagtttga	gttgtataaa	aggaccgaca	ttgtggaggt	ggatcgtgat	acggcacgca	8280
ggcatttggc	cgaagggaag	gtggacaccg	gggtggcggt	ctccaggggg	accgcaaagt	8340
taaggtggtt	ccatgagcgt	ggctatgtca	agctggaagg	tagggtgatt	gacctggggt	8400
gtggccgcgg	aggctggtgt	tactacgctg	ctgcgcaaaa	ggaagtgagt	ggggtcaaag	8460
gatttactct	tggaagagac	ggccatgaga	aacccatgaa	tgtgcaaagt	ctgggatgga	8520
acatcatcac	cttcaaggac	aaaactgata	tccaccgcct	agaaccagtg	aaatgtgaca	8580
cccttttgtg	tgacattgga	gagtcatcat	cgtcatcggt	cacagagggg	gaaaggaccg	8640
tgagagttet	tgatactgta	gaaaaatggc	tggettgtgg	ggttgacaac	ttctgtgtga	8700
aggtgttagc	tccatacatg	ccagatgttc	ttgagaaact	ggaattgctc	caaaggaggt	8760
ttggcggaac	agtgatcagg	aaccctctct	ccaggaattc	cactcatgaa	atgtactacg	8820
tgtctggagc	ccgcagcaat	gtcacattta	ctgtgaacca	aacateeege	ctcctgatga	8880
ggagaatgag	gcgtccaact	ggaaaagtga	ccctggaggc	tgacgtcatc	ctcccaattg	8940
ggacacgcag	tgttgagaca	gacaagggac	ccctggacaa	agaggccata	gaagaaaggg	9000
ttgagaggat	aaaatctgag	tacatgacct	cttggtttta	tgacaatgac	aacccctaca	9060
ggacctggca	ctactgtggc	tcctatgtca	caaaaacctc	aggaagtgcg	gcgagcatgg	9120
taaatggtgt	tattaaaatt	ctgacatatc	catgggacag	gatagaggag	gtcacaagaa	9180
tggcaatgac	tgacacaacc	ccttttggac	agcaaagagt	gtttaaagaa	aaagttgaca	9240
ccagagcaaa	ggatccacca	gcgggaacta	ggaagatcat	gaaagttgtc	aacaggtggc	9300
tgttccgcca	cctggccaga	gaaaagaacc	ccagactgtg	cacaaaggaa	gaatttattg	9360
caaaagtccg	aagtcatgca	gccattggag	cttacctgga	agaacaagaa	cagtggaaga	9420
ctgccaatga	ggctgtccaa	gacccaaagt	tctgggaact	ggtggatgaa	gaaaggaagc	9480
tgcaccaaca	aggcaggtgt	cggacttgtg	tgtacaacat	gatggggaaa	agagagaaga	9540

-continued

agctgtcaga	gtttgggaaa	gcaaagggaa	gccgtgccat	atggtatatg	tggctgggag	9600
cgcggtatct	tgagtttgag	gccctgggat	tcctgaatga	ggaccattgg	gcttccaggg	9660
aaaactcagg	aggaggagtg	gaaggcattg	gcttacaata	cctaggatat	gtgatcagag	9720
acctggctgc	aatggatggt	ggtggattct	acgcggatga	caccgctgga	tgggacacgc	9780
gcatcacaga	ggcagacctt	gatgatgaac	aggagatctt	gaactacatg	ageceacate	9840
acaaaaaact	ggcacaagca	gtgatggaaa	tgacatacaa	gaacaaagtg	gtgaaagtgt	9900
tgagaccagc	cccaggaggg	aaagcctaca	tggatgtcat	aagtcgacga	gaccagagag	9960
gatccgggca	ggtagtgact	tatgctctga	acaccatcac	caacttgaaa	gtccaattga	10020
tcagaatggc	agaagcagag	atggtgatac	atcaccaaca	tgttcaagat	tgtgatgaat	10080
cagttetgae	caggctggag	gcatggctca	ctgagcacgg	atgtgacaga	ctgaagagga	10140
tggcggtgag	tggagacgac	tgtgtggtcc	ggcccatcga	tgacaggttc	ggcctggccc	10200
tgtcccatct	caacgccatg	tccaaggtta	gaaaggacat	atctgaatgg	cagccatcaa	10260
aagggtggaa	tgattgggag	aatgtgccct	tctgttccca	ccacttccat	gaactacagc	10320
tgaaggatgg	caggaggatt	gtggtgcctt	gccgagaaca	ggacgagete	attgggagag	10380
gaagggtgtc	tccaggaaac	ggctggatga	tcaaggaaac	agettgeete	agcaaagcct	10440
atgccaacat	gtggtcactg	atgtatttc	acaaaaggga	catgaggcta	ctgtcattgg	10500
ctgtttcctc	agetgtteee	acctcatggg	ttccacaagg	acgcacaaca	tggtcgattc	10560
atgggaaagg	ggagtggatg	accacggaag	acatgcttga	ggtgtggaac	agagtatgga	10620
taaccaacaa	cccacacatg	caggacaaga	caatggtgaa	aaaatggaga	gatgtccctt	10680
atctaaccaa	gagacaagac	aagctgtgcg	gatcactgat	tggaatgacc	aatagggcca	10740
cctgggcctc	ccacatccat	ttagtcatcc	atcgtatccg	aacgctgatt	ggacaggaga	10800
aatacactga	ctacctaaca	gtcatggaca	ggtattctgt	ggatgctgac	ctgcaactgg	10860
gtgagcttat	ctgaaacacc	atctaacagg	aataaccggg	atacaaacca	cgggtggaga	10920
accggactcc	ccacaacctg	aaaccgggat	ataaaccacg	gctggagaac	cggactccgc	10980
acttaaaatg	aaacagaaac	cgggataaaa	actacggatg	gagaaccgga	ctccacacat	11040
tgagacagaa	gaagttgtca	gcccagaacc	ccacacgagt	tttgccactg	ctaagctgtg	11100
aggcagtgca	ggctgggaca	gccgacctcc	aggttgcgaa	aaacctggtt	tctgggacct	11160
cccaccccag	agtaaaaaga	acggagcctc	cgctaccacc	ctcccacgtg	gtggtagaaa	11220
gacggggtct	agaggttaga	ggagaccctc	cagggaacaa	atagtgggac	catattgacg	11280
ccagggaaag	accggagtgg	ttctctgctt	ttcctccaga	ggtctgtgag	cacagtttgc	11340
tcaagaataa	gcagaccttt	ggatgacaaa	cacaaaacca	ctgggtcggc	atggcatctc	11400
cacctcctcg	cggtccgacc	tgggcatccg	aaggaggacg	cacgtccact	cggatggcta	11460
agggagagcc	acgageteet	cgacagatca	taatcagcca	taccacattt	gtagaggttt	11520
tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	atgaatgcaa	11580
ttgttgttgt	taacttgttt	attgcagctt	ataatggtta	caaataaagc	aatagcatca	11640
caaatttcac	aaataaagca	ttttttcac	tgcattctag	ttgtggtttg	tccaaactca	11700
tcaagatctc	gagcaagacg	tttcccgttg	aatatggctc	ataacacccc	ttgtattact	11760
gtttatgtaa	gcagacagtt	ttattgttca	tgatgatata	ttttatctt	gtgcaatgta	11820
acatcagaga	ttttgagaca	caacgtggct	ttgttgaata	aatcgaactt	ttgctgagtt	11880
gaaggatcag	atcacgcatc	ttcccgacaa	cgcagaccgt	tccgtggcaa	agcaaaagtt	11940

-continued

caaaatcacc aactggtcca cctacaacaa ageteteate aacegtgget cceteaettt 12000 ctggctggat gatggggcga ttcaggcctg gtatgagtca gcaacacctt cttcacgagg 12060 cagaceteag egetagegga gtgtataetg gettaetatg ttggeaetga tgagggtgte 12120 agtgaagtgc ttcatgtggc aggagaaaaa aggctgcacc ggtgcgtcag cagaatatgt 12180 gatacaggat atatteeget teetegetea etgaeteget aegeteggte gttegaetge 12240 ggcgagcgga aatggcttac gaacggggcg gagatttcct ggaagatgcc aggaagatac 12300 ttaacaggga agtgagaggg ccgcggcaaa gccgtttttc cataggctcc gcccccctga 12360 caagcatcac gaaatctgac gctcaaatca gtggtggcga aacccgacag gactataaag 12420 ataccaggeg ttteecetgg eggeteeete gtgegetete etgtteetge ettteggttt 12480 accggtgtca ttccgctgtt atggccgcgt ttgtctcatt ccacgcctga cactcagttc 12540 cgggtaggca gttcgctcca agctggactg tatgcacgaa ccccccgttc agtccgaccg 12600 ctgcgcctta tccggtaact atcgtcttga gtccaacccg gaaagacatg caaaagcacc 12660 actggcagca gccactggta attgatttag aggagttagt cttgaagtca tgcgccggtt 12720 aaqqctaaac tqaaaqqaca aqttttqqtq actqcqctcc tccaaqccaq ttacctcqqt 12780 tcaaaqaqtt qqtaqctcaq aqaaccttcq aaaaaccqcc ctqcaaqqcq qttttttcqt 12840 tttcagagca agagattacg cgcagaccaa aacgatctca agaagatcat cttattaagg 12900 qqtctqacqc tcaqtqqaac qaaaactcac qttaaqqqat tttqqtcatq aqattatcaa 12960 aaaggatett caeetagate ettttaaatt aaaaatgaag ttttaaatea atetaaagta 13020 tatatgagta aacttggtet gacagttace aatgettaat cagtgaggea cetateteag 13080 cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga 13140 tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac 13200 cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc 13260 ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta 13320 gttcgccagt taatagtttg cgcaacgttg ttgccattgc tgcaggcatc gtggtgtcac 13380 gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat 13440 gatececcat gttgtgcaaa aaageggtta geteettegg teeteegate gttgteagaa 13500 gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg 13560 tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag 13620 aatagtgtat geggegaeeg agttgetett geeeggegte aacaeegggat aataeegege 13680 cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct 13740 caaggatett acceptigting agatecagtt egatgtaace caetegtigea eccaaetgat 13800 cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaaatg 13860 ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc 13920 aatattattg aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta 13980 tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctgacg 14040 tgtcgacgcg gccgctagcg atgaccctgc tgattggttc gctgaccatt tccgggtgcg 14100 ggacggcgtt accagaaact cagaaggttc gtccaaccaa accgactctg acggcagttt 14160 acgagagaga tgatagggtc tgcttcagta agccagatgc tacacaatta ggcttgtaca 14220

tattgtcgtt agaacgcggc tacaattaat acataacctt atgtatcata cacatacgat 14280

-continued

ttaggtgaca ctata

14295

<210> SEQ ID NO 7 <211> LENGTH: 10863 <212> TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE:									
<223> OTHER INFORMATION: synthetic polynucleotide									
<400> SEQUI	ENCE: 7								
gatgggcggc	gcatgagaga	agcccagacc	aattacctac	ccaaaatgga	gaaagttcac	60			
gttgacatcg	aggaagacag	cccattcctc	agagetttge	ageggagett	cccgcagttt	120			
gaggtagaag	ccaagcaggt	cactgataat	gaccatgcta	atgccagagc	gttttcgcat	180			
ctggcttcaa	aactgatcga	aacggaggtg	gacccatccg	acacgatcct	tgacattgga	240			
agtgcgcccg	cccgcagaat	gtattctaag	cacaagtatc	attgtatctg	tccgatgaga	300			
tgtgcggaag	atccggacag	attgtataag	tatgcaacta	agctgaagaa	aaactgtaag	360			
gaaataactg	ataaggaatt	ggacaagaaa	atgaaggagc	tggccgccgt	catgagcgac	420			
cctgacctgg	aaactgagac	tatgtgcctc	cacgacgacg	agtcgtgtcg	ctacgaaggg	480			
caagtcgctg	tttaccagga	tgtatacgcg	gttgacggac	cgacaagtct	ctatcaccaa	540			
gccaataagg	gagttagagt	cgcctactgg	ataggetttg	acaccacccc	ttttatgttt	600			
aagaacttgg	ctggagcata	tccatcatac	tctaccaact	gggccgacga	aaccgtgtta	660			
acggctcgta	acataggcct	atgcagctct	gacgttatgg	agcggtcacg	tagagggatg	720			
tccattctta	gaaagaagta	tttgaaacca	tccaacaatg	ttctattctc	tgttggctcg	780			
accatctacc	acgagaagag	ggacttactg	aggagctggc	acctgccgtc	tgtatttcac	840			
ttacgtggca	agcaaaatta	cacatgtcgg	tgtgagacta	tagttagttg	cgacgggtac	900			
gtcgttaaaa	gaatagctat	cagtccaggc	ctgtatggga	agccttcagg	ctatgctgct	960			
acgatgcacc	gcgagggatt	cttgtgctgc	aaagtgacag	acacattgaa	cggggagagg	1020			
gtctcttttc	ccgtgtgcac	gtatgtgcca	gctacattgt	gtgaccaaat	gactggcata	1080			
ctggcaacag	atgtcagtgc	ggacgacgcg	caaaaactgc	tggttgggct	caaccagcgt	1140			
atagtcgtca	acggtcgcac	ccagagaaac	accaatacca	tgaaaaatta	ccttttgccc	1200			
gtagtggccc	aggcatttgc	taggtgggca	aaggaatata	aggaagatca	agaagatgaa	1260			
aggccactag	gactacgaga	tagacagtta	gtcatggggt	gttgttgggc	ttttagaagg	1320			
cacaagataa	catctattta	taagcgcccg	gatacccaaa	ccatcatcaa	agtgaacagc	1380			
gatttccact	cattcgtgct	gcccaggata	ggcagtaaca	cattggagat	cgggctgaga	1440			
acaagaatca	ggaaaatgtt	agaggagcac	aaggagccgt	cacctctcat	taccgccgag	1500			
gacgtacaag	aagctaagtg	cgcagccgat	gaggctaagg	aggtgcgtga	agccgaggag	1560			
ttgcgcgcag	ctctaccacc	tttggcagct	gatgttgagg	agcccactct	ggaagccgat	1620			
gtcgacttga	tgttacaaga	ggctggggcc	ggctcagtgg	agacacctcg	tggcttgata	1680			
aaggttacca	gctacgatgg	cgaggacaag	atcggctctt	acgctgtgct	ttctccgcag	1740			
gctgtactca	agagtgaaaa	attatcttgc	atccaccctc	tcgctgaaca	agtcatagtg	1800			
ataacacact	ctggccgaaa	agggcgttat	gccgtggaac	cataccatgg	taaagtagtg	1860			
gtgccagagg	gacatgcaat	acccgtccag	gactttcaag	ctctgagtga	aagtgccacc	1920			
attgtgtaca	acgaacgtga	gttcgtaaac	aggtacctgc	accatattgc	cacacatgga	1980			
ggagcgctga	acactgatga	agaatattac	aaaactgtca	agcccagcga	gcacgacggc	2040			

gaatacctgt	acgacatcga	caggaaacag	tgcgtcaaga	aagaactagt	cactgggcta	2100
gggctcacag	gcgagctggt	ggateeteee	ttccatgaat	tcgcctacga	gagtctgaga	2160
acacgaccag	ccgctcctta	ccaagtacca	accatagggg	tgtatggcgt	gccaggatca	2220
ggcaagtctg	gcatcattaa	aagcgcagtc	accaaaaaag	atctagtggt	gagcgccaag	2280
aaagaaaact	gtgcagaaat	tataagggac	gtcaagaaaa	tgaaagggct	ggacgtcaat	2340
gccagaactg	tggactcagt	gctcttgaat	ggatgcaaac	accccgtaga	gaccctgtat	2400
attgacgaag	cttttgcttg	tcatgcaggt	actctcagag	cgctcatagc	cattataaga	2460
cctaaaaagg	cagtgctctg	cggggatccc	aaacagtgcg	gttttttaa	catgatgtgc	2520
ctgaaagtgc	attttaacca	cgagatttgc	acacaagtct	tccacaaaag	catctctcgc	2580
cgttgcacta	aatctgtgac	ttcggtcgtc	tcaaccttgt	tttacgacaa	aaaaatgaga	2640
acgacgaatc	cgaaagagac	taagattgtg	attgacacta	ccggcagtac	caaacctaag	2700
caggacgatc	tcattctcac	ttgtttcaga	gggtgggtga	agcagttgca	aatagattac	2760
aaaggcaacg	aaataatgac	ggcagctgcc	tctcaagggc	tgacccgtaa	aggtgtgtat	2820
gccgttcggt	acaaggtgaa	tgaaaatcct	ctgtacgcac	ccacctcaga	acatgtgaac	2880
gtcctactga	cccgcacgga	ggaccgcatc	gtgtggaaaa	cactagccgg	cgacccatgg	2940
ataaaaacac	tgactgccaa	gtaccctggg	aatttcactg	ccacgataga	ggagtggcaa	3000
gcagagcatg	atgccatcat	gaggcacatc	ttggagagac	cggaccctac	cgacgtcttc	3060
cagaataagg	caaacgtgtg	ttgggccaag	gctttagtgc	cggtgctgaa	gaccgctggc	3120
atagacatga	ccactgaaca	atggaacact	gtggattatt	ttgaaacgga	caaagctcac	3180
tcagcagaga	tagtattgaa	ccaactatgc	gtgaggttct	ttggactcga	tctggactcc	3240
ggtctatttt	ctgcacccac	tgttccgtta	tccattagga	ataatcactg	ggataactcc	3300
ccgtcgccta	acatgtacgg	gctgaataaa	gaagtggtcc	gtcagctctc	tcgcaggtac	3360
ccacaactgc	ctcgggcagt	tgccactgga	agagtctatg	acatgaacac	tggtacactg	3420
cgcaattatg	atccgcgcat	aaacctagta	cctgtaaaca	gaagactgcc	tcatgcttta	3480
gtcctccacc	ataatgaaca	cccacagagt	gacttttctt	cattcgtcag	caaattgaag	3540
ggcagaactg	tcctggtggt	cggggaaaag	ttgtccgtcc	caggcaaaat	ggttgactgg	3600
ttgtcagacc	ggcctgaggc	taccttcaga	gctcggctgg	atttaggcat	cccaggtgat	3660
gtgcccaaat	atgacataat	atttgttaat	gtgaggaccc	catataaata	ccatcactat	3720
cagcagtgtg	aagaccatgc	cattaagctt	agcatgttga	ccaagaaagc	ttgtctgcat	3780
ctgaatcccg	gcggaacctg	tgtcagcata	ggttatggtt	acgctgacag	ggccagcgaa	3840
agcatcattg	gtgctatagc	gcggcagttc	aagttttccc	gggtatgcaa	accgaaatcc	3900
tcacttgaag	agacggaagt	tctgtttgta	ttcattgggt	acgatcgcaa	ggcccgtacg	3960
cacaatcctt	acaagctttc	atcaaccttg	accaacattt	atacaggttc	cagactccac	4020
gaagccggat	gtgcaccctc	atatcatgtg	gtgcgagggg	atattgccac	ggccaccgaa	4080
ggagtgatta	taaatgctgc	taacagcaaa	ggacaacctg	gcggaggggt	gtgcggagcg	4140
ctgtataaga	aattcccgga	aagcttcgat	ttacagccga	tcgaagtagg	aaaagcgcga	4200
ctggtcaaag	gtgcagctaa	acatatcatt	catgccgtag	gaccaaactt	caacaaagtt	4260
tcggaggttg	aaggtgacaa	acagttggca	gaggettatg	agtccgctaa	gattgtcaac	4320
gataacaatt	acaagtcagt	agcgattcca	ctttgtccac	cggcatcttt	tccgggaaca	4380

46

45

aagatcgact	aacccaatca	ttgaaccatt	tgctgacagc	tttagacacc	actgatgcag	4440
atgtagccat	atactgcagg	gacaagaaat	gggaatgact	ctcaaggaag	cagtggctag	4500
gagagaagca	gtggaggaga	tatgcatatc	cgacgactct	tcagtgacag	aacctgatgc	4560
agagctggtg	agggtgcatc	cgaagagttc	tttggctgga	aggaagggct	acagcacaag	4620
cgatggcaaa	actttctcat	atttggaagg	gaccaagttt	caccaggcgg	ccaaggatat	4680
agcagaaatt	aatgccatgt	ggcccgttgc	aacggaggcc	aatgagcagg	tatgcatgta	4740
tatcctcgga	gaaagcatga	gcagtattag	gtcgaaatgc	cccgtcgaag	agtcggaagc	4800
ctccacacca	cctagcacgc	tgccttgctt	gtgcatccat	gccatgactc	cagaaagagt	4860
acagcgccta	aaagcctcac	gtccagaaca	aattactgtg	tgctcatcct	ttccattgcc	4920
gaagtataga	atcactggtg	tgcagaagat	ccaatgetee	cagcctatat	tgttctcacc	4980
gaaagtgcct	gcgtatattc	atccaaggaa	gtatctcgtg	gaaacaccac	cggtagacga	5040
gactccggag	ccatcggcag	agaaccaatc	cacagagggg	acacctgaac	aaccaccact	5100
tataaccgag	gatgagacca	ggactagaac	gcctgagccg	atcatcatcg	aagaggaaga	5160
agaggatagc	ataagtttgc	tgtcagatgg	cccgacccac	caggtgctgc	aagtcgaggc	5220
agacattcac	gggccgccct	ctgtatctag	ctcatcctgg	tccattcctc	atgcatccga	5280
ctttgatgtg	gacagtttat	ccatacttga	caccctggag	ggagctagcg	tgaccagcgg	5340
ggcaacgtca	gccgagacta	actcttactt	cgcaaagagt	atggagtttc	tggcgcgacc	5400
ggtgcctgcg	cctcgaacag	tattcaggaa	ccctccacat	cccgctccgc	gcacaagaac	5460
accgtcactt	gcacccagca	gggcctgctc	gagaaccagc	ctagtttcca	ccccgccagg	5520
cgtgaatagg	gtgatcacta	gagaggagct	cgaggcgctt	accccgtcac	gcactcctag	5580
caggtcggtc	tcgagaacca	gcctggtctc	caacccgcca	ggcgtaaata	gggtgattac	5640
aagagaggag	tttgaggcgt	tcgtagcaca	acaacaatga	cggtttgatg	cgggtgcata	5700
catcttttcc	tccgacaccg	gtcaagggca	tttacaacaa	aaatcagtaa	ggcaaacggt	5760
gctatccgaa	gtggtgttgg	agaggaccga	attggagatt	tcgtatgccc	cgcgcctcga	5820
ccaagaaaaa	gaagaattac	tacgcaagaa	attacagtta	aatcccacac	ctgctaacag	5880
aagcagatac	cagtccagga	aggtggagaa	catgaaagcc	ataacagcta	gacgtattct	5940
gcaaggccta	gggcattatt	tgaaggcaga	aggaaaagtg	gagtgctacc	gaaccctgca	6000
tcctgttcct	ttgtattcat	ctagtgtgaa	ccgtgccttt	tcaagcccca	aggtcgcagt	6060
ggaagcctgt	aacgccatgt	tgaaagagaa	ctttccgact	gtggcttctt	actgtattat	6120
tccagagtac	gatgcctatt	tggacatggt	tgacggagct	tcatgctgct	tagacactgc	6180
cagtttttgc	cctgcaaagc	tgcgcagctt	tccaaagaaa	cactcctatt	tggaacccac	6240
aatacgatcg	gcagtgcctt	cagcgatcca	gaacacgctc	cagaacgtcc	tggcagctgc	6300
cacaaaaaga	aattgcaatg	tcacgcaaat	gagagaattg	cccgtattgg	attcggcggc	6360
ctttaatgtg	gaatgcttca	agaaatatgc	gtgtaataat	gaatattggg	aaacgtttaa	6420
agaaaacccc	atcaggctta	ctgaagaaaa	cgtggtaaat	tacattacca	aattaaaagg	6480
accaaaagct	gctgctcttt	ttgcgaagac	acataatttg	aatatgttgc	aggacatacc	6540
aatggacagg	tttgtaatgg	acttaaagag	agacgtgaaa	gtgactccag	gaacaaaaca	6600
tactgaagaa	cggcccaagg	tacaggtgat	ccaggctgcc	gatccgctag	caacagcgta	6660
tctgtgcgga	atccaccgag	agctggttag	gagattaaat	gcggtcctgc	ttccgaacat	6720
tcatacactg	tttgatatgt	cggctgaaga	ctttgacgct	attatagccg	agcacttcca	6780

gcctggggat	tgtgttctgg	aaactgacat	cgcgtcgttt	gataaaagtg	aggacgacgc	6840
catggctctg	accgcgttaa	tgattctgga	agacttaggt	gtggacgcag	agctgttgac	6900
gctgattgag	gcggctttcg	gcgaaatttc	atcaatacat	ttgcccacta	aaactaaatt	6960
taaattcgga	gccatgatga	aatctggaat	gttcctcaca	ctgtttgtga	acacagtcat	7020
taacattgta	atcgcaagca	gagtgttgag	agaacggcta	accggatcac	catgtgcagc	7080
attcattgga	gatgacaata	tcgtgaaagg	agtcaaatcg	gacaaattaa	tggcagacag	7140
gtgcgccacc	tggttgaata	tggaagtcaa	gattatagat	gctgtggtgg	gcgagaaagc	7200
gccttatttc	tgtggagggt	ttattttgtg	tgactccgtg	accggcacag	cgtgccgtgt	7260
ggcagacccc	ctaaaaaggc	tgtttaagct	tggcaaacct	ctggcagcag	acgatgaaca	7320
tgatgatgac	aggagaaggg	cattgcatga	agagtcaaca	cgctggaacc	gagtgggtat	7380
tctttcagag	ctgtgcaagg	cagtagaatc	aaggtatgaa	accgtaggaa	cttccatcat	7440
agttatggcc	atgactactc	tagctagcag	tgttaaatca	ttcagctacc	tgagaggggc	7500
ccctataact	ctctacggct	aacctgaatg	gactacgaca	tagtctagtc	cgccaagtct	7560
agaccatgtc	tggtcgtaaa	gctcagggaa	aaaccctggg	cgtcaatatg	gtacgacgag	7620
gagttcgctc	cttgtcaaac	aaaataaaac	aaaaaacaaa	acaaattgga	aacagacctg	7680
gaccttcaag	aggtgttcaa	ggatttatct	ttttctttt	gttcaacatt	ttgactggaa	7740
aaaagatcac	agcccaccta	aagaggttgt	ggaaaatgct	ggacccaaga	caaggcttgg	7800
ctgttctaag	gaaagtcaag	agagtggtgg	ccagtttgat	gagaggattg	tcctcaagga	7860
aacgccgttc	ccatgatgtt	ctgactgtgc	aattcctaat	tttgggaatg	ctgttgatga	7920
cgggtggata	agggccccta	taactctcta	cggctaacct	gaatggacta	cgacatagtc	7980
tagtccgcca	agtctagagc	ttaccatgac	cgagtacaag	cccacggtgc	gcctcgccac	8040
ccgcgacgac	gtccccaggg	ccgtacgcac	cctcgccgcc	gcgttcgccg	actaccccgc	8100
cacgcgccac	accgtcgatc	cggaccgcca	catcgagcgg	gtcaccgagc	tgcaagaact	8160
cttcctcacg	cgcgtcgggc	tcgacatcgg	caaggtgtgg	gtcgcggacg	acggcgccgc	8220
ggtggcggtc	tggaccacgc	cggagagcgt	cgaagcgggg	gcggtgttcg	ccgagatcgg	8280
cccgcgcatg	gccgagttga	gcggttcccg	gctggccgcg	cagcaacaga	tggaaggcct	8340
cctggcgccg	caccggccca	aggagcccgc	gtggttcctg	gccaccgtcg	gcgtctcgcc	8400
cgaccaccag	ggcaagggtc	tgggcagcgc	cgtcgtgctc	cccggagtgg	aggcggccga	8460
gcgcgccggg	gtgcccgcct	tcctggagac	ctccgcgccc	cgcaacctcc	ccttctacga	8520
gcggctcggc	ttcaccgtca	ccgccgacgt	cgagtgcccg	aaggaccgcg	cgacctggtg	8580
catgacccgc	aagcccggtg	cctgacgccc	gccccacgac	ccgcagcgcc	cgaccgaaag	8640
gagcgcacga	ccccatgatc	gctagaccat	ggggtaccga	gtatgttacg	tgcaaaggtg	8700
attgtcaccc	cccgaaagac	catattgtga	cacaccctca	gtatcacgcc	caaacattta	8760
cagccgcggt	gtcaaaaacc	gcgtggacgt	ggttaacatc	cctgctggga	ggatcagccg	8820
taattattat	aattggcttg	gtgctggcta	ctattgtggc	catgtacgtg	ctgaccaacc	8880
agaaacataa	ttgaatacag	cagcaattgg	caagctgctt	acatagaact	cgcggcgatt	8940
ggcatgccgc	cttaaaattt	ttattttatt	ttttctttc	ttttccgaat	cggattttgt	9000
ttttaatatt	tcaaaaaaaa	aaaaaaaaaa	aaaaaacgc	gtcgagggga	attaattctt	9060
gaagacgaaa	gggccaggtg	gcacttttcg	gggaaatgtg	cgcggaaccc	ctatttgttt	9120

49

-continued

atttttctaa atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgct	9180
tcaataatat tgaaaaagga agagtatgag tattcaacat ttccgtgtcg cccttattcc	9240
cttttttgcg gcattttgcc ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa	9300
agatgetgaa gateagttgg gtgeaegagt gggttaeate gaaetggate teaaeagegg	9360
taagateett gagagtttte geeeegaaga aegtttteea atgatgagea ettttaaagt	9420
tetgetatgt ggegeggtat tatecegtgt tgaegeeggg caagageaae teggtegeeg	9480
catacactat teteagaatg aettggttga gtaeteacea gteacagaaa ageatettae	9540
ggatggcatg acagtaagag aattatgcag tgctgccata accatgagtg ataacactgc	9600
ggccaactta cttctgacaa cgatcggagg accgaaggag ctaaccgctt ttttgcacaa	9660
catgggggat catgtaactc gccttgatcg ttgggaaccg gagctgaatg aagccatacc	9720
aaacgacgag cgtgacacca cgatgcctgt agcaatggca acaacgttgc gcaaactatt	9780
aactggcgaa ctacttactc tagcttcccg gcaacaatta atagactgga tggaggcgga	9840
taaagttgca ggaccacttc tgcgctcggc ccttccggct ggctggttta ttgctgataa	9900
atotggagoo ggtgagogtg ggtotogogg tatoattgoa goaotggggo cagatggtaa	9960
gccctcccgt atcgtagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa	10020
tagacagatc gctgagatag gtgcctcact gattaagcat tggtaactgt cagaccaagt	10080
ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa ggatctaggt	10140
gaagateett tttgataate teatgaceaa aateeettaa egtgagtttt egtteeaetg	10200
agcgtcagac cccgtagaaa agatcaaagg atcttcttga gatccttttt ttctgcgcgt	10260
aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt tgccggatca	10320
agagetaeca aetetttte egaaggtaae tggetteage agagegeaga taecaaatae	10380
tgtccttcta gtgtagccgt agttaggcca ccacttcaag aactctgtag caccgcctac	10440
ataceteget etgetaatee tgttaceagt ggetgetgee agtggegata agtegtgtet	10500
taccgggttg gactcaagac gatagttacc ggataaggeg cageggtegg getgaaeggg	10560
gggttcgtgc acacageeea gettggageg aaegaeetae aeegaaetga gataeetaea	10620
gcgtgagcat tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt	10680
aageggeagg gteggaacag gagagegeae gagggagett eeagggggaa aegeetggta	10740
tetttatagt eetgtegggt ttegeeacet etgaettgag egtegatttt tgtgatgete	10800
gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg agctcgattt aggtgacact	10860
ata	10863
<210> SEQ ID NO 8 <211> LENGTH: 10796 <212> TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide	
<400> SEQUENCE: 8	
gatgggcggc gcatgagaga agcccagacc aattacctac ccaaaatgga gaaagttcac	60
gttgacatcg aggaagacag cccattcctc agagctttgc agcggagctt cccgcagttt	120
gaggtagaag ccaagcaggt cactgataat gaccatgcta atgccagagc gttttcgcat	180
ctggcttcaa aactgatcga aacggaggtg gacccatccg acacgatcct tgacattgga	240
agtgcgcccg cccgcagaat gtattctaag cacaagtatc attgtatctg tccgatgaga	300

tgtgcggaag	atccggacag	attgtataag	tatgcaacta	agctgaagaa	aaactgtaag	360
gaaataactg	ataaggaatt	ggacaagaaa	atgaaggagc	tggccgccgt	catgagcgac	420
cctgacctgg	aaactgagac	tatgtgcctc	cacgacgacg	agtcgtgtcg	ctacgaaggg	480
caagtcgctg	tttaccagga	tgtatacgcg	gttgacggac	cgacaagtct	ctatcaccaa	540
gccaataagg	gagttagagt	cgcctactgg	ataggetttg	acaccacccc	ttttatgttt	600
aagaacttgg	ctggagcata	tccatcatac	tctaccaact	gggccgacga	aaccgtgtta	660
acggctcgta	acataggcct	atgcagctct	gacgttatgg	agcggtcacg	tagagggatg	720
tccattctta	gaaagaagta	tttgaaacca	tccaacaatg	ttctattctc	tgttggctcg	780
accatctacc	acgagaagag	ggacttactg	aggagctggc	acctgccgtc	tgtatttcac	840
ttacgtggca	agcaaaatta	cacatgtcgg	tgtgagacta	tagttagttg	cgacgggtac	900
gtcgttaaaa	gaatagctat	cagtccaggc	ctgtatggga	agccttcagg	ctatgctgct	960
acgatgcacc	gcgagggatt	cttgtgctgc	aaagtgacag	acacattgaa	cggggagagg	1020
gtctctttc	ccgtgtgcac	gtatgtgcca	gctacattgt	gtgaccaaat	gactggcata	1080
ctggcaacag	atgtcagtgc	ggacgacgcg	caaaaactgc	tggttgggct	caaccagcgt	1140
atagtcgtca	acggtcgcac	ccagagaaac	accaatacca	tgaaaaatta	ccttttgccc	1200
gtagtggccc	aggcatttgc	taggtgggca	aaggaatata	aggaagatca	agaagatgaa	1260
aggccactag	gactacgaga	tagacagtta	gtcatggggt	gttgttgggc	ttttagaagg	1320
cacaagataa	catctattta	taagcgcccg	gatacccaaa	ccatcatcaa	agtgaacagc	1380
gatttccact	cattcgtgct	gcccaggata	ggcagtaaca	cattggagat	cgggctgaga	1440
acaagaatca	ggaaaatgtt	agaggagcac	aaggagccgt	cacctctcat	taccgccgag	1500
gacgtacaag	aagctaagtg	cgcagccgat	gaggctaagg	aggtgcgtga	agccgaggag	1560
ttgcgcgcag	ctctaccacc	tttggcagct	gatgttgagg	agcccactct	ggaagccgat	1620
gtcgacttga	tgttacaaga	ggctggggcc	ggctcagtgg	agacacctcg	tggcttgata	1680
aaggttacca	gctacgatgg	cgaggacaag	atcggctctt	acgctgtgct	ttctccgcag	1740
gctgtactca	agagtgaaaa	attatcttgc	atccaccctc	tcgctgaaca	agtcatagtg	1800
ataacacact	ctggccgaaa	agggcgttat	gccgtggaac	cataccatgg	taaagtagtg	1860
gtgccagagg	gacatgcaat	acccgtccag	gactttcaag	ctctgagtga	aagtgccacc	1920
attgtgtaca	acgaacgtga	gttcgtaaac	aggtacctgc	accatattgc	cacacatgga	1980
ggagcgctga	acactgatga	agaatattac	aaaactgtca	agcccagcga	gcacgacggc	2040
gaatacctgt	acgacatcga	caggaaacag	tgcgtcaaga	aagaactagt	cactgggcta	2100
gggctcacag	gcgagctggt	ggatcctccc	ttccatgaat	tcgcctacga	gagtetgaga	2160
acacgaccag	ccgctcctta	ccaagtacca	accatagggg	tgtatggcgt	gccaggatca	2220
ggcaagtctg	gcatcattaa	aagcgcagtc	accaaaaaag	atctagtggt	gagcgccaag	2280
aaagaaaact	gtgcagaaat	tataagggac	gtcaagaaaa	tgaaagggct	ggacgtcaat	2340
gccagaactg	tggactcagt	gctcttgaat	ggatgcaaac	accccgtaga	gaccctgtat	2400
attgacgaag	cttttgcttg	tcatgcaggt	actctcagag	cgctcatagc	cattataaga	2460
cctaaaaagg	cagtgctctg	cggggatccc	aaacagtgcg	gttttttaa	catgatgtgc	2520
ctgaaagtgc	attttaacca	cgagatttgc	acacaagtct	tccacaaaag	catctctcgc	2580
cgttgcacta	aatctgtgac	ttcggtcgtc	tcaaccttgt	tttacgacaa	aaaaatgaga	2640

54

53

acgacgaatc	cgaaagagac	taagattgtg	attgacacta	ccggcagtac	caaacctaag	2700
caggacgatc	tcattctcac	ttgtttcaga	gggtgggtga	agcagttgca	aatagattac	2760
aaaggcaacg	aaataatgac	ggcagctgcc	tctcaagggc	tgacccgtaa	aggtgtgtat	2820
gccgttcggt	acaaggtgaa	tgaaaatcct	ctgtacgcac	ccacctcaga	acatgtgaac	2880
gtcctactga	cccgcacgga	ggaccgcatc	gtgtggaaaa	cactagccgg	cgacccatgg	2940
ataaaaacac	tgactgccaa	gtaccctggg	aatttcactg	ccacgataga	ggagtggcaa	3000
gcagagcatg	atgccatcat	gaggcacatc	ttggagagac	cggaccctac	cgacgtcttc	3060
cagaataagg	caaacgtgtg	ttgggccaag	gctttagtgc	cggtgctgaa	gaccgctggc	3120
atagacatga	ccactgaaca	atggaacact	gtggattatt	ttgaaacgga	caaagctcac	3180
tcagcagaga	tagtattgaa	ccaactatgc	gtgaggttct	ttggactcga	tctggactcc	3240
ggtctatttt	ctgcacccac	tgttccgtta	tccattagga	ataatcactg	ggataactcc	3300
ccgtcgccta	acatgtacgg	gctgaataaa	gaagtggtcc	gtcagctctc	tcgcaggtac	3360
ccacaactgc	ctcgggcagt	tgccactgga	agagtctatg	acatgaacac	tggtacactg	3420
cgcaattatg	atccgcgcat	aaacctagta	cctgtaaaca	gaagactgcc	tcatgcttta	3480
gtcctccacc	ataatgaaca	cccacagagt	gacttttctt	cattcgtcag	caaattgaag	3540
ggcagaactg	tcctggtggt	cggggaaaag	ttgtccgtcc	caggcaaaat	ggttgactgg	3600
ttgtcagacc	ggcctgaggc	taccttcaga	gctcggctgg	atttaggcat	cccaggtgat	3660
gtgcccaaat	atgacataat	atttgttaat	gtgaggaccc	catataaata	ccatcactat	3720
cagcagtgtg	aagaccatgc	cattaagctt	agcatgttga	ccaagaaagc	ttgtctgcat	3780
ctgaatcccg	gcggaacctg	tgtcagcata	ggttatggtt	acgctgacag	ggccagcgaa	3840
agcatcattg	gtgctatagc	gcggcagttc	aagttttccc	gggtatgcaa	accgaaatcc	3900
tcacttgaag	agacggaagt	tctgtttgta	ttcattgggt	acgatcgcaa	ggcccgtacg	3960
cacaatcctt	acaagctttc	atcaaccttg	accaacattt	atacaggttc	cagactccac	4020
gaagccggat	gtgcaccctc	atatcatgtg	gtgcgagggg	atattgccac	ggccaccgaa	4080
ggagtgatta	taaatgctgc	taacagcaaa	ggacaacctg	gcggaggggt	gtgcggagcg	4140
ctgtataaga	aattcccgga	aagcttcgat	ttacagccga	tcgaagtagg	aaaagcgcga	4200
ctggtcaaag	gtgcagctaa	acatatcatt	catgccgtag	gaccaaactt	caacaaagtt	4260
tcggaggttg	aaggtgacaa	acagttggca	gaggcttatg	agtccatcgc	taagattgtc	4320
aacgataaca	attacaagtc	agtagcgatt	ccactgttgt	ccaccggcat	cttttccggg	4380
aacaaagatc	gactaaccca	atcattgaac	catttgctga	cagctttaga	caccactgat	4440
gcagatgtag	ccatatactg	cagggacaag	aaatgggaaa	tgactctcaa	ggaagcagtg	4500
gctaggagag	aagcagtgga	ggagatatgg	atatccgacg	actcttcagt	gacagaacct	4560
gatgcagagc	tggtgagggt	gcatccgaag	agttctttgg	ctggaaggaa	gggctacagc	4620
acaagcgatg	gcaaaacttt	ctcatatttg	gaagggacca	agtttcacca	ggcggccaag	4680
gatatagcag	aaattaatgc	catgtggccc	gttgcaacgg	aggccaatga	gcaggtatgc	4740
atgtatatcc	tcggagaaag	catgagcagt	attaggtcga	aatgccccgt	cgaagagtcg	4800
gaagceteca	caccacctag	cacgctgcct	tgcttgtgca	tccatgccat	gactccagaa	4860
agagtacagc	gcctaaaagc	ctcacgtcca	gaacaaatta	ctgtgtgctc	atcctttcca	4920
ttgccgaagt	atagaatcac	tggtgtgcag	aagatccaat	gctcccagcc	tatattgttc	4980
tcaccgaaag	tgcctgcgta	tattcatcca	aggaagtatc	tcgtggaaac	accaccggta	5040
_ 0			-			

gacgagactc	cggagccatc	ggcagagaac	caatccacag	aggggacacc	tgaacaacca	5100
ccacttataa	ccgaggatga	gaccaggact	agaacgcctg	agccgatcat	catcgaagag	5160
gaagaagagg	atagcataag	tttgctgtca	gatggcccga	cccaccaggt	gctgcaagtc	5220
gaggcagaca	ttcacgggcc	gccctctgta	tctagctcat	cctggtccat	tcctcatgca	5280
tccgactttg	atgtggacag	tttatccata	cttgacaccc	tggagggagc	tagcgtgacc	5340
agcggggcaa	cgtcagccga	gactaactct	tacttcgcaa	agagtatgga	gtttctggcg	5400
cgaccggtgc	ctgcgcctcg	aacagtattc	aggaaccctc	cacatcccgc	tccgcgcaca	5460
agaacaccgt	cacttgcacc	cagcagggcc	tgctcgagaa	ccagcctagt	ttccaccccg	5520
ccaggcgtga	atagggtgat	cactagagag	gagetegagg	cgcttacccc	gtcacgcact	5580
cctagcaggt	cggtctcgag	aaccagcctg	gtctccaacc	cgccaggcgt	aaatagggtg	5640
attacaagag	aggagtttga	ggcgttcgta	gcacaacaac	aatgacggtt	tgatgcgggt	5700
gcatacatct	tttcctccga	caccggtcaa	gggcatttac	aacaaaaatc	agtaaggcaa	5760
acggtgctat	ccgaagtggt	gttggagagg	accgaattgg	agatttcgta	tgccccgcgc	5820
ctcgaccaag	aaaaagaaga	attactacgc	aagaaattac	agttaaatcc	cacacctgct	5880
aacagaagca	gataccagtc	caggaaggtg	gagaacatga	aagccataac	agctagacgt	5940
attctgcaag	gcctagggca	ttatttgaag	gcagaaggaa	aagtggagtg	ctaccgaacc	6000
ctgcatcctg	ttcctttgta	ttcatctagt	gtgaaccgtg	ccttttcaag	ccccaaggtc	6060
gcagtggaag	cctgtaacgc	catgttgaaa	gagaactttc	cgactgtggc	ttcttactgt	6120
attattccag	agtacgatgc	ctatttggac	atggttgacg	gagcttcatg	ctgcttagac	6180
actgccagtt	tttgccctgc	aaagctgcgc	agctttccaa	agaaacactc	ctatttggaa	6240
cccacaatac	gatcggcagt	gccttcagcg	atccagaaca	cgctccagaa	cgtcctggca	6300
gctgccacaa	aaagaaattg	caatgtcacg	caaatgagag	aattgcccgt	attggattcg	6360
gcggccttta	atgtggaatg	cttcaagaaa	tatgcgtgta	ataatgaata	ttgggaaacg	6420
tttaaagaaa	accccatcag	gcttactgaa	gaaaacgtgg	taaattacat	taccaaatta	6480
aaaggaccaa	aagctgctgc	tctttttgcg	aagacacata	atttgaatat	gttgcaggac	6540
ataccaatgg	acaggtttgt	aatggactta	aagagagacg	tgaaagtgac	tccaggaaca	6600
aaacatactg	aagaacggcc	caaggtacag	gtgatccagg	ctgccgatcc	gctagcaaca	6660
gcgtatctgt	gcggaatcca	ccgagagctg	gttaggagat	taaatgcggt	cctgcttccg	6720
aacattcata	cactgtttga	tatgtcggct	gaagactttg	acgctattat	agccgagcac	6780
ttccagcctg	gggattgtgt	tctggaaact	gacatcgcgt	cgtttgataa	aagtgaggac	6840
gacgccatgg	ctctgaccgc	gttaatgatt	ctggaagact	taggtgtgga	cgcagagctg	6900
ttgacgctga	ttgaggcggc	tttcggcgaa	atttcatcaa	tacatttgcc	cactaaaact	6960
aaatttaaat	tcggagccat	gatgaaatct	ggaatgttcc	tcacactgtt	tgtgaacaca	7020
gtcattaaca	ttgtaatcgc	aagcagagtg	ttgagagaac	ggctaaccgg	atcaccatgt	7080
gcagcattca	ttggagatga	caatatcgtg	aaaggagtca	aatcggacaa	attaatggca	7140
gacaggtgcg	ccacctggtt	gaatatggaa	gtcaagatta	tagatgctgt	ggtgggcgag	7200
aaagcgcctt	atttctgtgg	agggtttatt	ttgtgtgact	ccgtgaccgg	cacagcgtgc	7260
cgtgtggcag	accccctaaa	aaggetgttt	aagcttggca	aacctctggc	agcagacgat	7320
gaacatgatg	atgacaggag	aagggcattg	catgaagagt	caacacgctg	gaaccgagtg	7380

-continued

ggtattcttt	cagagctgtg	caaggcagta	gaatcaaggt	atgaaaccgt	aggaacttcc	7440
atcatagtta	tggccatgac	tactctagct	agcagtgtta	aatcattcag	ctacctgaga	7500
ggggccccta	taactctcta	cggctaacct	gaatggacta	cgacatagtc	tagtccgcca	7560
aagaggtgtt	caaggattta	tctttttctt	tttgttcaac	attttgactg	gaaaaaagat	7620
cacageceae	ctaaagaggt	tgtggaaaat	gctggaccca	agacaaggct	tggctgttct	7680
aaggaaagtc	aagagagtgg	tggccagttt	gatgagagga	ttgtcctcaa	ggaaacgccg	7740
ttcccatgat	gttctgactg	tgcaattcct	aattttggga	atgctgttga	tgacgggtgg	7800
agtgaccttg	gtgcggaaaa	acagatggtt	gctcctaaat	gtgacatctg	aggacctcgg	7860
gtaagggccc	ctataactct	ctacggctaa	cctgaatgga	ctacgacata	gtctagtccg	7920
ccaagtctag	agcttaccat	gaccgagtac	aagcccacgg	tgcgcctcgc	cacccgcgac	7980
gacgtcccca	gggccgtacg	caccctcgcc	gccgcgttcg	ccgactaccc	cgccacgcgc	8040
cacaccgtcg	atccggaccg	ccacatcgag	cgggtcaccg	agctgcaaga	actcttcctc	8100
acgcgcgtcg	ggctcgacat	cggcaaggtg	tgggtcgcgg	acgacggcgc	cgcggtggcg	8160
gtctggacca	cgccggagag	cgtcgaagcg	ggggcggtgt	tcgccgagat	cggcccgcgc	8220
atggccgagt	tgagcggttc	ccggctggcc	gcgcagcaac	agatggaagg	cctcctggcg	8280
ccgcaccggc	ccaaggagcc	cgcgtggttc	ctggccaccg	tcggcgtctc	gcccgaccac	8340
cagggcaagg	gtctgggcag	cgccgtcgtg	ctccccggag	tggaggcggc	cgagcgcgcc	8400
ggggtgcccg	ccttcctgga	gacctccgcg	ccccgcaacc	tccccttcta	cgagcggctc	8460
ggcttcaccg	tcaccgccga	cgtcgagtgc	ccgaaggacc	gcgcgacctg	gtgcatgacc	8520
cgcaagcccg	gtgcctgacg	cccgccccac	gacccgcagc	gcccgaccga	aaggagcgca	8580
cgaccccatg	atcgctagac	catggggtac	cgagtatgtt	acgtgcaaag	gtgattgtca	8640
ccccccgaaa	gaccatattg	tgacacaccc	tcagtatcac	gcccaaacat	ttacagccgc	8700
ggtgtcaaaa	accgcgtgga	cgtggttaac	atccctgctg	ggaggatcag	ccgtaattat	8760
tataattggc	ttggtgctgg	ctactattgt	ggccatgtac	gtgctgacca	accagaaaca	8820
taattgaata	cagcagcaat	tggcaagctg	cttacataga	actcgcggcg	attggcatgc	8880
cgccttaaaa	tttttattt	attttttctt	ttcttttccg	aatcggattt	tgttttaat	8940
atttcaaaaa	aaaaaaaaaa	aaaaaaaaaa	cgcgtcgagg	ggaattaatt	cttgaagacg	9000
aaagggccag	gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	9060
taaatacatt	caaatatgta	tccgctcatg	agacaataac	cctgataaat	gcttcaataa	9120
tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	tcgcccttat	tccctttttt	9180
gcggcatttt	gccttcctgt	ttttgctcac	ccagaaacgc	tggtgaaagt	aaaagatgct	9240
gaagatcagt	tgggtgcacg	agtgggttac	atcgaactgg	atctcaacag	cggtaagatc	9300
cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	9360
tgtggcgcgg	tattatcccg	tgttgacgcc	gggcaagagc	aactcggtcg	ccgcatacac	9420
tattctcaga	atgacttggt	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	9480
atgacagtaa	gagaattatg	cagtgctgcc	ataaccatga	gtgataacac	tgcggccaac	9540
ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	cttttttgca	caacatgggg	9600
gatcatqtaa	ctcgccttqa	tcgttqqqaa	ccggaqctqa	atgaaqccat	accaaacqac	9660
gagegtgaca	ccacgatgcc	tqtaqcaatq	qcaacaacat	tgcgcaaact	attaactooc	9720
gaactactta	ctctagette	ccddcaacaa	ttaatagagt	ggatggaggg	ggataaagtt	9780
Janutuccua			- caucagaet	22~2224226	Jacadagee	

59

gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga taaatctgga

-continued

gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc 9900 cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg aaatagacag 9960 atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 10020 tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc 10080 ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca 10140 gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 10200 tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 10260 ccaactettt tteegaaggt aactggette ageagagege agataceaaa taetgteett 10320 ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 10380 gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 10440 ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac ggggggttcg 10500 tgcacacage ceagettgga gcgaacgaee tacacegaae tgagataeet acagegtgag 10560 cattqaqaaa qcqccacqct tcccqaaqqq aqaaaqqcqq acaqqtatcc qqtaaqcqqc 10620 aqqqtcqqaa caqqaqaqcq cacqaqqqaq cttccaqqqq qaaacqcctq qtatctttat 10680 agtectated agttteacea cetetaactt gagegtegat tittatgatg etegteaggg 10740 10796 qqqcqqaqcc tatqqaaaaa cqccaqcaac qcqaqctcqa tttaqqtqac actata <210> SEO TD NO 9 <211> LENGTH: 12839 <212> TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 9 gatgggcggc gcatgagaga agcccagacc aattacctac ccaaaatgga gaaagttcac 60 gttgacatcg aggaagacag cccattcctc agagctttgc agcggagctt cccgcagttt 120 gaggtagaag ccaagcaggt cactgataat gaccatgcta atgccagagc gttttcgcat 180 ctggcttcaa aactgatcga aacggaggtg gacccatccg acacgatcct tgacattgga 240 agtgcgcccg cccgcagaat gtattctaag cacaagtatc attgtatctg tccgatgaga 300 tgtgcggaag atccggacag attgtataag tatgcaacta agctgaagaa aaactgtaag 360 gaaataactg ataaggaatt ggacaagaaa atgaaggagc tggccgccgt catgagcgac 420 cctgacctgg aaactgagac tatgtgcctc cacgacgacg agtcgtgtcg ctacgaaggg 480 540 caaqtcqctq tttaccaqqa tqtatacqcq qttqacqqac cqacaaqtct ctatcaccaa gccaataaqq gaqttagaqt cgcctactqg ataggctttg acaccacccc ttttatgttt 600 aagaacttgg ctggagcata tccatcatac tctaccaact gggccgacga aaccgtgtta 660 acggetegta acataggeet atgeagetet gaegttatgg ageggteaeg tagagggatg 720 tccattctta gaaagaagta tttgaaacca tccaacaatg ttctattctc tgttggctcg 780 accatctacc acgagaagag ggacttactg aggagctggc acctgccgtc tgtatttcac 840 ttacgtggca agcaaaatta cacatgtcgg tgtgagacta tagttagttg cgacgggtac 900 gtcgttaaaa gaatagctat cagtccaggc ctgtatggga agccttcagg ctatgctgct 960

acgatgcacc gcgagggatt cttgtgctgc aaagtgacag acacattgaa cggggagagg

9840

62

61

gtctcttttc	ccgtgtgcac	gtatgtgcca	gctacattgt	gtgaccaaat	gactggcata	1080
ctggcaacag	atgtcagtgc	ggacgacgcg	caaaaactgc	tggttgggct	caaccagcgt	1140
atagtcgtca	acggtcgcac	ccagagaaac	accaatacca	tgaaaaatta	ccttttgccc	1200
gtagtggccc	aggcatttgc	taggtgggca	aaggaatata	aggaagatca	agaagatgaa	1260
aggccactag	gactacgaga	tagacagtta	gtcatggggt	gttgttgggc	ttttagaagg	1320
cacaagataa	catctattta	taagcgcccg	gatacccaaa	ccatcatcaa	agtgaacagc	1380
gatttccact	cattcgtgct	gcccaggata	ggcagtaaca	cattggagat	cgggctgaga	1440
acaagaatca	ggaaaatgtt	agaggagcac	aaggagccgt	cacctctcat	taccgccgag	1500
gacgtacaag	aagctaagtg	cgcagccgat	gaggctaagg	aggtgcgtga	agccgaggag	1560
ttgcgcgcag	ctctaccacc	tttggcagct	gatgttgagg	agcccactct	ggaagccgat	1620
gtcgacttga	tgttacaaga	ggctggggcc	ggctcagtgg	agacacctcg	tggcttgata	1680
aaggttacca	gctacgatgg	cgaggacaag	atcggctctt	acgctgtgct	ttctccgcag	1740
gctgtactca	agagtgaaaa	attatcttgc	atccaccctc	tcgctgaaca	agtcatagtg	1800
ataacacact	ctggccgaaa	agggcgttat	gccgtggaac	cataccatgg	taaagtagtg	1860
gtgccagagg	gacatgcaat	acccgtccag	gactttcaag	ctctgagtga	aagtgccacc	1920
attgtgtaca	acgaacgtga	gttcgtaaac	aggtacctgc	accatattgc	cacacatgga	1980
ggagcgctga	acactgatga	agaatattac	aaaactgtca	agcccagcga	gcacgacggc	2040
gaatacctgt	acgacatcga	caggaaacag	tgcgtcaaga	aagaactagt	cactgggcta	2100
gggctcacag	gcgagctggt	ggatcctccc	ttccatgaat	tcgcctacga	gagtctgaga	2160
acacgaccag	ccgctcctta	ccaagtacca	accatagggg	tgtatggcgt	gccaggatca	2220
ggcaagtctg	gcatcattaa	aagcgcagtc	accaaaaaag	atctagtggt	gagcgccaag	2280
aaagaaaact	gtgcagaaat	tataagggac	gtcaagaaaa	tgaaagggct	ggacgtcaat	2340
gccagaactg	tggactcagt	gctcttgaat	ggatgcaaac	accccgtaga	gaccctgtat	2400
attgacgaag	cttttgcttg	tcatgcaggt	actctcagag	cgctcatagc	cattataaga	2460
cctaaaaagg	cagtgctctg	cggggatccc	aaacagtgcg	gttttttaa	catgatgtgc	2520
ctgaaagtgc	attttaacca	cgagatttgc	acacaagtct	tccacaaaag	catctctcgc	2580
cgttgcacta	aatctgtgac	ttcggtcgtc	tcaaccttgt	tttacgacaa	aaaaatgaga	2640
acgacgaatc	cgaaagagac	taagattgtg	attgacacta	ccggcagtac	caaacctaag	2700
caggacgatc	tcattctcac	ttgtttcaga	gggtgggtga	agcagttgca	aatagattac	2760
aaaggcaacg	aaataatgac	ggcagctgcc	tctcaagggc	tgacccgtaa	aggtgtgtat	2820
gccgttcggt	acaaggtgaa	tgaaaatcct	ctgtacgcac	ccacctcaga	acatgtgaac	2880
gtcctactga	cccgcacgga	ggaccgcatc	gtgtggaaaa	cactagccgg	cgacccatgg	2940
ataaaaacac	tgactgccaa	gtaccctggg	aatttcactg	ccacgataga	ggagtggcaa	3000
gcagagcatg	atgccatcat	gaggcacatc	ttggagagac	cggaccctac	cgacgtcttc	3060
cagaataagg	caaacgtgtg	ttgggccaag	gctttagtgc	cggtgctgaa	gaccgctggc	3120
atagacatga	ccactgaaca	atggaacact	gtggattatt	ttgaaacgga	caaagctcac	3180
tcagcagaga	tagtattgaa	ccaactatgc	gtgaggttct	ttggactcga	tctggactcc	3240
ggtctatttt	ctgcacccac	tgttccgtta	tccattagga	ataatcactg	ggataactcc	3300
ccgtcgccta	acatgtacgq	gctgaataaa	gaagtggtcc	gtcagetete	tcgcaggtac	3360
ccacaactoc	ctcqqqcaqt	- tqccactqqa	aqaqtctatq	acatqaacac	tqqtacactq	3420
	55555		5 5 5	5		

cgcaattatg	atccgcgcat	aaacctagta	cctgtaaaca	gaagactgcc	tcatgcttta	3480
gtcctccacc	ataatgaaca	cccacagagt	gacttttctt	cattcgtcag	caaattgaag	3540
ggcagaactg	tcctggtggt	cggggaaaag	ttgtccgtcc	caggcaaaat	ggttgactgg	3600
ttgtcagacc	ggcctgaggc	taccttcaga	gctcggctgg	atttaggcat	cccaggtgat	3660
gtgcccaaat	atgacataat	atttgttaat	gtgaggaccc	catataaata	ccatcactat	3720
cagcagtgtg	aagaccatgc	cattaagctt	agcatgttga	ccaagaaagc	ttgtctgcat	3780
ctgaatcccg	gcggaacctg	tgtcagcata	ggttatggtt	acgctgacag	ggccagcgaa	3840
agcatcattg	gtgctatagc	gcggcagttc	aagttttccc	gggtatgcaa	accgaaatcc	3900
tcacttgaag	agacggaagt	tctgtttgta	ttcattgggt	acgatcgcaa	ggcccgtacg	3960
cacaatcctt	acaagctttc	atcaaccttg	accaacattt	atacaggttc	cagactccac	4020
gaagccggat	gtgcaccctc	atatcatgtg	gtgcgagggg	atattgccac	ggccaccgaa	4080
ggagtgatta	taaatgctgc	taacagcaaa	ggacaacctg	gcggaggggt	gtgcggagcg	4140
ctgtataaga	aattcccgga	aagcttcgat	ttacagccga	tcgaagtagg	aaaagcgcga	4200
ctggtcaaag	gtgcagctaa	acatatcatt	catgccgtag	gaccaaactt	caacaaagtt	4260
tcggaggttg	aaggtgacaa	acagttggca	gaggcttatg	agtccatcgc	taagattgtc	4320
aacgataaca	attacaagtc	agtagcgatt	ccactgttgt	ccaccggcat	cttttccggg	4380
aacaaagatc	gactaaccca	atcattgaac	catttgctga	cagctttaga	caccactgat	4440
gcagatgtag	ccatatactg	cagggacaag	aaatgggaaa	tgactctcaa	ggaagcagtg	4500
gctaggagag	aagcagtgga	ggagatatgc	atatccgacg	actcttcagt	gacagaacct	4560
gatgcagagc	tggtgagggt	gcatccgaag	agttctttgg	ctggaaggaa	gggctacagc	4620
acaagcgatg	gcaaaacttt	ctcatatttg	gaagggacca	agtttcacca	ggcggccaag	4680
gatatagcag	aaattaatgc	catgtggccc	gttgcaacgg	aggccaatga	gcaggtatgc	4740
atgtatatcc	tcggagaaag	catgagcagt	attaggtcga	aatgccccgt	cgaagagtcg	4800
gaagceteca	caccacctag	cacgctgcct	tgcttgtgca	tccatgccat	gactccagaa	4860
agagtacagc	gcctaaaagc	ctcacgtcca	gaacaaatta	ctgtgtgctc	atcctttcca	4920
ttgccgaagt	atagaatcac	tggtgtgcag	aagatccaat	gctcccagcc	tatattgttc	4980
tcaccgaaag	tgcctgcgta	tattcatcca	aggaagtatc	tcgtggaaac	accaccggta	5040
gacgagactc	cggagccatc	ggcagagaac	caatccacag	aggggacacc	tgaacaacca	5100
ccacttataa	ccgaggatga	gaccaggact	agaacgcctg	agccgatcat	catcgaagag	5160
gaagaagagg	atagcataag	tttgctgtca	gatggcccga	cccaccaggt	gctgcaagtc	5220
gaggcagaca	ttcacgggcc	gccctctgta	tctagctcat	cctggtccat	tcctcatgca	5280
tccgactttg	atgtggacag	tttatccata	cttgacaccc	tggagggagc	tagcgtgacc	5340
agcggggcaa	cgtcagccga	gactaactct	tacttcgcaa	agagtatgga	gtttctggcg	5400
cgaccggtgc	ctgcgcctcg	aacagtattc	aggaaccctc	cacatcccgc	tccgcgcaca	5460
agaacaccgt	cacttgcacc	cagcagggcc	tgctcgagaa	ccagcctagt	ttccaccccg	5520
ccaggcgtga	atagggtgat	cactagagag	gagetegagg	cgcttacccc	gtcacgcact	5580
cctagcaggt	cggtctcgag	aaccagcctg	gtctccaacc	cgccaggcgt	aaatagggtg	5640
attacaagag	aggagtttga	ggcgttcgta	gcacaacaac	aatgacggtt	tgatgcgggt	5700
gcatacatct	tttcctccqa	caccqqtcaa	gggcatttac	aacaaaaatc	agtaaqqcaa	5760
-		55.00			5 55	

66

65

acggtgctat	ccgaagtggt	gttggagagg	accgaattgg	agatttcgta	tgccccgcgc	5820
ctcgaccaag	aaaaagaaga	attactacgc	aagaaattac	agttaaatcc	cacacctgct	5880
aacagaagca	gataccagtc	caggaaggtg	gagaacatga	aagccataac	agctagacgt	5940
attctgcaag	gcctagggca	ttatttgaag	gcagaaggaa	aagtggagtg	ctaccgaacc	6000
ctgcatcctg	ttcctttgta	ttcatctagt	gtgaaccgtg	ccttttcaag	ccccaaggtc	6060
gcagtggaag	cctgtaacgc	catgttgaaa	gagaactttc	cgactgtggc	ttcttactgt	6120
attattccag	agtacgatgc	ctatttggac	atggttgacg	gagcttcatg	ctgcttagac	6180
actgccagtt	tttgccctgc	aaagctgcgc	agctttccaa	agaaacactc	ctatttggaa	6240
cccacaatac	gatcggcagt	gccttcagcg	atccagaaca	cgctccagaa	cgtcctggca	6300
gctgccacaa	aaagaaattg	caatgtcacg	caaatgagag	aattgcccgt	attggattcg	6360
gcggccttta	atgtggaatg	cttcaagaaa	tatgcgtgta	ataatgaata	ttgggaaacg	6420
tttaaagaaa	accccatcag	gcttactgaa	gaaaacgtgg	taaattacat	taccaaatta	6480
aaaggaccaa	aagctgctgc	tctttttgcg	aagacacata	atttgaatat	gttgcaggac	6540
ataccaatgg	acaggtttgt	aatggactta	aagagagacg	tgaaagtgac	tccaggaaca	6600
aaacatactg	aagaacggcc	caaggtacag	gtgatccagg	ctgccgatcc	gctagcaaca	6660
gcgtatctgt	gcggaatcca	ccgagagctg	gttaggagat	taaatgcggt	cctgcttccg	6720
aacattcata	cactgtttga	tatgtcggct	gaagactttg	acgctattat	agccgagcac	6780
ttccagcctg	gggattgtgt	tctggaaact	gacatcgcgt	cgtttgataa	aagtgaggac	6840
gacgccatgg	ctctgaccgc	gttaatgatt	ctggaagact	taggtgtgga	cgcagagctg	6900
ttgacgctga	ttgaggcggc	tttcggcgaa	atttcatcaa	tacatttgcc	cactaaaact	6960
aaatttaaat	tcggagccat	gatgaaatct	ggaatgttcc	tcacactgtt	tgtgaacaca	7020
gtcattaaca	ttgtaatcgc	aagcagagtg	ttgagagaac	ggctaaccgg	atcaccatgt	7080
gcagcattca	ttggagatga	caatatcgtg	aaaggagtca	aatcggacaa	attaatggca	7140
gacaggtgcg	ccacctggtt	gaatatggaa	gtcaagatta	tagatgctgt	ggtgggcgag	7200
aaagcgcctt	atttctgtgg	agggtttatt	ttgtgtgact	ccgtgaccgg	cacagcgtgc	7260
cgtgtggcag	accccctaaa	aaggctgttt	aagcttggca	aacctctggc	agcagacgat	7320
gaacatgatg	atgacaggag	aagggcattg	catgaagagt	caacacgctg	gaaccgagtg	7380
ggtattcttt	cagagctgtg	caaggcagta	gaatcaaggt	atgaaaccgt	aggaacttcc	7440
atcatagtta	tggccatgac	tactctagct	agcagtgtta	aatcattcag	ctacctgaga	7500
ggggccccta	taactctcta	cggctaacct	gaatggacta	cgacatagtc	tagtccgcca	7560
agtctagacc	atgtctggtc	gtaaagctca	gggaaaaacc	ctgggcgtca	atatggtacg	7620
acgaggagtt	cgctccttgt	caaacaaaat	aaaacaaaaa	acaaaacaaa	ttggaaacag	7680
acctggacct	tcaagaggtg	ttcaaggatt	tatctttttc	tttttgttca	acattttgac	7740
tggaaaaaag	atcacagccc	acctaaagag	gttgtggaaa	atgctggacc	caagacaagg	7800
cttggctgtt	ctaaggaaag	tcaagagagt	ggtggccagt	ttgatgagag	gattgtcctc	7860
aaggaaacgc	cgttcccatg	atgttctgac	tgtgcaattc	ctaattttgg	gaatgctgtt	7920
gatgacgggt	ggagtgacct	tggtgcggaa	aaacagatgg	ttgctcctaa	atgtgacatc	7980
tgaggacctc	gggaaaacat	tctctgtggg	cacaggcaac	tgcacaacaa	acattttgga	8040
agccaagtac	tggtgcccaq	actcaatgga	atacaactgt	cccaatctca	gtccaagaga	8100
ggagccagat	gacattqatt	gctggtqcta	tggggtqqaa	aacgttaqaq	tcgcatatqq	8160
			5555 55	5 5-5	5 55	

8220	tgcctacgca	gccattgact	gtcaagaagg	ggtctaggag	tcagcaggca	taagtgtgac
8280	tgggtgaaag	actggaagaa	aaaatggatg	cccggcaaga	ggtttgaaga	tgaaaaccat
8340	tgacggctct	tttttgcag	gaggaacccc	gatggttcgt	aagattgaga	gcaactccaa
8400	ccctactggt	gtcgtgattg	gacgcaacga	gaagcaacat	taccttgtgg	gaccattgcc
8460	gggatttcat	attactgaca	ctgcattgga	actcagctca	ggtccggcct	cttggctgtt
8520	agtgtgtcac	gagcaagaca	agctaccctg	cttgggtttc	catggaggaa	tgagggggtg
8580	ccattgatag	gagacagtag	catctcacta	cttcattgga	cctgacaagc	tgttatggcc
8640	agattaatga	actcatgtga	tgcagttctc	tgtgttacaa	gtgaggaaag	acctgctgag
8700	acaatgcgtg	aacgaagggg	agctgaagag	aggcccacct	agcactggag	caagtgcccc
8760	ggaaagggag	ggcctatttg	caatggctgt	gaggetgggg	tattctgata	caagcgcact
8820	aggttgatca	agtttgtttg	caaatccatg	tcacttgtgc	tgcgccaaat	cattgtggca
8880	aggaaaattg	ggggccaagc	attgcatgta	tcagagcaca	cagtatgtca	gaccaaaatt
8940	aagtcgagtt	ggctcccagg	tgccctgtca	tcaagtttga	attaagactc	gaataccgac
9000	actttggtaa	actgcggtgg	ccaggtgcaa	cactggaatg	ggaaaagcta	cattgggtat
9060	gggcccagga	gacagacagt	ctggatagtg	aaacagagag	gctgagatgg	cagttacatc
9120	atcatcttgt	agagagatgc	cggggtgtgg	gtggaagtgg	ccatggcaga	cttgaccctg
9180	accaggaagg	gccctgggaa	cagagtactg	ccgccactat	cctccgcatg	cgaatttgaa
9240	atgacaacaa	aaggacacaa	gagggttaca	ctggcgcaat	acagctctta	ctccttgaaa
9300	ctttgacact	aaattgtcag	ttgcagagtg	gacatgtttc	ctacatggtg	cctttacaaa
9360	acccaactga	tttgtcaaga	caaaatgttt	tatgcactga	tcctacaaaa	caaggggaca
9420	cctgcaggat	aaaggagccc	gaaagtgtca	tgatgcaggt	ggcactgttg	cactggccat
9480	tggttacagt	aaaggcattt	ggcaatcaat	atcttacagc	gtagctgatg	tccagtgata
9540	caccttttgg	gaggtgaacc	agtgctgatt	atgatgatga	gcctcaacca	taaccccatc
9600	ggcacaaaga	acttaccagt	ttcacgtctc	ggagaggaga	attatcgttg	agacagctac
9660	gcctggccgt	ggcgtggaac	gaccatgaaa	tgttcactca	ataggaaagt	gggaagctca
9720	cggttgggaa	ttcttcactt	cgctggaggg	atttcagctc	accgcctggg	catgggagac
9780	tgaactggat	tttggcggct	tcaggggcta	getetgeett	acggtgtttg	aggaattcat
9840	gaaacatgac	atcaacacaa	atgggttggc	cggtacttat	atcatggggg	aacaaaggtc
9900	taggagttgg	ttttgtctc	gatcatgatg	tggtaggagt	agcatgatct	aatgtccatg
9960	catagtctag	tggactacga	ctaacctgaa	ctctctacgg	gcccctataa	ggcgtaagcg
10020	tcgccacccg	acggtgcgcc	gtacaagccc	ccatgaccga	ctagagctta	tccgccaagt
10080	accccgccac	ttcgccgact	cgccgccgcg	tacgcaccct	cccagggccg	cgacgacgtc
10140	aagaactctt	accgagctgc	cgagcgggtc	accgccacat	gtcgatccgg	gcgccacacc
10200	gcgccgcggt	gcggacgacg	ggtgtgggtc	acatcggcaa	gtcgggctcg	cctcacgcgc
10260	agatcggccc	gtgttcgccg	agcggggggcg	agagcgtcga	accacgccgg	ggcggtctgg
10320	aaggeeteet	caacagatgg	ggccgcgcag	gttcccggct	gagttgagcg	gcgcatggcc
10380	tctcgcccga	accgtcggcg	gttcctggcc	agcccgcgtg	cggcccaagg	ggcgccgcac
10440	cggccgagcg	ggagtggagg	cgtgctcccc	gcagcgccgt	aagggtctgg	ccaccagggc
10500	tctacgagcg	aacctcccct	cgcgccccgc	tggagacctc	cccgccttcc	cgccggggtg
			-			

gctcggcttc	accgtcaccg	ccgacgtcga	gtgcccgaag	gaccgcgcga	cctggtgcat	10560
gacccgcaag	cccggtgcct	gacgcccgcc	ccacgacccg	cagcgcccga	ccgaaaggag	10620
cgcacgaccc	catgatcgct	agaccatggg	gtaccgagta	tgttacgtgc	aaaggtgatt	10680
gtcacccccc	gaaagaccat	attgtgacac	accctcagta	tcacgcccaa	acatttacag	10740
ccgcggtgtc	aaaaaccgcg	tggacgtggt	taacatccct	gctgggagga	tcagccgtaa	10800
ttattataat	tggcttggtg	ctggctacta	ttgtggccat	gtacgtgctg	accaaccaga	10860
aacataattg	aatacagcag	caattggcaa	gctgcttaca	tagaactcgc	ggcgattggc	10920
atgccgcctt	aaaatttta	ttttatttt	tctttcttt	tccgaatcgg	attttgtttt	10980
taatatttca	aaaaaaaaaa	aaaaaaaaaa	aaaacgcgtc	gaggggaatt	aattettgaa	11040
gacgaaaggg	ccaggtggca	cttttcgggg	aaatgtgcgc	ggaaccccta	tttgtttatt	11100
tttctaaata	cattcaaata	tgtatccgct	catgagacaa	taaccctgat	aaatgcttca	11160
ataatattga	aaaaggaaga	gtatgagtat	tcaacatttc	cgtgtcgccc	ttattccctt	11220
ttttgcggca	ttttgccttc	ctgtttttgc	tcacccagaa	acgctggtga	aagtaaaaga	11280
tgctgaagat	cagttgggtg	cacgagtggg	ttacatcgac	tggatctcaa	cagcggtaag	11340
atccttgaga	gttttcgccc	cgaagaacgt	tttccaatga	tgagcacttt	taaagttctg	11400
ctatgtggcg	cggtattatc	ccgtgttgac	gccgggcaag	agcaactcgg	tcgccgcata	11460
cactattctc	agaatgactt	ggttgagtac	tcaccagtca	cagaaaagca	tcttacggat	11520
ggcatgacag	taagagaatt	atgcagtgct	gccataacca	tgagtgataa	cactgcggcc	11580
aacttacttc	tgacaacgat	cggaggaccg	aaggagctaa	ccgcttttt	gcacaacatg	11640
ggggatcatg	taactcgcct	tgatcgttgg	gaaccggagc	tgaatgaagc	cataccaaac	11700
gacgagcgtg	acaccacgat	gcctgtagca	atggcaacaa	cgttgcgcaa	actattaact	11760
ggcgaactac	ttactctagc	ttcccggcaa	caattaatag	actggatgga	ggcggataaa	11820
gttgcaggac	cacttctgcg	ctcggccctt	ccggctggct	ggtttattgc	tgataaatct	11880
ggagccggtg	agcgtgggtc	tcgcggtatc	attgcagcac	tggggccaga	tggtaagccc	11940
tcccgtatcg	tagttatcta	cacgacgggg	agtcaggcaa	ctatggatga	acgaaataga	12000
cagatcgctg	agataggtgc	ctcactgatt	aagcattggt	aactgtcaga	ccaagtttac	12060
tcatatatac	tttagattga	tttaaaactt	catttttaat	ttaaaaggat	ctaggtgaag	12120
atcctttttg	ataatctcat	gaccaaaatc	ccttaacgtg	agttttcgtt	ccactgagcg	12180
tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	cttttttct	gcgcgtaatc	12240
tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcggtgg	tttgtttgcc	ggatcaagag	12300
ctaccaactc	tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	12360
cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	gcctacatac	12420
ctcgctctgc	taatcctgtt	accagtggct	gctgccagtg	gcgataagtc	gtgtcttacc	12480
gggttggact	caagacgata	gttaccggat	aaggcgcagc	ggtcgggctg	aacgggggggt	12540
tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	aactgagata	cctacagcgt	12600
gagcattgag	aaagcgccac	gcttcccgaa	gggagaaagg	cggacaggta	tccggtaagc	12660
ggcagggtcg	gaacaggaga	gcgcacgagg	gagetteeag	ggggaaacgc	ctggtatctt	12720
tatagtcctg	tcgggtttcg	ccacctctga	cttgagcgtc	gatttttgtg	atgctcgtca	12780
gggggggcgga	gcctatggaa	aaacgccagc	aacgcgagct	cgatttaggt	gacactata	12839

<pre><210> SEQ 1 <211> LENGT <212> TYPE: <213> ORGAN <220> FEATU <223> OTHEN</pre>	ID NO 10 TH: 10926 : DNA NISM: artif: JRE: R INFORMATIC	icial sequer DN: synthet:	nce ic polynucle	eotide		
<400> SEQUE	ENCE: 10					
gatgggcggc	gcatgagaga	agcccagacc	aattacctac	ccaaaatgga	gaaagttcac	60
gttgacatcg	aggaagacag	cccattcctc	agagctttgc	agcggagctt	cccgcagttt	120
gaggtagaag	ccaagcaggt	cactgataat	gaccatgcta	atgccagagc	gttttcgcat	180
ctggcttcaa	aactgatcga	aacggaggtg	gacccatccg	acacgatcct	tgacattgga	240
agtgcgcccg	cccgcagaat	gtattctaag	cacaagtatc	attgtatctg	tccgatgaga	300
tgtgcggaag	atccggacag	attgtataag	tatgcaacta	agctgaagaa	aaactgtaag	360
gaaataactg	ataaggaatt	ggacaagaaa	atgaaggagc	tggccgccgt	catgagcgac	420
cctgacctgg	aaactgagac	tatgtgcctc	cacgacgacg	agtcgtgtcg	ctacgaaggg	480
caagtcgctg	tttaccagga	tgtatacgcg	gttgacggac	cgacaagtct	ctatcaccaa	540
gccaataagg	gagttagagt	cgcctactgg	ataggetttg	acaccacccc	ttttatgttt	600
aagaacttgg	ctggagcata	tccatcatac	tctaccaact	gggccgacga	aaccgtgtta	660
acggctcgta	acataggcct	atgcagctct	gacgttatgg	agcggtcacg	tagagggatg	720
tccattctta	gaaagaagta	tttgaaacca	tccaacaatg	ttctattctc	tgttggctcg	780
accatctacc	acgagaagag	ggacttactg	aggagctggc	acctgccgtc	tgtatttcac	840
ttacgtggca	agcaaaatta	cacatgtcgg	tgtgagacta	tagttagttg	cgacgggtac	900
gtcgttaaaa	gaatagctat	cagtccaggc	ctgtatggga	agccttcagg	ctatgctgct	960
acgatgcacc	gcgagggatt	cttgtgctgc	aaagtgacag	acacattgaa	cggggagagg	1020
gtctcttttc	ccgtgtgcac	gtatgtgcca	gctacattgt	gtgaccaaat	gactggcata	1080
ctggcaacag	atgtcagtgc	ggacgacgcg	caaaaactgc	tggttgggct	caaccagcgt	1140
atagtcgtca	acggtcgcac	ccagagaaac	accaatacca	tgaaaaatta	ccttttgccc	1200
gtagtggccc	aggcatttgc	taggtgggca	aaggaatata	aggaagatca	agaagatgaa	1260
aggccactag	gactacgaga	tagacagtta	gtcatggggt	gttgttgggc	ttttagaagg	1320
cacaagataa	catctattta	taagcgcccg	gatacccaaa	ccatcatcaa	agtgaacagc	1380
gatttccact	cattcgtgct	gcccaggata	ggcagtaaca	cattggagat	cgggctgaga	1440
acaagaatca	ggaaaatgtt	agaggagcac	aaggagccgt	cacctctcat	taccgccgag	1500
gacgtacaag	aagctaagtg	cgcagccgat	gaggctaagg	aggtgcgtga	agccgaggag	1560
ttgcgcgcag	ctctaccacc	tttggcagct	gatgttgagg	agcccactct	ggaagccgat	1620
gtcgacttga	tgttacaaga	ggctggggcc	ggctcagtgg	agacacctcg	tggcttgata	1680
aaggttacca	gctacgatgg	cgaggacaag	atcggctctt	acgctgtgct	ttctccgcag	1740
gctgtactca	agagtgaaaa	attatcttgc	atccaccctc	tcgctgaaca	agtcatagtg	1800
ataacacact	ctggccgaaa	agggcgttat	gccgtggaac	cataccatgg	taaagtagtg	1860
gtgccagagg	gacatgcaat	acccgtccag	gactttcaag	ctctgagtga	aagtgccacc	1920
attgtgtaca	acgaacgtga	gttcgtaaac	aggtacctgc	accatattgc	cacacatgga	1980
ggagcgctga	acactgatga	agaatattac	aaaactgtca	agcccagcga	gcacgacggc	2040

gaatacctgt acgacatcga caggaaacag tgcgtcaaga aagaactagt cactgggcta 2100

74

73

gggctcacag	gcgagctggt	ggatcctccc	ttccatgaat	tcgcctacga	gagtctgaga	2160
acacgaccag	ccgctcctta	ccaagtacca	accatagggg	tgtatggcgt	gccaggatca	2220
ggcaagtctg	gcatcattaa	aagcgcagtc	accaaaaaag	atctagtggt	gagcgccaag	2280
aaagaaaact	gtgcagaaat	tataagggac	gtcaagaaaa	tgaaagggct	ggacgtcaat	2340
gccagaactg	tggactcagt	gctcttgaat	ggatgcaaac	accccgtaga	gaccctgtat	2400
attgacgaag	cttttgcttg	tcatgcaggt	actctcagag	cgctcatagc	cattataaga	2460
cctaaaaagg	cagtgctctg	cggggatccc	aaacagtgcg	gttttttaa	catgatgtgc	2520
ctgaaagtgc	attttaacca	cgagatttgc	acacaagtct	tccacaaaag	catctctcgc	2580
cgttgcacta	aatctgtgac	ttcggtcgtc	tcaaccttgt	tttacgacaa	aaaaatgaga	2640
acgacgaatc	cgaaagagac	taagattgtg	attgacacta	ccggcagtac	caaacctaag	2700
caggacgatc	tcattctcac	ttgtttcaga	gggtgggtga	agcagttgca	aatagattac	2760
aaaggcaacg	aaataatgac	ggcagctgcc	tctcaagggc	tgacccgtaa	aggtgtgtat	2820
gccgttcggt	acaaggtgaa	tgaaaatcct	ctgtacgcac	ccacctcaga	acatgtgaac	2880
gtcctactga	cccgcacgga	ggaccgcatc	gtgtggaaaa	cactagccgg	cgacccatgg	2940
ataaaaacac	tgactgccaa	gtaccctggg	aatttcactg	ccacgataga	ggagtggcaa	3000
gcagagcatg	atgccatcat	gaggcacatc	ttggagagac	cggaccctac	cgacgtcttc	3060
cagaataagg	caaacgtgtg	ttgggccaag	gctttagtgc	cggtgctgaa	gaccgctggc	3120
atagacatga	ccactgaaca	atggaacact	gtggattatt	ttgaaacgga	caaagctcac	3180
tcagcagaga	tagtattgaa	ccaactatgc	gtgaggttct	ttggactcga	tctggactcc	3240
ggtctatttt	ctgcacccac	tgttccgtta	tccattagga	ataatcactg	ggataactcc	3300
ccgtcgccta	acatgtacgg	gctgaataaa	gaagtggtcc	gtcagctctc	tcgcaggtac	3360
ccacaactgc	ctcgggcagt	tgccactgga	agagtctatg	acatgaacac	tggtacactg	3420
cgcaattatg	atccgcgcat	aaacctagta	cctgtaaaca	gaagactgcc	tcatgcttta	3480
gtcctccacc	ataatgaaca	cccacagagt	gacttttctt	cattcgtcag	caaattgaag	3540
ggcagaactg	tcctggtggt	cggggaaaag	ttgtccgtcc	caggcaaaat	ggttgactgg	3600
ttgtcagacc	ggcctgaggc	taccttcaga	gctcggctgg	atttaggcat	cccaggtgat	3660
gtgcccaaat	atgacataat	atttgttaat	gtgaggaccc	catataaata	ccatcactat	3720
cagcagtgtg	aagaccatgc	cattaagctt	agcatgttga	ccaagaaagc	ttgtctgcat	3780
ctgaatcccg	gcggaacctg	tgtcagcata	ggttatggtt	acgctgacag	ggccagcgaa	3840
agcatcattg	gtgctatagc	gcggcagttc	aagttttccc	gggtatgcaa	accgaaatcc	3900
tcacttgaag	agacggaagt	tctgtttgta	ttcattgggt	acgatcgcaa	ggcccgtacg	3960
cacaatcctt	acaagctttc	atcaaccttg	accaacattt	atacaggttc	cagactccac	4020
gaagccggat	gtgcaccctc	atatcatgtg	gtgcgagggg	atattgccac	ggccaccgaa	4080
ggagtgatta	taaatgctgc	taacagcaaa	ggacaacctg	gcggaggggt	gtgcggagcg	4140
ctgtataaga	aattcccgga	aagcttcgat	ttacagccga	tcgaagtagg	aaaagcgcga	4200
ctggtcaaaq	gtgcagctaa	acatatcatt	catgccgtaq	gaccaaactt	caacaaagtt	4260
tcqqaqqttq	aaqqtqacaa	acaqttqqca	gaggettatg	aqtccatcqc	- taagattotc	4320
aacgataaca	attacaadto	agtagcgatt	ccactottot	ccaccoocat	ttttccaaaa	4380
acaaacatoo	actaacces	trattraaco	atttactacc	addttadad	accactosto	4440
acaaayateg	accaaccoda		actigotydo	ayuuuayac	accaccyacy	1500
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtgg	4500

ctaggagaga	agcagtggag	gagatatgca	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgagggtg	catccgaaga	gttctttggc	tggaaggaag	ggctacagca	4620
caagcgatgg	caaaactttc	tcatatttgg	aagggaccaa	gtttcaccag	gcggccaagg	4680
atatagcaga	aattaatgcc	atgtggcccg	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgccccgtc	gaagagtcgg	4800
aagcctccac	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tagaatcact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgtat	attcatccaa	ggaagtatct	cgtggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gccgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccgac	ccaccaggtg	ctgcaagtcg	5220
aggcagacat	tcacgggccg	ccctctgtat	ctagctcatc	ctggtccatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacaccct	ggagggagct	agcgtgacca	5340
gcggggcaac	gtcagccgag	actaactctt	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgcgcctcga	acagtattca	ggaaccctcc	acatcccgct	ccgcgcacaa	5460
gaacaccgtc	acttgcaccc	agcagggcct	gctcgagaac	cagcctagtt	tccaccccgc	5520
caggcgtgaa	tagggtgatc	actagagagg	agctcgaggc	gcttaccccg	tcacgcactc	5580
ctagcaggtc	ggtctcgaga	accagcctgg	tctccaaccc	gccaggcgta	aatagggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacggttt	gatgcgggtg	5700
catacatctt	ttcctccgac	accggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cggtgctatc	cgaagtggtg	ttggagagga	ccgaattgga	gatttcgtat	geecegegee	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaatccc	acacctgcta	5880
acagaagcag	ataccagtcc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttgaagg	cagaaggaaa	agtggagtgc	taccgaaccc	6000
tgcatcctgt	tcctttgtat	tcatctagtg	tgaaccgtgc	cttttcaagc	cccaaggtcg	6060
cagtggaagc	ctgtaacgcc	atgttgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cggcctttaa	tgtggaatgc	ttcaagaaat	atgcgtgtaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtggt	aaattacatt	accaaattaa	6480
aaggaccaaa	agctgctgct	ctttttgcga	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaatccac	cgagagctgg	ttaggagatt	aaatgcggtc	ctgcttccga	6720
acattcatac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtgtt	ctggaaactg	acategegte	gtttgataaa	agtgaggacg	6840

78

77

acgccatggc	tctgaccgcg	ttaatgattc	tggaagactt	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttcct	cacactgttt	gtgaacacag	7020
tcattaacat	tgtaatcgca	agcagagtgt	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagegtgee	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgctgg	aaccgagtgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaaccgta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tacctgagag	7500
gggcccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtccgccaa	7560
gtctagacca	tgagcggccg	gaaggctcag	ggcaagaccc	tgggcgtgaa	catggtgagg	7620
cgcggcgtgc	gcagcctctc	caacaagatc	aagcagaaga	ccaagcagat	cggcaacaga	7680
cccggaccga	gccgggggcgt	ccaggggttc	atcttcttct	tcctgttcaa	catcctcaca	7740
ggtaagaaga	tcacggctca	cctgaagagg	ctctggaaga	tgctggaccc	tcgccagggg	7800
ctcgcggtgc	tcagaaaggt	gaagcgggtc	gtcgcctccc	tgatgcgcgg	cctgtcctct	7860
cgcaagaggc	gctcccacga	tgtgctcacc	gtccaattcc	tcattctgga	atgctgctga	7920
tgactggcgg	cgtgaccctg	gtgcgcaaga	accgctggct	gctgctgaat	gtgaccagtg	7980
aggacctcgg	gtaagggccc	ctataactct	ctacggctaa	cctgaatgga	ctacgacata	8040
gtctagtccg	ccaagtctag	agcttaccat	gaccgagtac	aagcccacgg	tgcgcctcgc	8100
cacccgcgac	gacgtcccca	gggccgtacg	caccctcgcc	gccgcgttcg	ccgactaccc	8160
cgccacgcgc	cacaccgtcg	atccggaccg	ccacatcgag	cgggtcaccg	agctgcaaga	8220
actcttcctc	acgcgcgtcg	ggctcgacat	cggcaaggtg	tgggtcgcgg	acgacggcgc	8280
cgcggtggcg	gtctggacca	cgccggagag	cgtcgaagcg	ggggcggtgt	tcgccgagat	8340
cggcccgcgc	atggccgagt	tgagcggttc	ccggctggcc	gcgcagcaac	agatggaagg	8400
cctcctggcg	ccgcaccggc	ccaaggagcc	cgcgtggttc	ctggccaccg	tcggcgtctc	8460
gcccgaccac	cagggcaagg	gtctgggcag	cgccgtcgtg	ctccccggag	tggaggcggc	8520
cgagcgcgcc	ggggtgcccg	ccttcctgga	gacctccgcg	ccccgcaacc	tccccttcta	8580
cgagcggctc	ggcttcaccg	tcaccgccga	cgtcgaggtg	cccgaaggac	cgcgcacctg	8640
gtgcatgacc	cgcaagcccg	gtgcctgacg	cccgccccac	gacccgcagc	gcccgaccga	8700
aaggagcgca	cgaccccatg	atcgctagac	catggggtac	cgagtatgtt	acgtgcaaag	8760
gtgattgtca	ccccccgaaa	gaccatattg	tgacacaccc	tcagtatcac	gcccaaacat	8820
ttacagccgc	ggtgtcaaaa	accgcgtgga	cgtggttaac	atccctgctg	ggaggatcag	8880
ccgtaattat	tataattggc	ttggtgctgg	ctactattgt	ggccatgtac	gtgctgacca	8940
accagaaaca	taattgaata	cagcagcaat	tggcaagctg	cttacataga	actcgcggcg	9000
attggcatgc	cgccttaaaa	ttttatttt	atttttttt	ttettteeq	aatcqqattt	9060
tqttttaat	atttcaaaaa	aaaaaaaaaa	aaaaaaaaaa	cqcatcaaaa	qqaattaatt	9120
cttgaagacg	aaaggggggag	atagcacttt	toggggaaat	atacacaasa	cccctatttq	9180
++++++++++	taaatagatt	desst state	tagatasta	adadaataat	actastssst	924.0
LLLALLETEC	LAAALACATT	caaalatgta	locycleatg	ayacaataad	uuuyaladat	2230

79

gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat

tccctttttt gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt

aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag

cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa

-continued

agttetgeta tgtggegegg tattateeeg tgttgaegee gggeaagage aacteggteg 9540 9600 ccgcatacac tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct 9660 tacggatggc atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac tgeggecaac ttacttetga caacgategg aggaeegaag gagetaaceg etttttgea 9720 caacatgggg gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat 9780 9840 accaaacqac qaqcqtqaca ccacqatqcc tqtaqcaatq qcaacaacqt tqcqcaaact attaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc 9900 ggataaagtt gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga 9960 10020 taaatctqqa gccqqtqaqc gtqqqtctcq cqqtatcatt gcaqcactqq ggccaqatqq taagccctcc cqtatcqtaq ttatctacac qacqqqqaqt caqqcaacta tqqatqaacq 10080 aaataqacaq atcqctqaqa taqqtqcctc actqattaaq cattqqtaac tqtcaqacca 10140 agtttactca tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta 10200 ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca 10260 ctgagegtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg 10320 cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga 10380 tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa 10440 tactgtcctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc 10500 tacatacete getetgetaa teetgttaee agtggetget geeagtggeg ataagtegtg 10560 tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac 10620 ggggggttcg tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct 10680 acagegtgag cattgagaaa gegeeaeget teeegaaggg agaaaggegg acaggtatee 10740 ggtaagcggc agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg 10800 gtatetttat agteetgteg ggtttegeea eetetgaett gagegtegat ttttgtgatg 10860 ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcgagctcga tttaggtgac 10920 actata 10926 <210> SEQ ID NO 11 <211> LENGTH: 12836 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic polynucleotide <400> SEOUENCE: 11 gatgggcggc gcatgagaga agcccagacc aattacctac ccaaaatgga gaaagttcac 60 gttgacatcg aggaagacag cccatteete bagagetttg cageggaget teeegcagtt 120 tgaggtagaa gccaagcagg tcactgataa tgaccatgct aatgccagag cgttttcgca 180 totggottca aaactgatcg aaacggaggt ggacccatcc gacacgatcc ttgacattgg 240 aagtgcgccc gcccgcagaa tgtattctaa gcacaagtat cattgtatct gtccgatgag 300

80

9300

9360

9420

81

atgtgcggaa	gatccggaca	gattgtataa	gtatgcaact	aagctgaaga	aaaactgtaa	360	
ggaaataact	gataaggaat	tggacaagaa	aatgaaggag	ctggccgccg	tcatgagcga	420	
ccctgacctg	gaaactgaga	ctatgtgcct	ccacgacgac	gagtcgtgtc	gctacgaagg	480	
gcaagtcgct	gtttaccagg	atgtatacgc	ggttgacgga	ccgacaagtc	tctatcacca	540	
agccaataag	ggagttagag	tcgcctactg	gataggcttt	gacaccaccc	cttttatgtt	600	
taagaacttg	gctggagcat	atccatcata	ctctaccaac	tgggccgacg	aaaccgtgtt	660	
aacggctcgt	aacataggcc	tatgcagctc	tgacgttatg	gagcggtcac	gtagagggat	720	
gtccattctt	agaaagaagt	atttgaaacc	atccaacaat	gttctattct	ctgttggctc	780	
gaccatctac	cacgagaaga	gggacttact	gaggagctgg	cacctgccgt	ctgtatttca	840	
cttacgtggc	aagcaaaatt	acacatgtcg	gtgtgagact	atagttagtt	gcgacgggta	900	
cgtcgttaaa	agaatagcta	tcagtccagg	cctgtatggg	aagcetteag	gctatgctgc	960	
tacgatgcac	cgcgagggat	tcttgtgctg	caaagtgaca	gacacattga	acggggagag	1020	
ggtctcttt	cccgtgtgca	cgtatgtgcc	agctacattg	tgtgaccaaa	tgactggcat	1080	
actggcaaca	gatgtcagtg	cggacgacgc	gcaaaaactg	ctggttgggc	tcaaccagcg	1140	
tatagtcgtc	aacggtcgca	cccagagaaa	caccaatacc	atgaaaaatt	accttttgcc	1200	
cgtagtggcc	caggcatttg	ctaggtgggc	aaaggaatat	aaggaagatc	aagaagatga	1260	
aaggccacta	ggactacgag	atagacagtt	agtcatgggg	tgttgttggg	cttttagaag	1320	
gcacaagata	acatctattt	ataagcgccc	ggatacccaa	accatcatca	aagtgaacag	1380	
cgatttccac	tcattcgtgc	tgcccaggat	aggcagtaac	acattggaga	tcgggctgag	1440	
aacaagaatc	aggaaaatgt	tagaggagca	caaggagccg	tcacctctca	ttaccgccga	1500	
ggacgtacaa	gaagctaagt	gcgcagccga	tgaggctaag	gaggtgcgtg	aagccgagga	1560	
gttgcgcgca	gctctaccac	ctttggcagc	tgatgttgag	gagcccactc	tggaagccga	1620	
tgtcgacttg	atgttacaag	aggctggggc	cggctcagtg	gagacacctc	gtggcttgat	1680	
aaaggttacc	agctacgatg	gcgaggacaa	gatcggctct	tacgctgtgc	tttctccgca	1740	
ggctgtactc	aagagtgaaa	aattatcttg	catccaccct	ctcgctgaac	aagtcatagt	1800	
gataacacac	tctggccgaa	aagggcgtta	tgccgtggaa	ccataccatg	gtaaagtagt	1860	
ggtgccagag	ggacatgcaa	tacccgtcca	ggactttcaa	gctctgagtg	aaagtgccac	1920	
cattgtgtac	aacgaacgtg	agttcgtaaa	caggtacctg	caccatattg	ccacacatgg	1980	
aggagcgctg	aacactgatg	aagaatatta	caaaactgtc	aagcccagcg	agcacgacgg	2040	
cgaatacctg	tacgacatcg	acaggaaaca	gtgcgtcaag	aaagaactag	tcactgggct	2100	
agggctcaca	ggcgagctgg	tggatcctcc	cttccatgaa	ttcgcctacg	agagtctgag	2160	
aacacgacca	gccgctcctt	accaagtacc	aaccataggg	gtgtatggcg	tgccaggatc	2220	
aggcaagtct	ggcatcatta	aaagcgcagt	caccaaaaaa	gatctagtgg	tgagcgccaa	2280	
gaaagaaaac	tgtgcagaaa	ttataaggga	cgtcaagaaa	atgaaagggc	tggacgtcaa	2340	
tgccagaact	gtggactcag	tgctcttgaa	tggatgcaaa	caccccgtag	agaccctgta	2400	
tattgacgaa	gcttttgctt	gtcatgcagg	tactctcaga	gcgctcatag	ccattataag	2460	
acctaaaaag	gcagtgctct	gcggggatcc	caaacagtgc	ggtttttta	acatgatgtg	2520	
cctgaaagtg	cattttaacc	acgagatttg	cacacaagtc	ttccacaaaa	gcatctctcg	2580	
ccgttgcact	aaatctgtga	cttcggtcgt	ctcaaccttg	ttttacgaca	aaaaatgag	2640	
aacgacgaat	ccgaaagaga	ctaagattgt	gattgacact	accggcagta	ccaaacctaa	2700	
	_ 00		-				
-continued

gcaggacgat	ctcattctca	cttgtttcag	agggtgggtg	aagcagttgc	aaatagatta	2760
caaaggcaac	gatatgacgg	cagetgeete	tcaagggctg	acccgtaaag	gtgtgtatgc	2820
cgttcggtac	aaggtgaatg	aaaatcctct	gtacgcaccc	acctcagaac	atgtgaacgt	2880
cctactgacc	cgcacggagg	accgcatcgt	gtggaaaaca	ctageeggeg	acccatggat	2940
aaaaacactg	actgccaagt	accctgggaa	tttcactgcc	acgatagagg	agtggcaagc	3000
agagcatgat	gccatcatga	ggcacatctt	ggagagaccg	gaccctaccg	acgtcttcca	3060
gaataaggca	aacgtgtgtt	gggccaaggc	tttagtgccg	gtgctgaaga	ccgctggcat	3120
agacatgacc	actgaacaat	ggaacactgt	ggattattt	gaaacggaca	aagctcactc	3180
agcagagata	gtattgaacc	aactatgcgt	gaggttcttt	ggactcgatc	tggactccgg	3240
tctattttct	gcacccactg	ttccgttatc	cattaggaat	aatcactggg	ataactcccc	3300
gtcgcctaac	atgtacgggc	tgaataaaga	agtggtccgt	cagctctctc	gcaggtaccc	3360
acaactgcct	cgggcagttg	ccactggaag	agtctatgac	atgaacactg	gtacactgcg	3420
caattatgat	ccgcgcataa	acctagtacc	tgtaaacaga	agactgcctc	atgctttagt	3480
cctccaccat	aatgaacacc	cacagagtga	cttttcttca	ttcgtcagca	aattgaaggg	3540
cagaactgtc	ctggtggtcg	gggaaaagtt	gtccgtccca	ggcaaaatgg	ttgactggtt	3600
gtcagaccgg	cctgaggcta	ccttcagagc	tcggctggat	ttaggcatcc	caggtgatgt	3660
gcccaaatat	gacataatat	ttgttaatgt	gaggacccca	tataaatacc	atcactatca	3720
gcagtgtgaa	gaccatgcca	ttaagcttag	catgttgacc	aagaaagctt	gtctgcatct	3780
gaatcccggc	ggaacctgtg	tcagcatagg	ttatggttac	gctgacaggg	ccagcgaaag	3840
catcattggt	gctatagcgc	ggcagttcaa	gttttcccgg	gtatgcaaac	cgaaatcctc	3900
acttgaagag	acggaagttc	tgtttgtatt	cattgggtac	gatcgcaagg	cccgtacgca	3960
caatccttac	aagctttcat	caaccttgac	caacatttat	acaggttcca	gactccacga	4020
agccggatgt	gcaccctcat	atcatgtggt	gcgaggggat	attgccacgg	ccaccgaagg	4080
agtgattata	aatgctgcta	acagcaaagg	acaacctggc	ggaggggtgt	gcggagcgct	4140
gtataagaaa	ttcccggaaa	gcttcgattt	acagccgatc	gaagtaggaa	aagcgcgact	4200
ggtcaaaggt	gcagctaaac	atatcattca	tgccgtagga	ccaaacttca	acaaagtttc	4260
ggaggttgaa	ggtgacaaac	agttggcaga	ggcttatgag	tccatcgcta	agattgtcaa	4320
cgataacaat	tacaagtcag	tagcgattcc	actgttgtcc	accggcatct	tttccgggaa	4380
caaagatcga	ctaacccaat	cattgaacca	tttgctgaca	gctttagaca	ccactgatgc	4440
agatgtagcc	atatactgca	gggacaagaa	atgggaaatg	actctcaagg	aagcagtggc	4500
taggagagaa	gcagtggagg	agatatgcat	atccgacgac	tcttcagtga	cagaacctga	4560
tgcagagctg	gtgagggtgc	atccgaagag	ttctttggct	ggaaggaagg	gctacagcac	4620
aagcgatggc	aaaactttct	catatttgga	agggaccaag	tttcaccagg	cggccaagga	4680
tatagcagaa	attaatgcca	tgtggcccgt	tgcaacggag	gccaatgagc	aggtatgcat	4740
gtatatcctc	ggagaaagca	tgagcagtat	taggtcgaaa	tgccccgtcg	aagagtcgga	4800
agcetecaca	ccacctagca	cgctgccttg	cttgtgcatc	catgccatga	ctccagaaag	4860
agtacagcgc	ctaaaagcct	cacgtccaga	acaaattact	gtgtgctcat	cctttccatt	4920

gccgaagtat agaatcactg gtgtgcagaa gatccaatgc tcccagccta tattgttctc

accgaaagtg cctgcgtata ttcatccaag gaagtatctc gtggaaacac caccggtaga

4980

5040

US 9,273,288 B2

86

85

-continued

cgagactccg	gagccatcgg	cagagaacca	atccacagag	gggacacctg	aacaaccacc	5100
acttataacc	gaggatgaga	ccaggactag	aacgcctgag	ccgatcatca	tcgaagagga	5160
agaagaggat	agcataagtt	tgctgtcaga	tggcccgacc	caccaggtgc	tgcaagtcga	5220
ggcagacatt	cacgggccgc	cctctgtatc	tageteatee	tggtccattc	ctcatgcatc	5280
cgactttgat	gtggacagtt	tatccatact	tgacaccctg	gagggagcta	gcgtgaccag	5340
cggggcaacg	tcagccgaga	ctaactctta	cttcgcaaag	agtatggagt	ttetggegeg	5400
accggtgcct	gcgcctcgaa	cagtattcag	gaaccctcca	catcccgctc	cgcgcacaag	5460
aacaccgtca	cttgcaccca	gcagggcctg	ctcgagaacc	agcctagttt	ccaccccgcc	5520
aggcgtgaat	agggtgatca	ctagagagga	gctcgaggcg	cttaccccgt	cacgcactcc	5580
tagcaggtcg	gtctcgagaa	ccagctggtc	tccaacccgc	caggcgtaaa	tagggtgatt	5640
acaagagagg	agtttgaggc	gttcgtagca	caacaacaat	gacggtttga	tgcgggtgca	5700
tacatctttt	cctccgacac	cggtcaaggg	catttacaac	aaaaatcagt	aaggcaaacg	5760
gtgctatccg	aagtggtgtt	ggagaggacc	gaattggaga	tttcgtatgc	cccgcgcctc	5820
gaccaagaaa	aagaagaatt	actacgcaag	aaattacagt	taaatcccac	acctgctaac	5880
agaagcagat	accagtccag	gaaggtggag	aacatgaaag	ccataacagc	tagacgtatt	5940
ctgcaaggcc	tagggcatta	tttgaaggca	gaaggaaaag	tggagtgcta	ccgaaccctg	6000
catcctgttc	ctttgtattc	atctagtgtg	aaccgtgcct	tttcaagccc	caaggtcgca	6060
gtggaagcct	gtaacgccat	gttgaaagag	aactttccga	ctgtggcttc	ttactgtatt	6120
attccagagt	acgatgccta	tttggacatg	gttgacggag	cttcatgctg	cttagacact	6180
gccagttttt	gccctgcaaa	gctgcgcagc	tttccaaaga	aacactccta	tttggaaccc	6240
acaatacgat	cggcagtgcc	ttcagcgatc	cagaacacgc	tccagaacgt	cctggcagct	6300
gccacaaaaa	gaaattgcaa	tgtcacgcaa	atgagagaat	tgcccgtatt	ggattcggcg	6360
gcctttaatg	tggaatgctt	caagaaatat	gcgtgtaata	atgaatattg	ggaaacgttt	6420
aaagaaaacc	ccatcaggct	tactgaagaa	aacgtggtaa	attacattac	caaattaaaa	6480
ggaccaaaag	ctgctgctct	ttttgcgaag	acacataatt	tgaatatgtt	gcaggacata	6540
ccaatggaca	ggtttgtaat	ggacttaaag	agagacgtga	aagtgactcc	aggaacaaaa	6600
catactgaag	aacggcccaa	ggtacaggtg	atccaggctg	ccgatccgct	agcaacagcg	6660
tatctgtgcg	gaatccaccg	agagctggtt	aggagattaa	atgcggtcct	gcttccgaac	6720
attcatacac	tgtttgatat	gtcggctgaa	gactttgacg	ctattatagc	cgagcacttc	6780
cagcctgggg	attgtgttct	ggaaactgac	atcgcgtcgt	ttgataaaag	tgaggacgac	6840
gccatggctc	tgaccgcgtt	aatgattctg	gaagacttag	gtgtggacgc	agagctgttg	6900
acgctgattg	aggcggcttt	cggcgaaatt	tcatcaatac	atttgcccac	taaaactaaa	6960
tttaaattcg	gagccatgat	gaaatctgga	atgttcctca	cactgtttgt	gaacacagtc	7020
attaacattg	taatcgcaag	cagagtgttg	agagaacggc	taaccggatc	accatgtgca	7080
gcattcattg	gagatgacaa	tatcgtgaaa	ggagtcaaat	cggacaaatt	aatggcagac	7140
aggtgcgcca	cctggttgaa	tatggaagtc	aagattatag	atgctgtggt	gggcgagaaa	7200
gcgccttatt	tctgtggagg	gtttatttg	tgtgactccg	tgaccggcac	agcgtgccgt	7260
gtggcagacc	ccctaaaaaq	gctgtttaaq	cttggcaaac	ctctggcage	agacgatgaa	7320
catqatqatq	acaqqaqaaq	qqcattqcat	qaaqaqtcaa	cacqctqqaa	ccqaqtqqqt	7380
attetttead	agetatacaa	gggagtagaa	tcaaggtatg	aaaccotago	aacttecate	7440
		Jorageagua				

-continued

atagttatgg	ccatgactac	tctagctagc	agtgttaaat	cattcagcta	cctgagaggg	7500
gcccctataa	ctctctacgg	ctaacctgaa	tggactacga	catagtctag	tccgccaagt	7560
ctagaccatg	agcggccgga	aggctcaggg	caagaccctg	ggcgtgaaca	tggtgaggcg	7620
cggcgtgcgc	agcctctcca	acaagatcaa	gcagaagacc	aagcagatcg	gcaacagacc	7680
cggaccgagc	cggggcgtcc	aggggttcat	cttcttcttc	ctgttcaaca	tcctcacagg	7740
taagaagatc	acggctcacc	tgaagaggct	ctggaagatg	ctggaccctc	gccagggggct	7800
cgcggtgctc	agaaaggtga	agcgggtcgt	cgcctccctg	atgcgcggcc	tgtcctctcg	7860
caagaggcgc	tcccacgatg	tgctcaccgt	ccaattcctc	attctgggaa	tgctgttgat	7920
gacgggtgga	gtgaccttgg	tgcggaaaaa	cagatggttg	ctcctaaatg	tgacatctga	7980
ggacctcggg	aaaacattct	ctgtgggcac	aggcaactgc	acaacaaaca	ttttggaagc	8040
caagtactgg	tgcccagact	caatggaata	caactgtccc	aatctcagtc	caagagagga	8100
gccagatgac	attgattgct	ggtgctatgg	ggtggaaaac	gttagagtcg	catatggtaa	8160
gtgtgactca	gcaggcaggt	ctaggaggtc	aagaagggcc	attgacttgc	ctacgcatga	8220
aaaccatggt	ttgaagaccc	ggcaagaaaa	atggatgact	ggaagaatgg	gtgaaaggca	8280
actccaaaag	attgagagat	ggttcgtgag	gaaccccttt	tttgcagtga	cggctctgac	8340
cattgcctac	cttgtgggaa	gcaacatgac	gcaacgagtc	gtgattgccc	tactggtctt	8400
ggctgttggt	ccggcctact	cageteactg	cattggaatt	actgacaggg	atttcattga	8460
gggggtgcat	ggaggaactt	gggtttcagc	taccctggag	caagacaagt	gtgtcactgt	8520
tatggcccct	gacaagcctt	cattggacat	ctcactagag	acagtagcca	ttgatagacc	8580
tgctgaggtg	aggaaagtgt	gttacaatgc	agttctcact	catgtgaaga	ttaatgacaa	8640
gtgccccagc	actggagagg	cccacctagc	tgaagagaac	gaaggggaca	atgcgtgcaa	8700
gcgcacttat	tctgatagag	gctggggcaa	tggctgtggc	ctatttggga	aagggagcat	8760
tgtggcatgc	gccaaattca	cttgtgccaa	atccatgagt	ttgtttgagg	ttgatcagac	8820
caaaattcag	tatgtcatca	gagcacaatt	gcatgtaggg	gccaagcagg	aaaattggaa	8880
taccgacatt	aagactctca	agtttgatgc	cctgtcaggc	tcccaggaag	tcgagttcat	8940
tgggtatgga	aaagctacac	tggaatgcca	ggtgcaaact	gcggtggact	ttggtaacag	9000
ttacatcgct	gagatggaaa	cagagagctg	gatagtggac	agacagtggg	cccaggactt	9060
gaccctgcca	tggcagagtg	gaagtggcgg	ggtgtggaga	gagatgcatc	atcttgtcga	9120
atttgaacct	ccgcatgccg	ccactatcag	agtactggcc	ctgggaaacc	aggaaggete	9180
cttgaaaaca	gctcttactg	gcgcaatgag	ggttacaaag	gacacaaatg	acaacaacct	9240
ttacaaacta	catggtggac	atgtttcttg	cagagtgaaa	ttgtcagctt	tgacactcaa	9300
ggggacatcc	tacaaaatat	gcactgacaa	aatgttttt	gtcaagaacc	caactgacac	9360
tggccatggc	actgttgtga	tgcaggtgaa	agtgtcaaaa	ggagccccct	gcaggattcc	9420
agtgatagta	gctgatgatc	ttacagcggc	aatcaataaa	ggcattttgg	ttacagttaa	9480
ccccatcgcc	tcaaccaatg	atgatgaagt	gctgattgag	gtgaacccac	cttttggaga	9540
cagctacatt	atcgttggga	gaggagattc	acgtctcact	taccagtggc	acaaagaggg	9600
aagctcaata	ggaaagttgt	tcactcagac	catgaaaggc	gtggaacgcc	tggccgtcat	9660
gggagacacc	gcctgggatt	tcagctccgc	tggagggttc	ttcacttcgg	ttgggaaagg	9720
aattcatacg	gtgtttggct	ctgcctttca	ggggctattt	ggcggcttga	actggataac	9780

US 9,273,288 B2

89

-continued

aaaggtcatc atggggg	gegg tacttatatg ggttggeate	aacacaagaa acatgacaat	9840
gtccatgagc atgatct	tgg taggagtgat catgatgttt	ttgtctctag gagttggggc	9900
gtaagcggcc cctataa	actc tctacggcta acctgaatgg	actacgacat agtctagtcc	9960
gccaagtcta gagctta	acca tgaccgagta caagcccacg	gtgcgcctcg ccacccgcga	10020
cgacgtcccc agggccg	ytac gcaccetege egeegegtte	gccgactacc ccgccacgcg	10080
ccacaccgtc gatccgg	gacc gccacatcga gcgggtcacc	gagctgcaag aactcttcct	10140
cacgegegte gggeteg	gaca teggeaaggt gtgggtegeg	gacgacggcg ccgcggtggc	10200
ggtctggacc acgccgg	yaga gcgtcgaagc gggggggggtg	ttcgccgaga tcggcccgcg	10260
catggccgag ttgagcg	ggtt cccggctggc cgcgcagcaa	cagatggaag gcctcctggc	10320
geegeacegg eecaage	gage cegegtggtt eetggeeace	gtcggcgtct cgcccgacca	10380
ccagggcaag ggtctg	ggca gcgccgtcgt gctccccgga	gtggaggcgg ccgagcgcgc	10440
cggggtgccc gccttco	etgg agaeeteege geeeegeaac	ctccccttct acgagcggct	10500
cggcttcacc gtcacco	geeg aegtegaggt geeegaagga	ccgcgcacct gatgcatgac	10560
ccgcaagccc ggtgcct	cgac gecegeeeca egaceegeag	cgcccgaccg aaaggagcgc	10620
acgaccccat gatcgct	aga ccatggggta ccgagtatgt	tacgtgcaaa ggtgattgtc	10680
accccccgaa agaccat	att gtgacacacc ctcagtatca	cgcccaaaca tttacagccg	10740
cggtgtcaaa aaccgcg	gtgg acgtggttaa catccctgct	gggaggatca gccgtaatta	10800
ttataattgg cttggtg	getg getactattg tggeeatgta	cgtgctgacc aaccagaaac	10860
ataattgaat acagcag	gcaa ttggcaagct gcttacatag	aactcgcggc gattgcatgc	10920
cgccttaaaa tttttat	ttt attttttttt ttcttttccg	aatcggattt tgtttttaat	10980
atttcaaaaa aaaaaaa	aaaa aaaaaaaaaa cgcgtcgagg	ggaattaatt cttgaagacg	11040
aaagggccag gtggcad	ettt teggggaaat gtgegeggaa	cccctatttg tttatttttc	11100
taaatacatt caaatat	igta teegeteatg agacaataac	cctgataaat gcttcaataa	11160
tattgaaaaa ggaagag	gtat gagtattcaa catttccgtg	tcgcccttat tccctttttt	11220
gcggcatttt gccttco	etgt ttttgeteac ceagaaaege	tggtgaaagt aaaagatgct	11280
gaagatcagt tgggtgo	cacg agtgggttac atcgaactgg	atctcaacag cggtaagatc	11340
cttgagagtt ttcgcco	ccga agaacgtttt ccaatgatga	gcacttttaa agttctgcta	11400
tgtggcgcgg tattato	cccg tgttgacgcc gggcaagagc	aactcggtcg ccgcatacac	11460
tattctcaga atgactt	iggt tgagtactca ccagtcacag	aaaagcatct tacggatggc	11520
atgacagtaa gagaatt	atg cagtgetgee ataaceatga	gtgataacac tgcggccaac	11580
ttacttctga caacgat	ccgg aggaccgaag gagctaaccg	cttttttgca caacatgggg	11640
gatcatgtaa ctcgcct	ttga togttgggaa ooggagotga	atgaagccat accaaacgac	11700
gagcgtgaca ccacgat	igcc tgtagcaatg gcaacaacgt	tgcgcaaact attaactggc	11760
gaactactta ctctago	cttc ccggcaacaa ttaatagact	ggatggaggc ggataaagtt	11820
gcaggaccac ttctgc	gete ggeeetteeg getggetggt	ttattgctga taaatctgga	11880
gccggtgagc gtgggtd	ctcg cggtatcatt gcagcactgg	ggccagatgg taagccctcc	11940
cgtatcgtag ttatcta	acac gacggggagt caggcaacta	tggatgaacg aaatagacag	12000
atcgctgaga taggtgo	cctc actgattaag cattggtaac	tgtcagacca agtttactca	12060
tatatacttt agattga	attt aaaacttcat ttttaattta	aaaggatcta ggtgaagatc	12120
ctttttgata atctcat	cgac caaaatccct taacgtgagt	tttcgttcca ctgagcgtca	12180

US 9,273,288 B2

91

-continued

gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 12240 tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 12300 ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 12360 ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 12420 getetgetaa teetgttaee agtggetget geeagtggeg ataagtegtg tettaeeggg 12480 ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac ggggggttcg 12540 tgcacacage ccagettgga gegaaegaee tacaeegaae tgagataeet acagegtgag 12600 cattgagaaa gegecaeget teeegaaggg agaaaggegg acaggtatee ggtaagegge 12660 agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 12720 agteetgteg ggtttegeea eetetgaett gagegtegat ttttgtgatg etegteaggg 12780 gggcggagcc tatggaaaaa cgccagcaac gcgagctcga tttaggtgac actata 12836 <210> SEQ ID NO 12 <211> LENGTH: 93 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEOUENCE: 12 augagcaaaa agccuggugg accuggaaaa uccagagcag ugaacauguu gaagagaggc 60 augccaaggg uccucagucu gaucggccuu aag 93 <210> SEO ID NO 13 <211> LENGTH: 21 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEOUENCE: 13 ucaaaacaaa agaaaagaua a 21 <210> SEQ ID NO 14 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: synthetic peptide <400> SEQUENCE: 14 Met Ser Lys Lys Pro Gly Gly Pro Gly Lys Ser Arg Ala Val Asn Met 1 5 10 Leu Lys Arg Gly Met Pro Arg Val Leu Ser Leu Ile Gly Leu Lys 20 25 30 <210> SEQ ID NO 15 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic peptide <400> SEQUENCE: 15 Ser Lys Gln Lys Lys Arg

1

-continued

<210> SEQ ID NO 16 <211> LENGTH: 90 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 16 augucuaaga aaccaggagg gcccggcaag agccgggcug ucaauaugcu aaaacgcgga 60 augeceegeg uguugueeuu gauuggaeuu 90 <210> SEQ ID NO 17 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic peptide <400> SEQUENCE: 17 Met Ser Lys Lys Pro Gly Gly Pro Gly Gly Pro Gly Lys Ser Arg Ala 15 1 10 Val Asn Met Leu Lys Arg Gly Met Pro Arg Val Leu Ser Leu Ile Gly 20 25 30 Leu <210> SEQ ID NO 18 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEOUENCE: 18 18 aagcaaaaga aaagagga <210> SEQ ID NO 19 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic peptide <400> SEQUENCE: 19 Lys Gln Lys Lys Arg Gly 1 5 <210> SEQ ID NO 20 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 20 11 cucaauaugc u <210> SEQ ID NO 21 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 21

gacaauaugc u

-continued

<210> SEQ ID NO 22		
<211> LENGTH: 11		
<212> TYPE: RNA		
<220> FEATURE:		
<223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 22		
~		
gugaauaugc u	11	
<210> SEQ ID NO 23		
<211> LENGIH: 11 <212> TYPE: RNA		
<213> ORGANISM: artificial sequence		
<220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 23		
gucuauaugc u	11	
<210> SEQ ID NO 24		
<211> LENGTH: 11		
<212> TYPE: RNA		
<220> FEATURE:		
<223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 24		
gucauuaugc u	11	
<210> SEQ ID NO 25		
<211> HENOTIC: TI <212> TYPE: RNA		
<213> ORGANISM: artificial sequence		
<220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 25		
gucaaaaugc u	11	
<210> SEQ ID NO 26		
<211> LENGTH: 11		
<212> TYPE: RNA		
<220> FEATURE:		
<223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 26		
	11	
yucaauuuyo u	±±	
010. (E0 TR NO 05		
<210> SEQ ID NO 27 <211> LENGTH: 11		
<212> TYPE: RNA		
<213> ORGANISM: artificial sequence		
<220> FEAIORE: <223> OTHER INFORMATION: synthetic polynucleotide		
<400> SEQUENCE: 27		
gucaauaucc u	11	
-		
-2105 SEO ID NO 28		
<211> LENGTH: 11		
<212> TYPE: RNA		
<213> ORGANISM: artificial sequence		
<zzu> FEATURE:</zzu>		

-continued

<223> OTHER INFORMATION: synthetic polynucleotide	
<400> SEQUENCE: 28	
gucaauaugg u	11
<210> SEQ ID NO 29 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide	
<400> SEQUENCE: 29	
gucaauaugc a	11
<210> SEQ ID NO 30 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 30	
agcauauuga c	11
<210> SEQ ID NO 31 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide	
<400> SEQUENCE: 31	
<400> SEQUENCE: 31 agcauauuga g	11
<400> SEQUENCE: 31 agcauauuga g <210> SEQ ID NO 32 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide	11
<400> SEQUENCE: 31 agcauauuga g <210> SEQ ID NO 32 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 32 agcauauugu c	11
<pre><400> SEQUENCE: 31 agcauauuga g </pre> <pre><210> SEQ ID NO 32 </pre> <pre><211> LENGTH: 11 </pre> <pre><212> TYPE: RNA </pre> <pre><220> FEATURE: </pre> <pre><220> FEATURE: </pre> <pre><220> SEQUENCE: 32 agcauauugu c </pre> <pre></pre> <p< td=""><td>11</td></p<>	11
<400> SEQUENCE: 31 agcauauuga g <210> SEQ ID NO 32 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 32 agcauauugu c <210> SEQ ID NO 33 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 33	11
<pre><400> SEQUENCE: 31 agcauauuga g </pre> <pre><210> SEQ ID NO 32 <211> LENGTH: 11 212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 32 agcauauugu c </pre> <pre></pre> <pre><210> SEQ ID NO 33 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <220> FEATURE: <220> FEATURE: <220> FEATURE: <220> CONCE: 33 agcauauuca c </pre>	11
<pre><400> SEQUENCE: 31 agcauauuga g </pre> <pre><210> SEQ ID NO 32 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 32 agcauauugu c </pre> <pre></pre> <pre></pre> <pre></pre> <pre><210> SEQ ID NO 33 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 33 agcauauuca c </pre> <pre></pre>	11

100

-continued <210> SEQ ID NO 35 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 35 agcauaauga c 11 <210> SEQ ID NO 36 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 36 agcauuuuga c 11 <210> SEQ ID NO 37 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 37 11 aqcaaauuqa c <210> SEQ ID NO 38 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 38 aggauauuga c 11 <210> SEQ ID NO 39 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 39 accauauuga c 11 <210> SEQ ID NO 40 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide <400> SEQUENCE: 40 ugcauauuga c 11 <210> SEQ ID NO 41 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE:

<223> OTHER INFORMATION: synthetic polynucleotide

-continued			
<400> SEQUENCE: 41			
gucuauuugc u	11		
<210> SEQ ID NO 42 <211> LENGTH: 11 <212> TYPE: RNA <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: synthetic polynucleotide			
<400> SEQUENCE: 42			
agcaaauaga c	11		

What is claimed is:

1. A replication-deficient pseudoinfectious virus comprising:

20 a mutant flavivirus genome having a deletion of nucleotide sequence encoding amino acids 26 to 93, 31 to 93, 31 to 100, or 26 to 100 of the flavivirus capsid protein, wherein the deletion mutant genome cannot produce capsid-containing viral particles in a cell that does not 25 express a capsid protein, and wherein the deletion does not disrupt the maturation of prM protein or the RNA sequence required for genome cyclization.

2. The replication-deficient pseudoinfectious virus of claim 1, wherein said virus is a chimeric virus comprising a 30 heterologous prM-E cassette.

3. The replication-deficient pseudoinfectious virus of claim 2, wherein the heterologous prM-E cassette is from a yellow fever virus, a West Nile virus, a dengue virus, a tickborne encephalitis virus, a Saint Louis encephalitis virus, a 35 Japanese encephalitis virus, or a Murray Valley encephalitis virus.

4. The replication-deficient pseudoinfectious virus of claim 1, wherein the mutant genome further encodes a heter-40 ologous marker protein or an antigen.

5. The replication-deficient pseudoinfectious virus of claim 4, wherein the marker protein is a green fluorescent protein.

claim 1, wherein the deletion mutant genome further comprises one or both of altered C-prM junction sequences SEQ ID NO:4 and SEQ ID NO:5.

7. An isolated host cell comprising a flavivirus deletion mutant genome having a deletion of nucleotide sequence 50 replicon expressing a flavivirus capsid protein. encoding amino acids 26 to 93, 31 to 93, 31 to 100, or 26 to 100 of the flavivirus capsid protein, wherein the deletion mutant genome cannot produce capsid-containing viral particles in a cell that does not express a capsid protein, and wherein the deletion does not disrupt the maturation of prM 55 protein or the RNA sequence required for genome cyclization

8. A cell culture system comprising:

(a) a flavivirus deletion mutant genome comprising a deletion of the nucleotide sequence encoding amino acids 26 60 to 93, 31 to 93, 31 to 100, or 26 to 100 of the capsid protein, wherein the deletion mutant genome cannot produce capsid-containing viral particles in a cell that does not express a capsid protein, and wherein the deletion does not disrupt the maturation of prM protein or the 65 RNA sequence required for genome cyclization; and

(b) a host cell expressing a flavivirus capsid protein.

9. The cell culture system of claim 8, wherein the cell comprises a replicon encoding a codon-optimized flavivirus capsid protein.

102

10. The cell culture system of claim 9, wherein the replicon is an alphavirus replicon.

11. The cell culture system of claim 8, wherein the flavivirus capsid protein expressed by the host cell is a Venezuelan Equine Encephalitis Virus capsid protein.

12. A method of producing a replication-deficient pseudoinfectious virus comprising:

- introducing into a cell expressing a flavivirus capsid protein a flavivirus deletion mutant genome comprising a deletion of the nucleotide sequence encoding amino acids 26 to 93, 31 to 93, 31 to 100, or 26 to 100 of the capsid protein, wherein the deletion mutant genome cannot produce capsid-containing viral particles in a cell that does not express a capsid protein, and wherein the deletion does not disrupt the maturation of prM protein or the RNA sequence required for genome cyclization; and
- culturing the cell comprising the flavivirus deletion mutant genome under conditions that result in the production of replication-deficient pseudoinfectious virus.

13. The method of claim 12, wherein the deletion mutant genome comprises a heterologous prM-E cassette.

14. The method of claim 13, wherein the heterologous 6. The replication-deficient pseudoinfectious virus of 45 prM-E cassette is from a yellow fever virus, a West Nile virus, a dengue virus, a tick-borne encephalitis virus, a Saint Louis encephalitis virus, a Japanese encephalitis virus, or a Murray Valley encephalitis virus.

15. The method of claim 12, wherein the cell comprises a

16. The method of claim 15, wherein the replicon is an alphavirus replicon.

17. The method of claim 16, wherein the alphavirus is Venezuelan Equine Encephalitis Virus, Sindbis virus, Eastern Equine Encephalitis virus, Western Equine Encephalitis virus, or Ross River virus.

18. The method of claim 15, wherein the replicon comprises a codon-optimized nucleic acid sequence encoding the flavivirus capsid protein.

19. The method of claim 15, wherein the replicon comprises a cyclization sequence of SEQ ID NO:3.

20. The method of claim 12, wherein the mutant flavivirus genome comprises an altered C-prM junction sequence of SEQ ID NO:4 and/or SEQ ID NO:5.

21. The replication-deficient pseudoinfectious virus of claim 1, wherein the mutant flavivirus genome is a dengue virus genome.

22. The host cell of claim 7, wherein the mutant flavivirus

22. The host cert of enamely, wherein the induction in a view distribution of the system of claim 8, wherein the mutant flavivirus genome is a dengue virus genome.
24. The method of claim 12, wherein the flavivirus is den-5

gue virus.

* * * * *